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CHAPTER I 
 
INTRODUCTION 
 
 “Knowledge speaks, but wisdom listens.”  
 
 
 Jimi Hendrix  
(°1942-†1970, American rock guitarist, singer, and songwriter) 
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CHAPTER I 
INTRODUCTION 
1. N-ALKYLAMIDES 
It is well-known that plants are used all over the world for their medicinal properties. Based upon the 
ethnopharmacological properties of plants, many drugs have been developed, with aspirin and 
morphine as renowned examples. Moreover, many of currently used synthetic drugs still originate 
from plants. Between 2001 and 2010, in the United States of America (USA), the Food and Drug 
Administration (FDA) approved 15 drugs derived from plants of which even 10 were new molecular 
entities (NME). The generic names of these NME approvals, with the natural lead compound 
between brackets, are nitisinone (leptospermone), miglustat (1-deoxynojirimycin), tiotropium 
bromide (atropine), trospium chloride (atropine), solifenacin (quinine), nabilone (Δ9-
tetrahydrocannabinol), methylnaltrexone bromide (morphine), tetrabenazine (emetine), artemether 
and lumefantrine (artemisinin) and cabazitaxel (paclitaxel). An important advantage of these and 
other natural products is the wide structural diversity. As such, natural products are a successful 
source for drug leads in drug discovery [1-3]. Europe has a very long tradition in herbal medicinal 
products and has a well-developed market in this area with established criteria for quality control 
and licensing. It is an important industrial sector in Europe, accounting for half of the worldwide sales 
of herbal medicinal products. Five billion US dollar was spent in European countries on over-the-
counter (OTC) herbal medicinal products. However, the importance of herbal medicinal products 
varies considerably in the Member States of the European Union (EU). Germany is the leading EU 
country for herbal drugs with annual sales of 2.5 billion US dollar. About 80% was sold as OTC 
products and 20% on prescription. Ginkgo biloba, Horse-chestnut, Hawthorn and St. John's Wort are 
the main plants prescribed in Germany. Other countries specialised in herbal drugs are France, Italy 
and Switzerland [4-7].  
 
The biomedical interest in N-alkylamides (NAAs), a large group of secondary metabolites found in 
various medicinal plants, has increased enormously. NAAs occur in more than 25 plant families, have 
a wide structural diversity and are potential lead compounds for functional food, food supplements, 
cosmetics and medicines. They are known to have analgesic, antimicrobial, insecticidal, sensory, anti-
inflammatory and immune-modulating properties and are traditionally used to treat toothaches, skin 
and gastric diseases, sexual dysfunctions and viral infections. Besides these ethnopharmacological 
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uses in traditional medicine, plants containing NAAs are also used as spices for their pungent and 
tingling sensations, and are incorporated in topical cosmetics for their wrinkle smoothing, anti-aging 
properties. These compounds thus have a broad biofunctional spectrum interacting with different 
targets via several mechanisms [8].   
N-alkylamides possess a wide structural diversity with as common feature a central amide bond. 
Generally, the plant NAAs consist of an aliphatic chain of poly-unsaturated fatty acids linked to a 
short-chain amine. The NAA structural classification is build up from these two parts, starting with ‘F’ 
(indicative for fatty acid part) followed by the fatty acid category (from 1 to 13) and ends with ‘M’ 
(indicative for the amino part) followed by the amino category (from 1 to 13). Combining the F part 
with the M part yields thus different chemical NAA classes (FxMy nomenclature) (Figure 1). A 
chemical and functional online available database, Alkamid®, has been developed in our research 
group to give a clear overview of the botanical occurrence of NAAs in the plant families, their 
chemistry, structural classification, physicochemical properties and their biofunctionalities [8]. At 
regular time points, this database is updated. Since 2011, 62 new NAAs were added to the database. 
 
 
Figure 1: FxMy classification of N-alkylamides (solid line: yes, dotted line: no) (source: Boonen et al. 2012 [8]). 
 
To date, Alkamid® contains 439 N-alkylamides. User information on the database illustrates that 
researchers originating from 84 countries (3043 sessions) consulted the database between 10 
December 2012 and 8 February 2016 (3 years and 2 months). After excluding countries having a 
bounce percentage of 100, however, 50 countries (1078 sessions) are left. There was a total bounce 
percentage of 65%, which is between the 40-60% bounce rate benchmark for content websites and 
70-98% bounce rate benchmark for blogs [9]. Figure 2 shows the top ten of countries by number of 
database users.    
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Figure 2: Countries of Alkamid® database users (%). 
 
The percentages in Figure 2 seem to display a correlation with the embeddedness of traditional 
medicine in local culture, with Mexico, China, Brazil and India as countries well-known for their use of 
plants consisting of N-alkylamides in traditional medicine [8, 10]. A similar correlation can be seen in 
the citation statistics of the database. Up till now, the paper by Boonen et al. (2012), which reported 
on the Alkamid® database, has been cited 24 times, with authors from Belgium, Mexico, USA, China, 
Brazil, India, Hungary, Colombia, Jordan, Austria, Finland, Portugal, Taiwan and Turkey (Web of 
Science 11/06/2016) [8].  
In the present research, two important NAAs, i.e. spilanthol and pellitorine (Figure 3) were studied 
for their transdermal and pharmacokinetic properties. Spilanthol (affinin) is an F3M1 N-alkylamide 
present in several plants like Spilanthes acmella, in which it is the best known and most abundant 
NAA. Pellitorine (F3M1 NAA) occurs in different plants and is the most abundant NAA in Anacyclus 
pyrethrum. Spilanthol (deca-2E,6Z,8E-trienoic acid isobutylamide) is a triene NAA, while pellitorine 
(deca-2E,4E-dienoic acid isobutylamide) is a diene NAA, possessing only two unsaturated carbon 
bonds. Different pharmacological effects are already described for spilanthol and pellitorine, such as 
antifungal and insecticidal properties [11-16]. Spilanthol also has analgesic, anti-inflammatory and 
antimutagenic properties, while pellitorine shows antithrombotic, antiseptic, antiprotozoal and 
anticancer properties, which will be further discussed in Chapter VII [17-27].  
 
  
Figure 3: Structures of spilanthol (F3M1 NAA) (left) and pellitorine (F3M1 NAA) (right). 
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Spilanthes acmella as well as Anacyclus pyrethrum belong to the Asteracea plant family, as do 
Achillea millefolium and Achillea ptarmica, two plants of which the NAA content will be analytically 
characterised (Figure 4).  
 
 
Figure 4: A: Spilanthes acmella, B: Anacyclus pyrethrum, C: Achillea millefolium, D: Achillea ptarmica. 
 
2. ANALYTICS OF PLANT N-ALKYLAMIDES    
The quality control of plants is very important as the consistent efficacy and safety of the plant-
derived products on the market are strongly related to the plants’ quality. A correct identification of 
compounds in commercially plant-derived products is vital, as misidentification of compounds can 
have serious consequences. For the extraction of plants, different extraction methods are applied, 
such as maceration, hydrodistillation, Soxhlet extraction and supercritical fluid extraction [28, 29]. 
Various analytical methods are used for the chromatographic profiling of plants, such as thin layer 
chromatography (TLC), high performance liquid chromatography coupled to ultraviolet / photo diode 
array detection (HPLC-UV/PDA) and gas chromatography (GC) [30]. Chromatography is an analytical 
technique which is essential for quality control and standardisation of phytotherapeutics. HPLC is 
often used in phytochemistry to isolate natural products and to control their purity. HPLC coupled to 
PDA is widely used as it allows to detect multiple compounds at different wavelengths. It is 
frequently used for screening of plant extracts in which the UV spectra offers valuable information 
about the type of compounds. However, liquid chromatography - mass spectrometry (LC-MS) is a 
more sensitive and selective analytical method to detect and identify compounds [31]. There are 
different kind of mass analyser systems, such as a single quadrupole and a triple quadrupole MS 
system. A single quad MS detection system provides additional information compared to UV as the 
m/z values are available of the eluting compounds. A triple quad MS is a tandem MS consisting of 
three quadrupoles, with two mass analysers in series and in between a cell for collision induced 
dissociation (CID). Using MS², information about the molecular weight of a compound and its 
structure becomes available.  
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During the last decades, a growing interest can be observed in bioanalytical methods to quantify 
NAAs in biological matrices (e.g. plasma, serum, tissues). However, to date, there are only few 
bioanalytical methods reported in literature for the quantification of NAAs. Woelkart et al. (2005) for 
instance investigated the bioavailability and pharmacokinetics of six NAAs from the roots of 
Echinacea angustifolia in humans after oral administration. A sample preparation method was 
performed on the plasma samples using a solid phase extraction (SPE) technique. 1.0 ml of plasma 
was applied on a C18 100 mg SPE column. Final samples were analysed on a LiChroCART (55x2 mm, 3 
μm) RP-C18 end-capped column with HPLC-electrospray ionisation (ESI) ion trap MS. The injection 
volume was 10 μl and the run time was 20 min per sample. No ion suppression effects and no 
interferences of the analytes were observed. The limit of detection (LoD) was 3 ng/ml. After oral 
intake, NAAs were absorbed with maximum concentration values reached between 20 and 30 
minutes [32]. Matthias et al. (2005) reported absorption data of NAAs in humans after taking 
Echinacea tablets. 1 ml of supernatant of the plasma samples was needed for the extraction of the 
NAAs on a SPE C18 cartridge. The samples were analysed with a C18 column (2x100 mm, 3 μm) using 
a HPLC coupled to a single quad MS with an atmospheric pressure chemical ionisation (APCI) source 
operating in positive ion selected ion monitoring (SIM) mode. The limit of quantification (LoQ) was 1 
ng/ml. Per sample, the run time was 13 min. Resulting from this method, the pharmacokinetic data 
showed that the maximum NAA concentration in human plasma was reached after 2 hours post 
ingestion [33]. The same bioanalytical method was used in another study by Matthias et al. (2007) in 
which it was shown that there is no significant difference in bioavailability of NAAs between liquid 
and tablet preparations in humans [34]. Woelkart et al. (2009) described the pharmacokinetics of 
dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides in rats after oral administration. For the 
sample preparation, 200 μl of plasma was needed. Concentrations of the N-alkylamides were 
analysed in tissues (liver and brain) as well. The NAAs were extracted using a SPE C18 100 mg 
column. Final samples were injected (20 μl) on a C18 column (2x50 mm, 5 μm) and analysed using 
HPLC-ESI quadrupole MS. There was a short run time of 5 min per sample. The maximum 
concentration of N-alkylamides appeared already within 8 min post administration in the brain [35]. 
Furthermore, Goey et al. (2011) developed a sensitive HPLC-MS/MS method for the quantification of 
undeca-2-ene-8,10-diynoic acid isobutylamide in human plasma. A liquid-liquid extraction was 
performed of the plasma samples (1 ml plasma needed). A C18 HPLC column (50x2 mm, 3 μm) and a 
triple quadrupole MS with ESI source was used. The injection volume was 15 μl. The lower limit of 
quantification (LLoQ) was 0.05 ng/ml [36]. Goey et al. (2012) also developed a LC-MS/MS method for 
the bioanalysis of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides in human plasma [37]. The 
same HPLC-MS equipment and column were used as described previously [36]. The injection volume 
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was 20 μl and a run time of 7.5 min was used. 300 μl plasma volume was needed for the liquid-liquid 
sample preparation and a LLoQ of 0.01 ng/ml was obtained [37].  
 
The methods described above have a number of important drawbacks. A first disadvantage is the 
large volume of plasma needed for the analysis of the samples, ranging between 200 μl – 1 ml. Since 
such quantities of blood are not always available in in vivo experiments, there is a need for a sample 
preparation method requiring lesser volume. When experiments are performed with humans, larger 
blood volumes are available, but this is however not the case when working with small animals like 
mice. Secondly, also the long run times in the available studies are problematic. The run times on 
HPLC-MS vary between 5 and 20 min per sample. Only one method has an acceptable run time of 5 
min. This is definitely a drawback that has to be overcome in the future. A third important weakness 
in the available research is the high injection volumes used. All methods use a HPLC system, requiring 
higher injection volumes (10-20 μl) compared to ultra high performance liquid chromatography 
(UHPLC). Moreover, the run time can be shortened using UHPLC. In conclusion, there is a need for a 
sample preparation method requiring small blood volumes, which can be analysed with a more 
sensitive UHPLC-MS/MS method.  
 
3. SKIN AS BARRIER  
Drugs can be administered in various ways, e.g. through oral or dermal route. Several physiological 
barriers in the human body can however complicate or prevent the absorption of compounds into 
the systemic blood circulation. Transdermal drug delivery offers several advantages in comparison 
with the traditional oral administration route, such as: minimisation of the first pass effect and 
avoiding the acidic environment of the stomach, which could be responsible for drug degradation. 
This results in a higher bioavailability of the drug, a decrease in side effects and more stable plasma 
levels. In addition, it provides more controlled drug delivery [38]. However, when topically applied, 
compounds must be able to penetrate the stratum corneum (SC), the outer layer of the skin, and 
reach the viable cells of the epidermis and underlying dermis with its blood vessels in order to obtain 
a biological effect (Figure 5). The 10-20 μm thick SC acts as a penetration barrier, which protects the 
body against bacterial, enzymatic or chemical impacts and prevents excess of water loss. The SC is 
mainly composed of several layers (12-16) corneocytes which are surrounded by multilamellar 
organised lipids. Corneocytes are flattened dead cells, filled with keratin filaments and water, which 
are encapsulated by the cornified envelope, consisting of protein layers and a covalent bound lipid 
envelope. The lipid phase is essentially composed of ceramides (50%), cholesterol (25%) and free 
fatty acids (10%), as well as small amounts of cholesterol esters and cholesterol sulphate. The SC is 
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often presented as a ‘brick and mortar’ model, where the corneocytes are the bricks and the lipids 
correspond to the mortar. The 50-100 μm thick viable epidermis is directly adjacent to the SC. This 
epithelium is composed of layers (from bottom to top: stratum basale, stratum spinosum, stratum 
granulosum and stratum lucidum) with various states of differentiation of keratinocytes. Underlying 
the epidermis, the vascular dermis (1-2 mm thick) offers the mechanical support [39-41]. Often, 
topically applied compounds are not able to penetrate the SC, because they do not have the ideal 
physicochemical properties to pass the SC.  
 
 
Figure 5: Structure of the skin (source: MacNeil, 2007 [42]). 
 
Besides the permeation of drugs through sweat glands and hair follicles, two other ways to pass the 
SC constitute the intercellular or the transcellular pathway through the corneocytes. Via the 
intercellular pathway, diffusion of substances into the body largely occurs through the lipid domains 
between the corneocytes. Certain drugs can easily pass the skin, such as clonidine, nicotine, 
estradiol, testosteron, fentanyl, lidocaine, nitroglycerin, ethinyl estradiol, norelgestromin, 
norethindrone, oxybutynin and scopolamine. These drugs have a molecular weight lower than 500 
g/mol, an optimal partition coefficient, low melting point and a certain water-oil solubility [38, 43-
45].  
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The passive diffusion process of compounds for steady state flux (J), to evaluate the drug permeation 
rate through SC is described by Fick’s first law: 
 ൌ െ ൈ


 
in which D is the diffusion coefficient and dC/dx a concentration differential across a membrane [46].  
 
Previous research by our group already indicated the successful dermal administration of spilanthol 
in which spilanthol was able to reach the systemic blood circulation [47-49]. When spilanthol is 
topically applied on pig buccal mucosa, systemic effects can be expected next to local mucosa effects 
as spilanthol is able to significantly penetrate buccal mucosa. Depending on the formulation of the 
dose solution (e.g. as commercially available products, ethanolic extract or dissolved in propylene 
glycol/H2O mixtures), spilanthol mucosal permeability coefficient (Kp) values ranging between 5.3 and 
47.5·10-3 cm/h were observed [48]. Spilanthol penetrates through the human stratum corneum and 
the viable epidermis as well, thereby reaching the dermis and thus the systemic circulation, with Kp 
values between 0.6 and 53.3·10-4 cm/h [47]. 
 
4. BRAIN AS BARRIER  
Once present in the blood, compounds distribute to different tissues and some compounds can even 
cross the blood-brain barrier (BBB) and modulate central nervous system (CNS) effects. The BBB 
(Figure 6), consisting of capillary endothelia, is almost a continues cell layer differing from endothelial 
cells elsewhere in the body due to the absence of fenestrae, the presence of tight junctions between 
the endothelial cells and the fact that the pores in the endothelial cells are much smaller. The 
capillary endothelia is surrounded by a basal lipid membrane. The layer of astrocytes, glial cells in the 
brain, biochemically supports endothelial cells of the BBB. Due to the BBB, the passage of drugs from 
the brain capillaries to the brain tissues is much more complicated than in other places of the body. 
The brain acts as a physical and metabolic barrier and hence strictly regulates the brain entry of 
compounds. The BBB is substantially only permeable for good lipid-soluble molecules (passive 
diffusion) and to molecules that make use of a carrier. The resorption of a drug is influenced by the 
ionisation degree at pH 7.4, the lipid/water partition coefficient and the plasma protein binding. If 
there is an infection, the permeability of the barrier increases. Brain penetration of drugs is typically 
described by the brain to plasma concentration ratio and the influx clearance [50-54]. 
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Figure 6: Structure of the blood-brain barrier (source: Abbott and Yusof, 2010 [55]).  
 
Concerning the ability of N-alkylamides to penetrate the BBB, only little pharmacokinetic research is 
at present available. Woelkart et al. (2009) present the only study which has already measured the 
concentration of NAAs in the brain. They demonstrated that dodeca-2E,4E,8Z,10E/Z-tetraenoic acid 
isobutylamides (tetraenes originating from Echinacea), orally given to rats, are bioavailable with a 
rapid passage across the blood-brain barrier [35].  
 
Besides this pharmacokinetic study, there are numerous pharmacodynamic studies with NAAs or 
NAA-containing plant extracts exerting central nervous system effects. Due to the structural 
similarities of N-alkylamides with the endocannabinoid anandamide or arachidonoylethanolamine 
(AEA) (cannabinoid receptor (CBR) agonist), several binding studies were conducted with NAAs and 
the cannabinoid receptors. To date, two types of cannabinoid receptors are known: cannabinoid 
receptor 1 (CB1R) and cannabinoid receptor 2 (CB2R), both belonging to the G-protein coupled 
receptors. The CB1Rs are predominantly located in the central nervous system and to a lesser extent 
in peripheral cells, tissues and organs like leukocytes, spleen and heart, while CB2Rs are mainly found 
on immune cells, in the spleen and to a lesser extent in the brain. In the brain, CB1Rs are present in 
(1) the cerebellum, basal ganglia and substantia nigra, which are areas involved in the coordination 
of movement; (2) amygdala and hippocampus, areas involved in emotions, memory and learning and 
(3) cerebral cortex, which is involved in complex cognitive functions and attention [56]. Due to 
modulating cytokine release, CB2Rs exert anti-inflammatory effects. In case of cerebral hypoxia-
ischemia or neuro-inflammation, CB2Rs expression on microglial cells in brain are upregulated. When 
activated, CB1Rs reduce cell activity of neurons and modulate the release of neurotransmitters 
CHAPTER I – INTRODUCTION 
  
 
30 
(gamma-aminobutyric acid (GABA), glutamate, serotonin, dopamine, acetylcholine, noradrenaline 
and histamine) [56]. The endocannabinoid system is involved in various biological functions like 
memory, pain, movement, appetite and immune regulation. The endocannabinoid signaling is 
modified in many neurodegenerative diseases, such as Parkinson’s disease, Huntington’s disease and 
Alzheimer’s disease. Therefore, it is believed that ligands of CBRs are highly therapeutic interesting 
[57].    
Various binding studies were performed with NAAs to determine the binding affinity to CB1R and 
CB2R. Woelkart et al. (2005) showed that NAAs from Echinacea angustifolia roots exhibited affinity 
to CB1R and CB2R. Modest inhibition of fatty acid amide hydrolase (FAAH) was moreover detected at 
25 nM of tetradeca-2E-ene-10,12-diynoic acid isobutylamide, while weak inhibition was observed 
with dodeca-2E,4E,8Z-trienoic acid isobutylamide and dodeca-2E,4E-dienoic acid isobutylamide. 
FAAH is an enzyme which hydrolyses anandamide and consequently, inhibition of the enzyme 
prolongs the activity of CB ligands [58]. Raduner et al. (2006) investigated the binding affinity of the 
N-alkylamides dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide and dodeca-2E,4E-dienoic acid 
isobutylamide towards cannabinoid receptors on HEK293 cells. A higher affinity was observed 
towards CB2R compared to CB1R. Undeca-2E-ene-8,10-diynoic acid isobutylamide did not bind the 
CB2R [59]. Another study carried out by Matovic et al. (2007) demonstrated that dodeca-
2E,4E,8Z,10Z-tetraenoic acid isobutylamide from Echinacea species is a high affinity binder for the 
CB2R, while dodeca-2E,4E,8Z,10E-tetraenoic acid isobutylamide and dodeca-2E,4E,8E,10Z-tetraenoic 
acid isobutylamide showed lower affinities towards the CB2R. On the contrary, the synthetic dodeca-
2E,4E,8E,10E-tetraenoic acid isobutylamide did not exhibit binding affinity for the CB2R [60]. 
Furthermore, it has been shown that several N-alkyl diene and triene amides from Otanthus 
maritimus and NAAs from Heliopsis helianthoides and Lepidium meyenii exhibited binding affinity for 
CB1R and CB2R [61, 62]. In the majority of the studies, the binding affinity of the NAA towards the 
CB2R was higher compared to the CB1R.  
 
Other functional studies into the CNS effects of NAAs are the various investigations related to the 
analgesic properties of NAAs. Plants containing NAAs have already been used for many years for 
these medicinal properties. Spilanthes acmella for instance, also known as ‘toothache plant’, is 
frequently used in traditional medicine for its ability to reduce toothaches [63]. Rios et al. (2007) 
demonstrated analgesic properties of a 10 μg/ml dichloromethane Heliopsis longipes extract by 
means of a GABA release experiment in mice brain slices. Also spilanthol (1·10-8 M - 1·10-4 M) showed 
a dose dependent GABA release and thus displayed analgesic properties [17]. It has furthermore 
been demonstrated that 3-100 mg/kg of an ethanol extract of Heliopsis longipes (contains 10% 
spilanthol) exerted analgesic effects in mice using the acetic acid induced writhing and hot-plate tests 
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[64]. A study of Nomura et al. (2013) showed analgesic effects of an ethanolic Acmella oleracea 
extract in mice by means of the hot plate test (thermal heat hyperalgesia). The underlying 
mechanism of this analgesic action is still unclear and it is difficult to conclude if its action is centrally 
or peripherally mediated [65]. Moreover, NAAs present in Echinacea inhibit cyclooxygenase-2 (COX-
2) enzyme activity in human neuroglioma cells, which can suppress pain and inflammation [66]. 
Déciga-Campos et al. (2012) confirmed the analgesic activity of spilanthol and the Heliopsis longipes 
extract. Other CNS effects were also investigated: a prolonged time of hypnosis induced by sodium 
pentobarbital, an altered anxiety behaviour and a decrease in time of clonic and tonic 
pentylenetetrazole (PTZ)-induced seizures (anticonvulsant effect) were observed [19]. Another NAA, 
capsaicin, which is the major NAA in hot peppers, also showed anti-epileptic properties: it has been 
shown that capsaicin can prevent epileptogenic seizures induced by kainic acid [67].  
 
5. REGULATORY STATUS OF PLANT N-ALKYLAMIDES    
Some unfortunate events have influenced the development of regulations considering the safety of 
medicines and food. Council Directive 65/65/EEC of 26 January 1965 on medicinal products, for 
instance, came into force after the thalidomide disaster. In the 1960s, thousands of pregnant woman 
suffering from nausea, who had taken the sedative drug thalidomide, gave birth to babies with born 
birth deformities. The implementation of this Directive gave rise to a requirement of prior marketing 
approval for medicinal products before gaining access to the market. Not only in the pharmaceutical 
industry, but also in the food industry, serious incidents took place, such as the bovine spongiform 
encephalopathy and dioxin crises in the 1990s. Regulation (EC) No. 178/2002 of the European 
Parliament and of the Council of 28 January 2002 laying down the general principles and 
requirements of food law, establishing the European Food Safety Authority and laying down 
procedures in matters of food safety, was adapted in 2002. To guarantee safety in the cosmetic 
industry, Regulation (EC) No. 1223/2009 of the European Parliament and of the Council of 30 
November 2009 on cosmetic products was issued, replacing Directive 76/768/EC [68-72].  
 
A special category of medicinal products are the herbal medicinal products, consisting of herbal 
substances/preparations. These herbal medicinal products also apply to Directive 2001/83/EC, 
relating to medicinal products for human use, but for traditional herbal medicinal products, a 
simplified registration procedure is described in Directive 2004/24/EC, amending Directive 
2001/83/EC [73, 74]. In the majority of the EU countries, herbal drugs are generally sold in 
pharmacies as licensed (non-)prescription drugs. However, in certain Member States (e.g. the 
Netherlands and the United Kingdom), herbal products are sold as food supplements or dietary 
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supplements. In the latter case, they may not be represented with therapeutic or prophylactic claims 
[7]. There are different routes to bring herbal products on the market in Europe. They can be 
classified as (1) medicinal products (well-established used herbal medicinal product or traditional 
herbal medicinal products), (2) cosmetics, (3) food and (4) medical devices. The classification 
depends on the route of administration, the formulation, the safety and the intended use and the 
choice is made by the responsible manufacturer or company. Authorities verify if the right decision is 
made [75]. 
Currently, worldwide there are products on the market containing N-alkylamides or NAA containing 
plants and no unequivocal regulation exists for these products. Often, there is no control on the 
composition, quality and claims of these products. Some of these products are marketed as 
medicinal products containing the well-known Echinacea purpurea plant, famous for its anti-
inflammatory properties. A critical discussion of present and advisable future regulations in this 
respect seems imperative. 
 
6. STUDY OBJECTIVES 
N-alkylamides are secondary metabolites occurring in many plants. These bioactive compounds, with 
many structural variations, are known to exert various pharmacological properties. Many central 
nervous system pharmacodynamic effects are reported. However, only one study has described the 
ability of NAAs in Echinacea to penetrate the almost impermeable BBB [35]. As spilanthol (deca-
2E,6Z,8E-trienoic acid isobutylamide) and pellitorine (deca-2E,4E-dienoic acid isobutylamide) are two 
promising NAAs, the question rises whether these NAAs are able to cross the BBB and possibly elicit 
CNS effects. In order to explore physiological barrier properties of these NAAs, the following 
questions are put forward: 
(1) Which N-alkylamides are present in the plants Achillea millefolium and Achillea 
ptarmica? 
Achillea millefolium and Achillea ptarmica are plants belonging to the Asteracea family and 
are traditionally used for their medicinal properties. It has already been shown that some 
NAAs are responsible for these pharmacological actions. Often, there is no information 
available on the specific bioactive compounds present in plants. Therefore, the present study 
sets out to characterise the NAA content of the two plants.  
(2) Is the plant N-alkylamide pellitorine able to penetrate the human skin?  
The transdermal behaviour of pellitorine is questioned, and if so, the quantitative character 
of its kinetics is searched for to allow pharmacokinetic estimations.    
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(3) Is the use of a single quad MS detector in high-throughput transdermal research of plant 
extracts a useful analytical tool? 
After performing a Franz Diffusion Cell (FDC) experiment, many samples are obtained and a 
simple and easy-to-use analytical method is needed to quantify compounds. The use of 
UHPLC, coupled to a single quad MS detector to quantify NAAs in samples obtained from 
transdermal research, might be appropriate. By using this method, the local skin 
pharmacokinetic properties of spilanthol in Spilanthes acmella extract and pellitorine in 
Anacyclus pyrethrum extract will be evaluated.  
(4) Is the plant N-alkylamide spilanthol able to cross the intestinal barrier in vitro and in vivo 
and furthermore to cross the BBB? 
Are NAAs able to be absorbed from the gastrointestinal lumen after oral administration, 
thereby passing the oral and/or intestinal mucosal barriers? Few studies about the 
pharmacokinetic properties of NAAs are available. One study of Matthias et al. (2004) 
investigated the transport of selected NAAs present in Echinacea through the Caco-2 cell 
monolayer. After 90 minutes, more than 50% of the NAAs penetrated the monolayer [76]. In 
our study, the permeability of spilanthol will be investigated using a Caco-2 cell monolayer. 
We want to confirm these findings in vivo: the intestinal barrier properties of spilanthol will 
be explored in rats in an oral gavage experiment. Furthermore, the ability of spilanthol, once 
present in the blood, to cross the blood-brain barrier in mice is also questioned. Moreover, 
the distribution of spilanthol within the brains (tissue versus capillaries) will be evaluated as 
well. For this, a sample preparation method must be developed in order to quantify 
spilanthol in blood/brain samples and to analyse samples with a self-developed bio-analytical 
UHPLC-MS² method.  
(5) Is pellitorine able to cross the intestinal barrier in vitro and in vivo and furthermore to 
cross the BBB? 
Pellitorine is an N-alkylamide showing slight structural differences with spilanthol. The same 
pharmacokinetic properties as mentioned for spilanthol are questioned for pellitorine, i.e. is 
pellitorine able to cross the Caco-2 cell monolayer, the rat intestinal barrier and the BBB of 
mice?  
(6) What is the regulatory status of N-alkylamide containing health products? 
At present, products containing N-alkylamides are available on the market as food 
supplements, cosmetics or medicinal products. As these NAAs have shown to be able to 
penetrate physiological barriers and have demonstrated various biological effects, the 
regulatory status of these various health products has to be questioned.   
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7. THESIS OUTLINE 
The content of this research is presented in six logically ordered chapters. All the chapters can 
however also be read alone, as a separate introduction covers the content of each chapter.   
 
In Chapter II, the N-alkylamide profiling of ethanolic Achillea millefolium and Achillea ptarmica roots, 
flowers, leaves and stem extracts is performed. NAAs are identified using two analytical techniques, 
i.e. HPLC-ESI-MS and GC-EI-MS.  
The skin pharmacokinetic properties of pellitorine are investigated in Chapter III. A FDC experiment 
using human skin is performed using two different pellitorine dose solutions: one containing the 
Anacyclus pyrethrum extract and the other containing purified pellitorine. Pellitorine was isolated 
and purified from the Anacyclus pyrethrum extract using semi-preparative HPLC. Pellitorine is 
quantified in the receptor fluid at predefined time points and in the different skin layers at the end of 
the experiment (i.e. 24h). Moreover, the permeability coefficient of pellitorine is calculated.   
In Chapter IV, the transdermal properties of spilanthol and pellitorine in Spilanthes acmella extract 
and Anacyclus pyrethrum extract, respectively, are evaluated and quantified using a UHPLC coupled 
to a new type of single quadrupole MS detector. The advantages of using this type of detector in 
high-throughput transdermal research are discussed.    
Chapter V describes the permeation behaviour of spilanthol through several biological barriers. 
Transport experiments are performed in vitro and in vivo. The permeation of spilanthol through a 
Caco-2 cell monolayer and the rat intestinal barrier after oral administration are investigated. 
Transport experiments using the Caco-2 cell monolayer are carried out in both the apical-to-
basolateral and the basolateral-to-apical direction. The initial blood to brain barrier rate kinetics are 
investigated using multiple time regression (MTR) after injection of spilanthol in mice. Furthermore, 
the efflux of spilanthol from the brain to the blood is evaluated in an efflux study with mice. In both 
experiments (influx and efflux), blood is obtained and brains are collected at specified time points. 
Quantification of spilanthol in brain and serum samples is conducted using a bio-analytical UHPLC-MS 
method. Prior to the analyses of the samples, a sample preparation method is developed using solid-
phase extraction.  
In Chapter VI, the physiological barrier penetration properties of pellitorine are investigated. For this 
purpose, a similar methodology as the one discussed in Chapter V is used. Chapter VI also offers an 
evaluation of the in vitro metabolic stability of pellitorine. Brain and blood samples are analysed 
using a self-developed bio-analytical UHPLC-MS method.  
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Lastly, in chapter VII, the regulatory status of NAAs or NAA containing plants in health products is 
discussed, considering their pharmacological properties, the NAA containing products on the market 
and the current regulatory regulations and guidelines of health products in Europe.   
To conclude, the relevance of this research and future perspectives are discussed.  
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“The beauty of a living thing is not the atoms that go into it, but the way those atoms are put 
together.”  
 
  Carl Sagan (°1934-†1996, American astronomer) 
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ABSTRACT 
The analytical N-alkylamide (NAA) profiling of two plants belonging to the Asteracea family, i.e. 
Achillea millefolium and Achillea ptarmica, was performed. The structures of NAAs have been 
assigned in ethanolic extracts of Achillea millefolium and Achillea ptarmica using HPLC-ESI-MS and 
GC-EI-MS. Different extracts were prepared from the roots, the leaves, the stems and the flowers. 
Using both analytical techniques, the structures of 14 and 15 NAAs have been assigned in Achillea 
ptarmica and Achillea millefolium, respectively. Two new NAAs, previously never observed in Achillea 
ptarmica, were assigned: deca-2E,6Z,8E-trienoic acid 2-methylbutylamide (homospilanthol) or a 
related isomeric compound and deca-2E,4E-dienoic acid N-methyl isobutylamide. The structure of 
homospilanthol or a related isomeric compound was also assigned in Achillea millefolium for the first 
time.  
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CHAPTER II 
LIQUID AND GAS CHROMATOGRAPHIC 
MASS SPECTROMETRIC N-ALKYLAMIDE 
PROFILING OF ACHILLEA PTARMICA AND 
ACHILLEA MILLEFOLIUM EXTRACTS 
Main focus in this chapter: 
 To analytically characterise the N-alkylamide content in Achillea ptarmica using HPLC-ESI-MS 
and GC-EI-MS. 
 To profile the N-alkylamides in Achillea millefolium with HPLC-ESI-MS and GC-EI-MS.  
 
1. INTRODUCTION  
The genus Achillea (A.) consists of more than 120 species worldwide, mainly distributed in the 
Northern Hemisphere. Achillea species have been used in traditional folk medicine for many years to 
treat various diseases and are especially known to cure slow-healing wounds, which explains the 
name of the genus Achillea [1, 2]. It might originate from the Greek mythological character Achilles, 
as he used the plants to treat the soldiers’ wounds during Trojan War [3]. Two species of the Achillea 
genus (millefolium and ptarmica) will be discussed in detail: A. millefolium L. and A. ptarmica L., both 
belonging to the Anthemideae tribe and Asteraceae plant family. A. millefolium and A. ptarmica 
plants are both ethnopharmacologically used to treat stomach disorders and stomach ache, 
respectively [4, 5].   
 
Achillea millefolium, also known as yarrow, consists of several closely related species, named a 
species complex or aggregate. It is one of the most important plants belonging to the Achillea genus, 
due to its medicinal features. A diversity of pharmacological properties is ascribed to this plant, such 
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as spasmolytic, anti-inflammatory, analgesic, haemostatic, antidiabetic, cholagogue, antitumor, 
antioxidant, antiseptic and liver protective effects. Furthermore, tea from Achillea millefolium is used 
to treat diseases of the gastrointestinal tract, like dyspepsia, flatulence, abdominal pain, diarrhea, 
stomach ache and digestive complaints. Achillea millefolium can be consumed as essential oil, 
infusion or alcohol extract, decoction, hydroalcoholic, methanolic or aqueous extracts [1, 2, 6-10].  
An aqueous extract of the aerial parts of the plant protected the gastric mucosa in Wistar rats against 
ethanol- and indomethacin induced gastric lesions. It also healed acetic acid induced chronic gastric 
lesions [6]. Potrich et al. (2010) reported that the antioxidant properties are at least partly 
responsible for the gastroprotective effects of the extract [11]. Furthermore, an Achillea millefolium 
extract of the aerial parts (hexane:ether:methanol 1:1:1) showed antimicrobial activity against 
Staphylococcus aureus, Escherichia coli, Klebsiella pneumonia, Pseudomonas aeruginosa and 
Salmonella enteritidis [9]. Safety studies in Wistar rats showed that there were no signs of relevant 
toxicity after daily treatment with the extract in a concentration of 0.3-1.2 g/kg (p.o.) for 28 or 90 
days [6].  
Achillea millefolium is used in cosmetics as it has been proven in vivo that a 2% A. millefolium extract 
has a rejuvenating effect on the appearance and feeling of the skin surface [12]. The extract is a 
biological additive ingredient in 65 cosmetic product formulations and creams to accelerate the 
wound healing rate consist of 2%, 5% or 10% Achillea millefolium extract [13, 14]. Furthermore, there 
are European national pharmacopoeia monographs about A. millefolium: Hungarian, German, 
Austrian, Czech, French, Romanian pharmacopoeias, extra pharmacopoeia Martindale, British herbal 
pharmacopoeia and the Polish herbal compendium [15]. 
 
Another plant belonging to the Asteracea family is Achillea ptarmica L. (sneezewort yarrow). Althaus 
et al. (2014) reported that a dichloromethane extract of flowering aerial parts of A. ptarmica was 
found to possess antiprotozoal activity in vitro. The extract showed anti-Trypanosoma brucei 
rhodesiense activity (IC50 of 0.67 μg/ml) as well as anti-Plasmodium falciparum activity (IC50 of 6.6 
μg/ml) [16]. 
 
Of special pharmacological interest, the genus Achillea produces several N-alkylamides (NAAs), which 
are secondary metabolites in plants and because of their wide structural diversity, they are classified 
according to a structural classification system, indicated as FxMy. The F and M stand for the fatty acid 
chain and the amine part of the NAA, respectively. X and Y represent numbers (1-13), indicative for 
the structure of the chains. Both chains are linked to each other through an amide bond [17]. Achillea 
NAAs consist of the more widespread isobutylamides and phenethyl amides, and especially saturated 
and unsaturated 5- and 6-ring alkylamides (piperidides, pyrrolidides, piperideides, pyrrolideides). 
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C10-, C11- and C14-olefinic and acetylenic alkylamides are characteristic for the genus Achillea and 
are mainly found in the roots of the plant [2, 3, 18-20].  
 
Typical NAAs present in A. millefolium are NAAs consisting of a C10 fatty acid chain linked to a 
piperideide function. 2E,4E,6Z-decatrienoic acid piperideide is the main compound, while the 
corresponding all trans-isomer only occurs in small amounts. N-isobutyl-2,4-decadiene amide 
(pellitorine); 2,4-decadienoic acid piperidide; 2,4-decadienoic acid piperideide and 2,4,6-decatrienoic 
acid piperideide are N-alkylamides identified using GC-MS in the roots of A. distans Willd. subsp. 
distans, however the correct stereoisomer could not be determined. A. distans Willd. subsp. distans 
belongs to the Achillea millefolium aggregate [2]. Greger and Hofer (1989) identified 17 N-
alkylamides in A. millefolium, while Greger and Werner (1990) were able to identify two additional 
NAAs, namely undeca-2E,4E-diene-8,10-diynoic acid piperidide and tetradeca-2E,4E,12Z-triene-8,10-
diynoic acid isobutylamide [21, 22]. Besides NAAs, other compounds present in A. millefolium L. are 
volatile oils, sesquiterpene lactones, flavonoids, amino acids, polyacetylenes, polysaccharides, 
phenolic acids, fatty acids, vitamins, alkanes, alkaloids and bases, saponins, sterols, sugars, 
coumarins, and tannins [15]. 
 
The main components of A. ptarmica are flavonoids, some essential oils and N-alkylamides 
(carboxamides of olefinic and polyynic carboxylic acids with various amines) [16]. Kuropka et al. 
(1986) and Althaus et al. (2014) identified five and six NAAs in Achillea ptarmica, respectively [16, 
23].  
 
In this study, a thorough N-alkylamide profiling of ethanolic extracts from the roots, flowers, leaves 
and stems of A. millefolium and A. ptarmica was performed using HPLC-ESI-MS (high performance 
liquid chromatography electrospray ionisation mass spectrometry) and GC-EI-MS (gas 
chromatography electron impact mass spectrometry). This study led to the structural assignment of 
N-alkylamides, previously never reported in both plants.   
 
2. MATERIALS AND METHODS  
Chemicals and reagents 
Ultrapure water (H2O) of 18.2 MΩ.cm quality was produced by an Arium 611 purification system 
(Sartorius, Göttingen, Germany). Acetic acid was purchased from Sigma-Aldrich (Diegem, Belgium), 
while denaturated ethanol (95% ethanol denaturated with 5% diethylether) was obtained from 
Chem-Lab (Zedelgem, Belgium). Absolute ethanol (EtOH) and HPLC gradient grade acetonitrile (ACN) 
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came from Fisher Scientific (Erembodegem, Belgium). Pellitorine was purchased from Adipogen Life 
Sciences (99.8% purity determined by HPLC). 
 
Plant material and extraction 
Achillea millefolium (type: Wesersandstein) and Achillea ptarmica (type: The Pearl) were bought at 
tree nursery ‘De Bock’ in Belgium (Oudenaarde). Plants were harvested in September 2013. The fresh 
stems, the flowers, the roots and the leaves were collected from the plants and washed with 
ultrapure water. The plant parts were dried at room temperature for approximately six weeks. The 
dried plant parts were cut into smaller pieces (parts of approximately 1 cm) with a scissor. Extraction 
was performed at a ratio of plant part:solvent (w/V), ranging from 1/12 to 1/64 in case of A. 
millefolium and from 1/12 to 1/34 in case of A. ptarmica. As extraction solvent, 90:10 denaturated 
ethanol:H2O (V/V) was used. After maceration in darkness for approximately 48h at room 
temperature (20-27°C, 230 rpm), the plant parts were removed by filtration (Whatman). Thereafter, 
the extraction solvent was removed using a rotavapor (Heidolph and Büchi), protected from light. 
The extraction yield of A. millefolium and A. ptarmica was between 3-8% (w/w) and 3-11% (w/w), 
respectively. The extract was kept in the dark at 4°C until analysis.  
 
HPLC-UV/ESI-MS analysis   
The HPLC-MS analyses were done on a HPLC system which consisted of a Spectra System SN4000 
interface, a Spectra System SCM1000 degasser, a Spectra System P1000XR pump, a Spectra System 
AS3000 autosampler, and a Finnigan LCQ Classic ion trap mass spectrometer in positive ion mode (all 
Thermo, San José, CA, USA) equipped with Xcalibur 2.0 software (Thermo) for data acquisition. The 
plant extracts (roots, stems, leaves, flowers) were dissolved in 50:50 ACN:H2O (V/V) (final extract 
ranging between 5 and 155 mg/ml) and filtered over a 0.45 μm PVDF membrane HPLC filter 
(Whatman) before analysis. 10 μl of this solution was injected on a Grace Prevail C18 column (250 x 
4.6 mm, 5 μm) using a Waters HPLC equipped with a Waters 2487 Dual Absorbance detector set at 
260 nm. A gradient with a flow rate of 1.0 ml/min, was applied as follows: t=0 min: 80:20 A:B (V/V), 
t=0-150 min: 10:90 A:B (V/V), t=150-151 min: 80:20 A:B (V/V), t=151-166 min: 80:20 A:B (V/V) (with A 
= 1% acetic acid in H2O and B = ACN). The needle was rinsed with methanol. ESI was conducted with 
a capillary voltage of 3 kV. Nitrogen was used as sheath and auxiliary gas. The temperature of the 
heated capillary was kept at 275°C. MS-MS spectra were obtained by collision induced dissociation 
(CID) of the parent m/z, with the relative collision energy set to 35%. Structural assignment was 
based on the parent m/z values and fragmentation ions. Assuming all NAA peaks have a response 
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factor of 1 relative to pellitorine, the total amount of NAAs is estimated as 0.6 % w/w in Achillea 
ptarmica and 0.2 % w/w in Achillea millefolium.   
 
GC-EI-MS analysis 
The GC-MS analyses were performed on an Agilent 6890 instrument consisting of an automatic 
injector 7683 and coupled to a Mass Selective Detector 5973 (Agilent), operating in EI mode at 70 eV. 
The output signal was recorded and processed using Instrument Analysis MSD Chemstation (Agilent). 
The root plant extracts were dissolved in absolute ethanol (final extract ranging between 31 and 35 
mg/ml) and samples were injected by the instrument's autosampler with an injection volume of 1 μl. 
Ethanol was used to rinse the syringe between injections (3 x wash post injection). An HP-5MS 
column (30 m length, 0.25 mm i.d., 0.25 μm film thickness) (Agilent, Belgium) was used for 
separation. The column oven was programmed with an initial oven temperature of 100°C, and 
increased to 180°C at a rate of 10°C/min, ramped to 200°C at a rate of 1°C/min, followed by 
increasing the temperature to 320°C at a rate of 10°C/min and held at 320°C for 1 minute. The total 
run time was 41 minutes. The split ratio was set at 10:1. The injector and MS transfer line 
temperature were kept at 210°C and 250°C, respectively. Helium (Air Products and Chemicals, 
Allentown, PA, USA) was used as a carrier gas with a head pressure of 71.3 kPa resulting in an 
average velocity of 37 cm/s. The ion source and quadrupole temperature were 150°C and 230°C, 
respectively. The MS detection scan range was between 40-550 m/z.  
 
3. RESULTS AND DISCUSSION  
The structures of N-alkylamides in the ethanolic A. millefolium and A. ptarmica extracts were 
assigned based on their MS spectra. NAAs have characteristic CID fragmentation patterns, related to 
the amide part of the compound and typical fragment losses are presented in Table 1 [24-26]. The 
loss of (1) the alkyl group directly attached to the amine; (2) the entire amine functional group, 
resulting in an acylium ion; (3) the amide portion of the molecule and saturation of one of the double 
bonds on the alkyl chain and (4) the loss of the amide portion, results in the loss of characteristic m/z 
values. From the corresponding alkyl chain of the two last losses and from the m/z value of the 
acylium ion, the number of carbons present in the alkyl chain can be determined [27]. Furthermore, 
also with electron impact, characteristic product ions of spilanthol, as a prototypical NAA, are formed 
[28-30].  
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Table 1: Characteristic fragment ions of NAAs after CID fragmentation.   
Amine alkyl group 
Loss alkyl group 
directly attached to 
the amine 
Loss of entire amine 
functional group 
Loss of the amide 
portion and 
saturation of one of 
the double bonds on 
the alkyl chain 
Loss of the amide 
portion 
Isobutylamide 
Ion [(M+H)-C4H8]+ [(M+H)-C4H11N]+ [(M+H)-C5H9NO]+ [(M+H)-C5H11NO]+ 
-m/z 56 73 99 101 
Phenylethylamide 
Ion [(M+H)-C8H8]+ [(M+H)-C8H11N]+ [(M+H)-C9H9NO]+ [(M+H)-C9H11NO]+ 
-m/z 104 121 147 149 
2-methyl 
isobutylamide 
Ion [(M+H)-C5H10]+ [(M+H)-C5H13N]+ [(M+H)-C6H11NO]+ [(M+H)-C6H13NO]+ 
-m/z 70 87 113 115 
N-methyl 
isobutylamide 
Ion [(M+H)-C4H8]+ [(M+H)-C5H13N]+ [(M+H)-C6H11NO]+ [(M+H)-C6H13NO]+ 
-m/z 56 87 113 115 
4-hydroxy  
phenylethylamide 
Ion [(M+H)-C8H8O]+  [(M+H)-C8H11NO]+  [(M+H)-C9H9NO2]+  [(M+H)-C9H11NO2]+  
-m/z 120 137 163 165 
4-methoxy 
phenylethylamide 
Ion [(M+H)-C9H10O]+  [(M+H)-C9H13NO]+  [(M+H)-C10H11NO2]+  [(M+H)-C10H13NO2]+  
-m/z 134 151 177 179 
 
Achillea ptarmica  
N-alkylamide profiling using HPLC-ESI-MS    
The total ion chromatogram (TIC) of the root extract of A. ptarmica is given in Figure 1. Peak labels 
correspond to N-alkylamide designations.  
 
Figure 1: TIC of Achillea ptarmica obtained using HPLC-ESI-MS. 
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The major ions observed in the MS1 spectra correspond to the protonated forms of NAAs. The MS² 
spectra are shown in Figure 2, while an overview of all the NAAs assigned in A. ptarmica is given in 
Table 2 with their corresponding retention time (Rt), structure, chemical name, molecular weight 
(MW, average mass) and classification. Structures of fourteen NAAs were assigned with different 
types of amides in the Achillea ptarmica extract: 6 N-alkylamides having an isobutylamide function 
(compounds P1, P5, P7, P10, P11, P12), 3 NAAs with a piperidide function (saturated 6-ring C5H10N, 
compounds P2, P9, P13), 1 NAA with a piperideide function (unsaturated 6-ring C5H8N, compound 
P6), 2 NAAs with a 2-methylbutylamide function (compounds P3, P8), 1 NAA with a 
phenylethylamide function (compound P4) and 1 NAA having a N-methyl isobutylamide function 
(compound P14). Furthermore, the fatty acid chain of the NAAs varies in length (C10, C11, C14) and 
consists of many sites of unsaturated bonds (double and triple bonds) (Table 2). Complex MS-MS 
spectra are due to fragmentation of this chain [24]. As can be seen in Table 2, NAAs with terminal 
alkynes elute early with reversed phase HPLC [27].  
 
Characteristic fragment ions of NAAs with an isobutylamide group are formed by CID (Table 1) and 
these typical m/z values are indicated in bold in Table 3 for compounds P1, P5, P7, P10, P11 and P12. 
In case of compound P1, there were cleavages in the fatty acid chain between C1-C2 (m/z 129) and 
between C2-C3 (m/z 116). The product ions with m/z 174, 157, 131, 129, 116, 91 have been reported 
previously for undeca-2E,4E-diene-8,10-diynoic acid isobutylamide [24, 26, 31]. For compound P11 
(deca-2E,4E-dienoic acid isobutylamide or pellitorine), product ions with m/z 182, 168, 154, 151, 133, 
123, 109, 95, 83 and 69 are consistent with values reported in literature [26, 32]. In addition, a 
cleavage between C4-C5 (m/z 140) and C9-C10 (m/z 209) of the fatty acid chain was observed. For 
compound P12 (tetradeca-2E,4E-diene-8,10-diynoic acid isobutylamide or anacycline), there was a 
cleavage in the fatty acid chain between C1-C2 (m/z 171), C3-C4 (m/z 145) and C6-C7 (m/z 167). 
Moreover, the assignment of compounds P1, P11 and P12 was also based on comparison of the 
retention time [26]. For compound P5 (deca-2E,4E,8Z-trienoic acid isobutylamide), cleavages 
occurred in the fatty acid between C1-C2 (m/z 121) and C8-C9 (m/z 194). Furthermore, as the fatty 
acid chain contains doubly allylic carbon atoms, there is the formation of a distonic radical cation (C6-
C7, m/z 167) and cationic species with the loss of H, due to cleavage between C5-C6 (m/z 152) [32]. 
There were cleavages between C1-C2 (m/z 169), C3-C4 (m/z 143), C5-C6 (m/z 117) and C12-C13 (m/z 
242) for compound P10 (tetradeca-2E,4E,12Z-triene-8,10-diynoic acid isobutylamide).  
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NAAs having a phenylethylamide alkyl group show similarly formed fragments as the isobutylamide 
NAAs, i.e. the typical losses are presented in Table 1. The typical m/z values of these losses for 
compound P4 (undeca-2E,4E-diene-8,10-diynoic acid phenylethylamide) are indicated in bold in 
Table 3. Furthermore, a tropylium ion was formed (benzene and D C) (m/z 91). A cleavage was 
observed in the fatty acid between C1-C2 (m/z 129). Product ions of compound P4 with m/z 168, 
157, 131, 105 and 91 are consistent with values reported earlier. Moreover, assignment of the NAA 
was also based upon retention time comparison [26]. 
 
Characteristic losses of the NAAs with a 2-methyl isobutylamide function are presented in Table 1 
and indicated for compounds P3 and P8 in Table 3. For compound P3, a cleavage occurred in the 
fatty acid chain between C1-C2 (m/z 129), C2-C3 (m/z 116) and C6-C7 (m/z 181). The MS spectrum of 
compound P8 corroborates well with the structure of deca-2E,6Z,8E-trienoic acid 2-
methylbutylamide (homospilanthol) or a related isomeric compound and has never previously been 
reported in this plant (Figure 3). A cleavage was observed in the fatty acid between C6-C7 (m/z 182) 
and C9-C10 (m/z 221). Furthermore, structural assignment of compound P8 was done based on 
comparison of retention time and product ions. Product ions with m/z 166, 149, 123, 121 and 81 
were already reported for this NAA [25].   
 
 
Figure 3: MS2 spectra of deca-2E,6Z,8E-trienoic acid 2-methylbutylamide or homospilanthol (compound P8) 
with [M+H]+ = m/z 236.  
 
The characteristic losses for NAAs having a N-methyl isobutylamide function are shown in Table 1 
and indicated in Table 3 for compound P14. Interestingly, deca-2E,4E-dienoic acid N-methyl 
isobutylamide is the second NAA, never previously reported in this plant. The MS² spectrum is shown 
in Figure 4 and corroborates well with this structure. A cleavage occurred in the fatty acid part 
between C8-C9 (m/z 209). Moreover, the structural assignment of compound P14 was also based on 
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comparison of the retention time and the product ions m/z 182, 168, 151 and 109, which were 
previously reported [26].  
 
 
Figure 4: MS2 spectra of deca-2E,4E-dienoic acid N-methyl isobutylamide (compound P14)  
with [M+H]+ = m/z 238.  
 
For compounds P2 (undeca-2E,4E-diene-8,10-diynoic acid piperidide), P9 (deca-2E,4E,8Z-trienoic acid 
piperidide) and P13 (tetradeca-2E,4E,12Z-triene-8,10-diynoic acid piperidide), having a piperidide 
function, acylium ions are formed with m/z values of 157, 149 and 197, respectively, corresponding 
with a loss of m/z 85. There was a cleavage in the fatty acid chain of these compounds between C6-
C7 (m/z 179) (Table 3). Furthermore, cleavages were found in the fatty acid chain between C3-C4 
(m/z 143) and C12-C13 (m/z 254) of compound P13. Compound P9 has doubly allylic carbon atoms in 
the fatty acid part and formed a distonic radical cation due to cleavage between C6-C7 (m/z 179) 
[32]. An acylium ion was also formed in case of compound P6, having a piperideide function, with a 
m/z value of 157 (loss of m/z 83) and as compound P6 contains doubly allylic carbon atoms, a 
distonic radical cation was formed (C6-C7, m/z 177) (Table 3) [32].   
 
All the reported NAAs were found in the roots of Achillea ptarmica, except for compound P4, which 
was only found in the leaves. Furthermore, compounds P1, P2, P3, P5, P6 and P7 were also observed 
in the leaves, while compounds P1, P2, P3, P5 and P6 were found in the stem as well (data not 
shown). No NAAs could be found in the flowers, as the concentration of NAAs was probably too low. 
In conclusion, the highest amount of NAAs was found in the roots, which is consistent with literature 
[33].  
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N-alkylamide profiling using GC-EI-MS    
Compounds P1, P5, P7, P9, P10, P11 and P12, observed using HPLC-ESI-MS, were also observed with 
GC-EI-MS. The TIC is shown in Figure 5, using the same numbers as indicated in HPLC-MS.  
 
 
Figure 5: TIC of Achillea ptarmica obtained using GC-EI-MS. 
 
The molecular ions were detected for all compounds. Product ions characteristic for isobutylamide 
NAAs were found for compounds P1, P5, P7, P10, P11 and P12. These product ions are indicated in 
bold in Table 4. This was also done for compound P9, an NAA having a piperidide function. Typical 
product ions for the amide part are also indicated in bold in Table 4. Furthermore, V-cleavages were 
observed in the fatty acid chain of all the NAAs. These product ions were for compound P1: m/z 
63/166 (C6-C7), m/z 77 (C5-C6), m/z 103 (C3-C4); for compound P5: m/z 206 (C9-C10), m/z 41 (C7-
C8), m/z 55/166 (C6-C7), m/z 69 (C5-C6), m/z 95 (C3-C4), m/z 100/121 (C1-C2); for compound P7: 
m/z 198 (C9-C10), m/z 63 (C5-C6), m/z 87 (C3-C4), m/z 113 (C1-C2); for compound P10: m/z 254 
(C13-C14), m/z 41 (C11-C12), m/z 103 (C6-C7), m/z 117 (C5-C6), m/z 143 (C3-C4), m/z 169 (C1-C2); 
for compound P11: m/z 208 (C9-C10), m/z 194 (C8-C9), m/z 180 (C7-C8), m/z 166 (C6-C7), m/z 152 
(C5-C6), m/z 126 (C3-C4); for compound P12: m/z 256 (C13-C14), m/z 242 (C12-C13), m/z 43/228 
(C11-C12), m/z 67 (C9-C10), m/z 91 (C7-C8), m/z 105/166 (C6-C7), m/z 119/152 (C5-C6), m/z 100/171 
(C1-C2) and for compound P9: m/z 41 (C7-C8), m/z 55 (C6-C7), m/z 69 (C5-C6), m/z 95/138 (C3-C4), 
m/z 121/112 (C1-C2). In addition, product ions were also detected consistent with a (H-
)rearrangement between C4-C5 in the fatty acid chain, for compound P5: m/z 81, m/z 140; for 
compound P10: m/z 129; for compound P11: m/z 83; for compound P12: m/z 131 and for compound 
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P9: m/z 81, m/z 152. The product ions of compound P11 with m/z 223, 208, 180, 166, 151, 113, 110, 
96, 81, 66, 57, 55, 53 and 41 were also described by Lazarevic et al. (2010) [2]. Compound P1 was 
also recognized by the Nist library.      
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Achillea millefolium  
N-alkylamide profiling using HPLC-ESI-MS    
The TIC of the root extract of A. millefolium is shown in Figure 6 in which peak labels correspond to 
N-alkylamide designations.  
 
 
Figure 6: TIC of Achillea millefolium obtained using HPLC-ESI-MS. 
 
In the MS1 spectra, the major ions are the protonated forms of the NAAs. MS² spectra are presented 
in Figure 7. All the NAAs assigned in A. millefolium are summarised in Table 5 with their 
corresponding retention time (Rt), structure, chemical name, molecular weight (MW, average mass) 
and classification. Structures of ten NAAs were assigned in the Achillea millefolium extract with 
different types of amides: 4 NAAs having an isobutylamide function (compounds M1, M3, M6, M7), 2 
NAAs with a piperidide function (compounds M5, M10), 1 NAA with a piperideide function 
(compound M8), 1 NAA with a 2-methylbutylamide function (compound M4), 1 NAA with a 4-
hydroxyphenylethylamide function (compound M2) and 1 NAA having a 4-methoxy 
phenylethylamide function (compound M9).  
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Table 1 contains characteristic fragment ions formed by CID for NAAs with an isobutylamide, a 2-
methylbutylamide, a 4-hydroxyphenylethylamide and 4-methoxy phenylethylamide function. Typical 
m/z values of fragment losses of NAAs with an isobutylamide function are indicated in bold in Table 6 
for compounds M1 (undeca-2E,4E-diene-8,10-diynoic acid isobutylamide), M3 (deca-2E,4E,8Z-
trienoic acid isobutylamide), M6 (deca-2E,4E-dienoic acid isobutylamide or pellitorine) and M7 
(tetradeca-2E,4E-diene-8,10-diynoic acid isobutylamide or anacycline). In case of compound M1, 
there was a cleavage in the fatty acid chain between C1-C2 (m/z 129), C2-C3 (m/z 116), C3-C4 (m/z 
103) and C4-C5 (m/z 90). Moreover, for compounds M1 and M6 of A. millefolium and compounds P1 
and P11 of A. ptarmica, identical product ions are previously reported [24, 26, 31, 32]. Furthermore, 
cleavages between C1-C2 (m/z 123) and C4-C5 (m/z 140) of the fatty acid chain in compound M6 
were observed. For compound M7, there was a cleavage in the fatty acid chain between C1-C2 (m/z 
171), C3-C4 (m/z 145) and C8-C9 (m/z 79). Moreover, the assignment of compounds M1, M6 and M7 
was also based on comparison of the retention time [26]. For compound M3, cleavages occurred in 
the fatty acid chain between C1-C2 (m/z 121) and C8-C9 (m/z 194). As compound M3 contains doubly 
allylic carbon atoms, there is the formation of a distonic radical cation due to cleavage between C6-
C7 (m/z 167). This distonic radical cation undergoes a hydrogen rearrangement to form an acylium 
ion and the subsequent loss of CO results in a C5 cation (m/z 67) [32].  
 
NAAs having a 4-hydroxyphenylethylamide also show typical fragment ions and are described in 
Table 1 and indicated in bold in Table 6 for compound M2 (deca-2E,4E-dienoic acid tyramide). A 
cleavage occurred in the fatty acid chain between C2-C3 (m/z 178) and a tropylium ion was formed 
(benzene and D-C) (m/z 91). Moreover, the assignment of compound M2 was also based on 
comparison of the retention time and product ions: m/z 178, 151, 133, 121 and 95 were previously 
reported [26].  
 
Characteristic fragment ions for NAAs with a 4-methoxy phenylethylamide function are described in 
Table 1 and are indicated in Table 6 for compound M9 (deca-2E,4E-dienoic acid 4-methoxy 
phenylethylamide). A cleavage occurred in the fatty acid chain between C4-C5 (m/z 218) and C7-C8 
(m/z 259).  
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For NAAs having a 2-methyl isobutylamide function, the characteristic fragmentation ions are 
summarised in Table 1. Typical fragment losses of compound M4 are marked in Table 6. The 
obtained MS spectra corroborate well with the structure of deca-2E,6Z,8E-trienoic acid 2-
methylbutylamide (homospilanthol) or a related isomeric compound. This NAA has never been 
reported before in A. millefolium. A cleavage occurred in the fatty acid part between C3-C4 (m/z 95) 
and C4-C5 (m/z 81). Compound M4 (A. millefolium) was also reported for the first time in A. ptarmica 
(compound P8) and is shown in Figure 3 together with its MS² spectrum.  
 
In case of NAAs having a piperidide function, namely compounds M5 (deca-2E,4E,8Z-trienoic acid 
piperidide) and M10 (deca-2E,4E-dienoic acid piperidide), there was the formation of acylium ions 
with m/z values of 149 and 151, respectively, corresponding with a loss of m/z 85. There was a 
cleavage in the fatty acid chain of compound M5 between C6-C7 (m/z 179), C7-C8 (m/z 193) and C8-
C9 (m/z 206). Furthermore, compound M5, containing doubly allylic carbon atoms in the fatty acid 
part, formed a distonic radical cation due to cleavage between C6-C7 (m/z 179) and a cationic species 
as a result of the cleavage between C5-C6 and loss of a hydrogen atom (m/z 164) [32]. For compound 
M8, possessing a piperideide function, there were cleavages in the fatty acid chain between C6-C7 
(m/z 177) and C8-C9 (m/z 204) and the formation of a distonic radical cation (C6-C7, m/z 177). This 
cation undergoes a hydrogen rearrangement to form an acylium ion and the subsequent loss of CO 
results in a C5 cation (m/z 67). There is also the formation of a cationic species (C5-C6 + loss of H, m/z 
162) [32]. An acylium ion was also formed in case of compound M8, with a m/z value of 149 (loss of 
m/z 83).   
 
The previously mentioned NAAs in Achillea millefolium were all observed in the roots, while in the 
stems only compounds M1, M3, M5, M6 and M10 were found. Due to too low NAA concentrations in 
the flowers and leaves, no NAAs could be observed.  
 
N-alkylamide profiling using GC-EI-MS    
Using GC-EI-MS, compounds M1, M3, M6, and M7, observed with HPLC-ESI-MS, were also found. The 
TIC is shown in Figure 8, with the same numbers as indicated in HPLC-MS. Additional compounds 
assigned using GC-MS are indicated starting numbering from 11.  
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Figure 8: TIC of Achillea millefolium obtained using GC-EI-MS. 
 
Other NAAs were structurally assigned using GC-MS and were not observed with HPLC-MS: 
compounds M11 (deca-2E,4E-dienoic acid piperideide), M12 (dodeca-2Z,4E-diene-8,10-diynoic acid 
isobutylamide), M13 (deca-2E,4E,6Z-trienoic acid piperideide) and M17 (tetradeca-2E,4E,12Z-triene-
8,10-diynoic acid isobutylamide). With the current MS information, no distinction can be made 
between the isomeric compounds M8 (deca-2E,4E,8Z-trienoic acid piperideide), M13 (deca-2E,4E,6Z-
trienoic acid piperideide) and M14 (deca-2E,4E,6E-trienoic acid piperideide) and between compound 
M15 (deca-2E,4E,6Z,8Z-tetraenoic acid piperideide) and its isomer M16 (deca-2E,4E,6E,8Z-tetraenoic 
acid piperideide). For all compounds, the molecular ions were detected, except for compound M12. 
Characteristic product ions were found for compounds M1, M3, M6, M7, M12 and M17, having an 
isobutylamide function and are indicated in bold in Table 7. This was also done for compounds M8, 
M11, M13/14, M15/16, which are NAAs having a piperideide function. Furthermore, in all NAAs, V-
cleavages were observed in the fatty acid chain. These product ions were for compound M1: m/z 204 
(C9-C10), m/z 63/166 (C6-C7), m/z 77 (C5-C6), m/z 103 (C3-C4), m/z 129 (C1-C2); for compound M3: 
m/z 206 (C9-C10), m/z 41/180 (C7-C8), m/z 55/166 (C6-C7), m/z 152 (C5-C6), m/z 95 (C3-C4), m/z 121 
(C1-C2); for compound M6: m/z 208 (C9-C10), m/z 194 (C8-C9), m/z 43/180 (C7-C8), m/z 57 (C6-C7), 
m/z 152 (C5-C6), m/z 97 (C3-C4), m/z 123 (C1-C2); for compound M7: m/z 242 (C12-C13), m/z 43/228 
(C11-C12), m/z 67 (C9-C10), m/z 91 (C7-C8), m/z 105 (C6-C7), m/z 171 (C1-C2); for compound M12: 
m/z 77 (C6-C7), m/z 143 (C1-C2); for compound M17: m/z 254 (C13-C14), m/z 41 (C11-C12), m/z 103 
(C6-C7); for compound M8: m/z 41 (C7-C8), m/z 55 (C6-C7), m/z 69 (C5-C6), m/z 95 (C3-C4), m/z 
121/110 (C1-C2); for compound M11: m/z 218 (C9-C10), m/z 204 (C8-C9), m/z 190 (C7-C8), m/z 57 
(C6-C7), m/z 162 (C5-C6), m/z 97 (C3-C4), m/z 123 (C1-C2); for compound M13/14: m/z 202 (C8-C9), 
m/z 43 (C7-C8), m/z 69 (C5-C6), m/z 95 (C3-C4) and for compound M15/16: m/z 41 (C7-C8), m/z 67 
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(C5-C6), m/z 93 (C3-C4), m/z 119 (C1-C2). In addition, product ions were also detected consistent 
with a (H-)rearrangement between C4-C5 in the fatty acid chain, for compound M3: m/z 81; for 
compound M6: m/z 83; for compound M17: m/z 129; for compound M8: m/z 81; for compound 
M11: m/z 83 and for compound M13/14: m/z 81. Compound M6 in the A. millefolium extract 
corresponds to compound P11 in the A. ptarmica extract and product ions were already described in 
literature for pellitorine. Moreover, the following product ions of compound M11 were reported as 
well: m/z 233, 162, 151, 95, 81, 81, 69, 67, 66, and 55 [2]. Compound M1 was also recognized by the 
Nist library.  
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4. CONCLUSION  
In this research, the N-alkylamide profiling in two ethanolic plant extracts of the Achillea genus, 
namely Achillea ptarmica and Achillea millefolium was performed using two different analytical 
techniques, HPLC-ESI-MS and GC-EI-MS, allowing tentative structural assignments. Our obtained MS 
spectra corroborate well with the structures of these NAAs. Although, full confirmation of the 
identity can be obtained by NMR and synthetic standards. In the Achillea ptarmica extract, in total 14 
N-alkylamides were assigned: six NAAs having an isobutylamide function, three NAAs with a 
piperidide function, two NAAs with a 2-methylbutylamide function, one NAA with a 
phenylethylamide function, one NAA having a piperideide function and one NAA having a N-methyl 
isobutylamide function. Using both analytical methods, compounds P1, P5, P7, P9, P10, P11 and P12 
were reported. Compounds P2, P3, P4, P6, P8, P13 and P14 were assigned with HPLC-ESI-MS, but not 
with GC-EI-MS. Interestingly, it is the first time that compounds P8 and P14 are assigned in Achillea 
ptarmica. The MS spectra corroborate well with the structures of deca-2E,6Z,8E-trienoic acid 2-
methylbutylamide (homospilanthol) or a related isomeric compound and deca-2E,4E-dienoic acid N-
methyl isobutylamide, respectively. In the Achillea millefolium extract, 15 NAAs were assigned: six 
NAAs having a isobutylamide function, one NAA with a 4-hydroxyphenylethylamide function, one 
NAA with a 2-methylbutylamide function, two NAAs having a piperidide function, four NAAs with a 
piperideide function and one NAA with a 4-methoxyphenylethylamide function. Using HPLC-MS and 
GC-MS, five NAAs were assigned using both analytical techniques: compounds M1, M3, M6, M7 and 
M8, whereas compounds M2, M4, M5, M9, M10 were only assigned using HPLC-ESI-MS. 
Furthermore, five additional NAAs were reported using GC-EI-MS: compounds M11, M12, M13/14, 
M15/16 and M17. Like in the A. ptarmica extract, the MS spectra of compound M4 in A. millefolium 
extract corroborate well with the structure of homospilanthol or a related isomeric compound. This 
is the first time that homospilanthol has been assigned in A. ptarmica and A. millefolium.  
 
  
 CHAPTER II – LIQUID AND GAS CHROMATOGRAPHIC MASS SPECTROMETRIC NAA PROFILING OF A. PTARMICA AND A. MILLEFOLIUM EXTRACTS 
  
 
73 
5. REFERENCES 
[1] Si XT, Zhang ML, Shi QW, Kiyota H. Chemical constituents of the plants in the genus Achillea. 
Chemistry & Biodiversity 2006;3:1163-1180. 
[2] Lazarevic J, Radulovic N, Zlatkovic B, Palic R. Composition of Achillea distans Willd. subsp. 
distans root essential oil. Natural Product Research 2010;24:718-731. 
[3] Nemeth E, Bernath J. Biological activities of yarrow species (Achillea spp.). Current 
Pharmaceutical Design 2008;14:3151-3167. 
[4] Rigat M, Bonet MA, Garcia S, Garnatje T, Valles J. Studies on pharmaceutical ethnobotany in 
the high river Ter valley (Pyrenees, Catalonia, Iberian Peninsula). Journal of 
Ethnopharmacology 2007;113:267-277. 
[5] Savikin K, Zdunic G, Menkovic N, Zivkovic J, Cujic N, Terescenko M, Bigovic D. Ethnobotanical 
study on traditional use of medicinal plants in South-Western Serbia, Zlatibor district. Journal 
of Ethnopharmacology 2013;146:803-810. 
[6] Cavalcanti AM, Baggio CH, Freitas CS, Rieck L, de Sousa RS, Da Silva-Santos JE, Mesia-Vela S, 
Marques MC. Safety and antiulcer efficacy studies of Achillea millefolium L. after chronic 
treatment in Wistar rats. Journal of Ethnopharmacology 2006;107:277-284. 
[7] Karamenderes C, Apaydin S. Antispasmodic effect of Achillea nobilis L. subsp. sipylea (O. 
Schwarz) Bassler on the rat isolated duodenum. Journal of Ethnopharmacology 2003;84:175-
179. 
[8] Tajik H, Jalali FSS, Sobhani A, Shahbazi Y, Zadeh MS. In vitro Assessment of Antimicrobial 
Efficacy of Alcoholic Extract of Achillea Millefolium in Comparison with Penicillin Derivatives. 
Journal of Animal and Veterinary Advances 2008;7:508-511. 
[9] Stojanovic G, Radulovic N, Hashimoto T, Palic R. In vitro antimicrobial activity of extracts of 
four Achillea species: the composition of Achillea clavennae L. (Asteraceae) extract. Journal 
of Ethnopharmacology 2005;101:185-190. 
[10] Dias MI, Barros L, Duenas M, Pereira E, Carvalho AM, Alves RC, Oliveira MB, Santos-Buelga C, 
Ferreira IC. Chemical composition of wild and commercial Achillea millefolium L. and 
bioactivity of the methanolic extract, infusion and decoction. Food Chemistry 2013;141:4152-
4160. 
[11] Potrich FB, Allemand A, da Silva LM, Dos Santos AC, Baggio CH, Freitas CS, Mendes DA, Andre 
E, Werner MF, Marques MC. Antiulcerogenic activity of hydroalcoholic extract of Achillea 
millefolium L.: involvement of the antioxidant system. Journal of Ethnopharmacology 
2010;130:85-92. 
[12] Pain S, Altobelli C, Boher A, Cittadini L, Favre-Mercuret M, Gaillard C, Sohm B, Vogelgesang B, 
Andre-Frei V. Surface rejuvenating effect of Achillea millefolium extract. International Journal 
of Cosmetic Science 2011;33:535-542. 
[13] Hemmati A, Arzi A, Amin M. Effect of Achillea millefolium extract in wound healing of rabbit. 
Journal of natural remedies 2002;2/2:164-167. 
[14] Final report on the safety assessment of Yarrow (Achillea millefolium) Extract. International 
Journal of Toxicology 2001;20 Suppl 2:79-84. 
[15] EMA/HMPC/290309/2009. Assessment report on Achillea millefolium L., herba. 
[16] Althaus JB, Kaiser M, Brun R, Schmidt TJ. Antiprotozoal activity of Achillea ptarmica 
(Asteraceae) and its main alkamide constituents. Molecules 2014;19:6428-6438. 
[17] Boonen J, Bronselaer A, Nielandt J, Veryser L, De Tre G, De Spiegeleer B. Alkamid database: 
Chemistry, occurrence and functionality of plant N-alkylamides. Journal of 
Ethnopharmacology 2012;142:563-590. 
[18] Greger H, Zdero C, Bohlmann F. Pyrrole Amides from Achillea-Ageratifolia. Phytochemistry 
1987;26:2289-2291. 
[19] Greger H, Hofer O, Werner A. Biosynthetically Simple C-18-Alkamides from Achillea Species. 
Phytochemistry 1987;26:2235-2242. 
CHAPTER II – LIQUID AND GAS CHROMATOGRAPHIC MASS SPECTROMETRIC NAA PROFILING OF A. PTARMICA AND A. MILLEFOLIUM EXTRACTS 
  
 
74  
[20] Christensen LP. Acetylenes and Related-Compounds in Asteraceae (= Compositae) .4. 
Acetylenes and Related-Compounds in Anthemideae. Phytochemistry 1992;31:7-49. 
[21] Greger H, Hofer O. Polyenoic Acid Piperideides and Other Alkamides from Achillea-
Millefolium. Phytochemistry 1989;28:2363-2368. 
[22] Greger H, Werner A. Comparative HPLC Analyses of Alkamides within the Achillea millefolium 
Group. Planta Medica 1990;56:482-486. 
[23] Kuropka G, Koch M, Glombitza KW. Acid-Amides from Achillea-Ptarmica. Planta Medica 
1986:244-245. 
[24] Cech NB, Eleazer MS, Shoffner LT, Crosswhite MR, Davis AC, Mortenson AM. High 
performance liquid chromatography/electrospray ionization mass spectrometry for 
simultaneous analysis of alkamides and caffeic acid derivatives from Echinacea purpurea 
extracts. Journal of Chromatography A 2006;1103:219-228. 
[25] Boonen J, Baert B, Burvenich C, Blondeel P, De Saeger S, De Spiegeleer B. LC-MS profiling of 
N-alkylamides in Spilanthes acmella extract and the transmucosal behaviour of its main bio-
active spilanthol. Journal of Pharmaceutical and Biomedical Analysis 2010;53:243-249. 
[26] Boonen J, Sharma V, Dixit VK, Burvenich C, De Spiegeleer B. LC-MS N-alkylamide Profiling of 
an Ethanolic Anacyclus pyrethrum Root Extract. Planta Medica 2012;78:1787-1795. 
[27] Spelman K, Wetschler MH, Cech NB. Comparison of alkylamide yield in ethanolic extracts 
prepared from fresh versus dry Echinacea purpurea utilizing HPLC-ESI-MS. Journal of 
Pharmaceutical and Biomedical Analysis 2009;49:1141-1149. 
[28] Leng TC, Ping NS, Lim BP, Keng CL. Detection of bioactive compounds from Spilanthes 
acmella (L.) plants and its various in vitro culture products. Journal of Medicinal Plants 
Research 2011;5:371-378. 
[29] Nakatani N, Nagashima M. Pungent Alkamides from Spilanthes-Acmella L Var Oleracea 
Clarke. Bioscience Biotechnology and Biochemistry 1992;56:759-762. 
[30] Costa SS, Arumugam D, Gariepy Y, Rocha SCS, Raghavan V. Spilanthol Extraction Using 
Microwave: Calibration Curve for Gas Chromatography. Icheap-11: 11th International 
Conference on Chemical and Process Engineering, Pts 1-4 2013;32:1783-1788. 
[31] Bae SS, Ehrmann BM, Ettefagh KA, Cech NB. A Validated Liquid Chromatography-Electrospray 
Ionization-Mass Spectrometry Method for Quantification of Spilanthol in Spilanthes acmella 
(L.) Murr. Phytochemical Analysis 2010;21:438-443. 
[32] Hiserodt RD, Pope BM, Cossette M, Dewis ML. Proposed mechanisms for the fragmentation 
of doubly allylic alkenamides (tingle compounds) by low energy collisional activation in a 
triple quadrupole mass spectrometer. Journal of the American Society for Mass 
Spectrometry 2004;15:1462-1470. 
[33] Stuart DL, Wills RBH. Effect of drying temperature on alkylamide and cichoric acid 
concentrations of Echinacea purpurea. Journal of Agricultural and Food Chemistry 
2003;51:1608-1610. 
 
 
 
 
 
 
 
 
 
  CHAPTER III – SKIN PERMEATION KINETICS OF PELLITORINE 
  
 
75 
 
CHAPTER III 
 
SKIN PERMEATION 
KINETICS OF PELLITORINE 
 
 
 “Make everything as simple as possible, but not simpler.”  
 
  Albert Einstein  (°1879-†1955, physicist, developer the general theory of relativity) 
 
 
 
 
 
 
 
 
 
Parts of this chapter were published: 
 
Veryser L, Taevernier L, Roche N, Peremans K, Burvenich C, De Spiegeleer B. Quantitative 
transdermal behavior of pellitorine from Anacyclus pyrethrum extract. Phytomedicine 
2014;21:1801-1807. 
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ABSTRACT 
The plant Anacyclus pyrethrum (AP) consists of several N-alkylamides with pellitorine as main 
constituent. AP extracts are known to be biologically active and some products for topical 
administration containing AP plant extracts are already commercially available with functional 
cosmeceutical claims. However, no transdermal data for pellitorine are currently available. 
Therefore, our general goal was to investigate the local skin pharmacokinetics of the plant N-
alkylamide pellitorine using a Franz diffusion cell set-up. Two different forms were applied on human 
skin: purified pellitorine and the AP extract. Our study demonstrated that pellitorine is able to cross 
the stratum corneum and the subsequent skin layers. A significantly higher permeability coefficient 
was observed when the AP extract (Kp = 2.3·10-4 cm/h) was administered, compared to purified 
pellitorine (Kp = 1.1·10-4 cm/h). With the obtained pellitorine concentrations in the skin layers and the 
receptor fluid, it is concluded that local and systemic effects can be expected after topical 
application. Due to these findings and as a regulatory consequence, products containing reasonable 
concentrations of pellitorine are recommended to be classified as a medicinal product.   
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CHAPTER III 
SKIN PERMEATION KINETICS OF 
PELLITORINE 
Main focus in this chapter: 
 To purify and isolate pellitorine from the Anacyclus pyrethrum extract.  
 To quantitatively investigate the penetration behaviour of pellitorine through the skin. 
 
1. INTRODUCTION  
Anacyclus pyrethrum (L.) Lag. (AP) is a plant belonging to the Asteracea family. Several N-alkylamides 
(NAAs) present in the AP extract have already been identified and reported. Thirteen NAAs were 
identified in an ethanolic AP root extract with HPLC-UV/ESI-MS: N-isobutylamides, N-
methylisobutylamides, 4-hydroxyphenylethylamides and 2-phenylethylamides. The most abundant 
NAA in this AP extract is pellitorine (deca-2E,4E-dienoic acid isobutylamide) [1]. The structure of 
pellitorine is given in Figure 1.      
 
 
Figure 1. Structure of pellitorine. 
 
Extracts of Anacyclus pyrethrum are ethnopharmacologically used to treat various diseases. Root 
extracts are known to have antimicrobial, local anaesthetical, anti-depressive, insecticidal, and saliva 
stimulating features and are used to treat epilepsy, paralysis, toothache and rheumatism [2, 3]. 
Hydro-alcoholic and chloroform extracts of AP have anticonvulsive effects [4, 5]. In addition, aqueous 
extracts are used as aphrodisiac to improve the libido of men [6].  
It was shown that the main biologically active AP constituents, N-alkylamides, inhibit cyclooxygenase 
[7]. This anti-inflammatory effect was confirmed in vitro with different AP extracts [8]. In addition, 
pellitorine was demonstrated in vivo to have a strong tingling and saliva stimulating effect [9].  
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Topical products containing Anacyclus pyrethrum extracts are already commercially available with 
functional, cosmeceutical claims. AP root extracts are used in lotions, creams, toners, gels, 
moisturizers and bath care products, marketed as a cosmetic not only for moisturizing the skin but 
also for stimulating cell regeneration to reduce discolouration. 
 
In order to exert a biological effect after topical application, the active N-alkylamides must permeate 
through the stratum corneum into the viable skin layers for a local effect and penetrate through the 
skin for a systemic effect. Previous research from our group has shown that spilanthol, present in 
Spilanthes acmella extract, can permeate pig mucosa and human skin, with systemic effects very 
likely to be present [10, 11]. Until now, spilanthol (deca-2E,6Z,8E-trienoic acid isobutylamide), 
containing three unsaturated double bounds in the fatty acid chain (a triene), is the only plant N-
alkylamide on which research was done to evaluate the permeation through human skin: no other 
plant N-alkylamides were investigated yet for transdermal purposes. In this study, the skin 
permeability of another N-alkylamide, with a different structure, was investigated: pellitorine, 
containing two double bounds (a diene). Pellitorine and spilanthol have the same isobutylamide 
group and both alkylamides possess a 2E double bound in the fatty acid chain, but pellitorine 
contains 2 double bounds instead of three and the second double bound is on C4, instead of C6 or C8 
in case of spilanthol. Both purified pellitorine, as well as the ethanolic extract of Anacyclus pyrethrum 
were used in this study to investigate if there was a difference in penetration of pellitorine through 
human skin, as co-compounds in the plant extract could influence the skin penetration as well.       
 
2. MATERIALS AND METHODS  
Chemicals and reagents 
Ultrapure water (H2O) of 18.2 MΩ.cm quality was produced by an Arium 611 purification system 
(Sartorius, Göttingen, Germany). Absolute ethanol (EtOH, 99.8% V/V) and acetic acid were purchased 
from Sigma-Aldrich (Bornem, Belgium). 0.01 M phosphate buffered saline (PBS) was purchased from 
Sigma-Aldrich as well and prepared according to the instructions of the supplier. HPLC gradient grade 
methanol (MeOH) and acetonitrile (ACN) came from Fisher Scientific (Erembodegem, Belgium), while 
formic acid (FA) was bought from Riedel-de Haën (Seelze-Hannover, Germany). Denaturated ethanol 
(up to 5% ether) came from Chem Lab (Zedelgem, Belgium). 
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Analytical characterisation of Anacyclus pyrethrum extract 
The Anacyclus pyrethrum root extract was prepared as previously described [1]. For the analytical 
characterisation of the extract, the extract was dissolved in ethanol, vortexed, sonificated for 2 hours 
and centrifuged for 15 minutes at 3220 g at room temperature. A 30:70 H2O/EtOH (V/V) solution was 
prepared, centrifuged again and the supernatant was filtered using a 0.45 μm nylon HPLC filter 
(Whatman). 25 μl of this solution was injected on a Grace Prevail C18 (250 x 4.6 mm, 5 μm) column 
using a Waters HPLC equipped with a Waters 2487 Dual Absorbance detector set at 258 nm. A 
gradient with a flow rate of 1.0 ml/min, was used as follows: t=0 min: 80:20 A:B (V/V), t=0-150 min: 
10:90 A:B (V/V), t=150-151 min: 80:10 A:B (V/V), t=151-166 min: 80:20 A:B (V/V), t=166 min: 80:20 
A:B (V/V) (with A = 1% acetic acid in H2O and B = ACN). The identity of the mean peak in the AP 
extract was determined using HPLC-MS, based upon the precursor ion m/z and the fragmentation 
pattern. The HPLC-MS analysis was done on a HPLC system which consisted of a Spectra System 
SN4000 interface, a Spectra System SCM1000 degasser, a Spectra System P1000XR pump, a Spectra 
System AS3000 autosampler, and a Finnigan LCQ Classic ion trap mass spectrometer in positive ion 
mode (all Thermo, San José, CA, USA) equipped with a Waters 2487 Dual Absorbance detector 
(Shimadzu, Kyoto, Japan) and Xcalibur 2.0 software (Thermo) for data acquisition. The extract, 
dissolved in 50:50 ACN:H2O (V/V), was injected into the LC-MS apparatus and the MS method 
according to Boonen et al. (2012) was used [1].  
 
Purification of pellitorine  
Pellitorine was isolated and purified from the Anacyclus pyrethrum extract by means of semi-
preparative HPLC as follows. The Anacyclus pyrethrum root extract was dissolved in acetonitrile, 
vortexed and sonificated for 2 hours and centrifuged for 15 minutes at 3220 g at room temperature. 
A 1:1 dilution of the supernatant was prepared with H2O. The solution was centrifuged again and the 
supernatant was filtered using a HPLC filter. 1.0 ml of the solution was injected on a Vydac C18 
monomeric semi-preparative column (Grace, 250 mm x 10 mm, 5 μm) using a Waters HPLC equipped 
with a Waters 2487 Dual Absorbance detector. The sample compartment and column temperature 
were maintained at room temperature. An isocratic elution mode was used with as mobile phase 
50:50 A:B (V/V) (A: 0.1% FA in H2O and B: 0.1% FA in MeOH). A flow rate of 6.0 ml/min was used and 
UV detection was performed at 258 nm. Fractions between 50 and 57 minutes retention time on the 
semi-preparative HPLC were collected and evaporated to dryness using a rotavapor (Büchi rotavapor 
R-200 with Büchi heating batch B-490). The obtained dried fractions were dissolved in methanol, 
combined and evaporated to dryness under nitrogen.  
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Analytical characterisation of purified pellitorine  
The identity of the purified pellitorine was confirmed using HPLC-MS. The equipment is already 
described in the section ‘Analytical characterisation of Anacyclus pyrethrum extract’. A prevail RP C18 
column (Grace, 250 x 4.6 mm, 5 μm) with a suitable guard column was used. The sample 
compartment was kept constant at 20°C, while the column temperature was maintained at 30°C. The 
purified pellitorine was dissolved in 50:50 ACN:H2O (V/V), 25 μl was injected and the flow rate was 
set to 1.0 ml/min. A gradient was used as follows: t=0 min: 60:40 A:B (V/V), t=0-5 min: 50:50 A:B 
(V/V), t=5-35 min: 40:60 A:B (V/V), t=35-40 min: 10:90 A:B (V/V), t=40-41 min: 60:40 A:B (V/V) and 
t=41-46 min: 60:40 A:B (V/V) (with A = 1% acetic acid in H2O and B = ACN). ESI was conducted with a 
capillary voltage of 3 V. Nitrogen was used as sheath and auxiliary gas. The temperature of the 
heated capillary was set at 275°C. MS-MS spectra were obtained by collision-induced dissociation 
(CID) of the parent m/z, with the relative collision energy set to 35%. Identification was based on the 
parent m/z values and fragmentation ions.  
The purity of purified pellitorine was determined using HPLC-UV. 25 μl of purified pellitorine, 
dissolved in 30:70 H2O:EtOH (V/V) was injected on a Prevail C18 column (Grace, 250 x 4.6 mm, 5 μm) 
with guard column. HPLC analysis was performed on a Waters Alliance 2695 HPLC equipped with a 
Waters 2998 Photo Diode Array detector. The same gradient method was used as previously 
described above for the characterisation of the extract. The reporting threshold was set on 0.10%.   
 
Preparations of Franz diffusion dose solutions  
Dose solutions of the Anacyclus pyrethrum extract and the purified pellitorine were prepared in 
30:70 H2O:EtOH (V/V). In these dose solutions, the experimentally determined pellitorine 
concentration was 816 μg/ml in case of the purified pellitorine (purity factor: 0.93) and 316 μg/ml in 
case of the Anacyclus pyrethrum extract. The purified pellitorine concentration was determined using 
ultraviolet-visible (UV-vis) spectrophotometry (Ultrospec 4000 Pharmacia Biotech), using ܧଵ௖௠
ଵΨ ൌ
ͳ͵͵Ͳ, while the concentration in the AP extract was determined using the purified pellitorine as 
reference standard [12]. Negative controls were included in the study as well (dose solutions without 
NAA).  
 
In vitro skin permeation study 
Static Franz diffusion cells (Logan Instruments Corp., New Jersey, USA) with a receptor compartment 
of 5 ml and an available diffusion area of 0.64 cm² were used to determine the skin permeation of 
pellitorine in the different formulations. Human skin was used and the analyses were done in 
fourfold for the purified pellitorine and in sextuplicate for the Anacyclus pyrethrum extract, using a 
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randomized blocked design. The skin samples were obtained from aesthetic body contouring surgery 
of three healthy female patients (40 years old ± 10, mean ± SD), supplied by the Department of 
Plastic and Reconstructive Surgery of the University Hospital (Ghent, Belgium). Confidentiality 
procedures with informed consent were applied. Immediately after the surgical procedure, the skin 
was cleaned with 0.01 M PBS pH 7.4, the subcutaneous fat was removed and the skin was 
subsequently stored at -20°C for not longer than 6 months. Just before the start of the FDC 
experiments, the full-thickness skin was thawed, mounted on a template and sliced to obtain split-
thickness human skin, using an electrical powered dermatome. An actual skin thickness of 295 ± 15.5 
μm (mean ± SEM, n=20), 220 ± 9.35 μm (mean ± SEM, n=30) and 235 ± 9.09 μm (mean ± SEM, n=23) 
was experimentally determined with a micrometer (Mitutoyo, Tokyo, Japan) from the different 
patients. The receptor chambers were filled with 0.01 M PBS. The skin samples were visually 
inspected for skin damage and were mounted on the FDC between the donor and the receptor 
chambers, with the epidermis side upwards ensuring that no air was present under the skin. A Teflon 
coated magnetic stirring bar (400 rpm) allowed that the receptor fluid was continuously mixed. Skin 
integrity was controlled by measuring the skin impedance using an automatic micro-processor 
controlled Tinsley LCR Impedance Bridge (Croydon, U.K.). Skin pieces displaying an impedance value 
below 10 kΩ were discarded and replaced by a new skin piece [13]. 500 μl of the dose solutions were 
applied on the skin surface with a micropipette. The donor chamber was covered with parafilm to 
prevent evaporation of the dose formulations. During the FDC experiment, the temperature of the 
receptor compartment was kept constant at 32°C by a water jacket. 200 μl samples of receptor fluid 
were taken at regular time intervals (0h, 1h, 2h, 4h, 8h, 12h, 18h, 21h, 24h) from the sample port and 
were immediately replaced by 200 μl fresh receptor fluid. This was taken into account for the 
calculation of the cumulative permeated concentrations. Immediately after the last sample had been 
drawn, the remaining dose formulation was removed from the skin surfaces using a cotton swab. The 
epidermis and dermis were separated with forceps and pellitorine was extracted from the skin layers 
with ethanol. In addition, the ratio C24h,epidermis/C24h,vehicle was obtained. The concentration of 
pellitorine in the (epi)dermis was obtained by dividing the amount of extracted pellitorine 
(experimentally determined) by the volume of the (epi)dermis (thickness of (epi)dermis (cm) x skin 
surface (0.64 cm²)). The thickness of the epidermis was assumed to be 50 μm, and the thickness of 
the dermis was the total measured skin thickness minus the thickness of the epidermis. The 
concentration of pellitorine in the remaining dose solution after 24 hours was calculated by dividing 
the amount of pellitorine in the dose solution left after 24h (experimentally determined) by the 
applied volume of the dose solution, i.e. 500 μl. A linear relationship of the individual cumulative 
amount of pellitorine versus time was observed, confirming steady-state conditions. Sink conditions 
were confirmed by the data.  
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Liquid chromatography of the FDC samples 
Two methods were used, i.e. HPLC-UV and UHPLC-UV. The HPLC-UV method was applied for the FDC 
experiments with the purified pellitorine. However, this method required too long run times when 
applied on AP extract samples due to the presence of other compounds which had to be eliminated 
from the column before a next run. Hence, an adapted UHPLC method was applied on the FDC 
samples of the extract.  
The HPLC-UV method used a Waters Alliance 2695 separation module and a dual absorbance 
detector 2487, equipped with Empower 2 software (Waters, Millford, USA) were part of the UHPLC 
apparatus. 25 μl of each sample was injected on a Symmetry C18 column (75 mm x 4.6 mm, 3.5 μm) 
(Waters, Milford, USA) with an appropriate guard column. The sample compartment was kept 
constant at 20°C, while the column temperature was maintained at 30°C. A degassed isocratic mobile 
phase of 0.1% FA in 30:70 H2O:MeOH (V/V) was used at a flow rate of 1.5 ml/min was used. The run 
time was 5 min and UV detection was performed at 258 nm with peak areas used for quantification. 
An analytical validation was performed and the LoD and LoQ, defined as the concentrations 
equivalent to a signal to noise value of 3 and 10, respectively, were determined to be 6.92 ng/ml and 
23.06 ng/ml. Linearity, with determination coefficient R² = 1.000, is assured in a working range of 
23.06 ng/ml (LoQ) up to 204 μg/ml. 
The UHPLC-UV method used a Waters Acquity UPLC with a Waters Photo Diode Array (PDA) detector, 
equipped with Empower software (Waters, Millford, USA) were part of the UHPLC apparatus. 2 μl of 
each sample was injected on a Acquity UPLC C18 column (50 mm x 2.1 mm, 1.7 μm) (Waters, Milford, 
USA) with an appropriate guard column. The sample compartment was kept constant at 5°C, while 
the column temperature was maintained at 30°C. A gradient was used (t=0-1.8 min: 100% A, t=1.8-
2.3 min: 100% B, t=2.3-3.55 min: 100% B, t=3.55-4.05 min: 100% A, t=4.05-6.55 min: 100% A with A: 
0.1% FA in 30:70 (V/V) H2O:MeOH and B: 0.1% FA in MeOH) at a flow rate of 0.5 ml/min was used. 
UV detection was performed at 258 nm with peak areas used for quantification. An analytical 
validation was performed and the LoD and LoQ, defined as the concentrations equivalent to a signal 
to noise value of 3 and 10, respectively, were determined to be 2.97 ng/mL and 9.91 ng/ml. Linearity, 
with determination coefficient R² = 1.000, is assured in a working range of 9.91 ng/ml (LoQ) up to 204 
μg/ml. 
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Calculation of skin permeation parameters 
The cumulative amounts of pellitorine (in μg) permeated through human skin were plotted as a 
function of time (in hours). For the calculations of the transdermal parameters, the individual graphs 
were used. Steady-state flux (Jss, μg/(cm²·h)) was calculated from the slope of the linear portion of 
the cumulative amount versus time curve divided by 0.64 to correct for the exposed skin area (cm2). 
The lag time (h) was obtained by setting y = 0 in the individual linear regression equation. There 
exists different interpretations of the term lag time and this will be discussed in more detail in 
Chapter IV. The Q1d is the cumulative quantity, expressed as % of the effective dose applied, obtained 
after 1 day. The indicated parameters are the secondary parameters, i.e. directly obtained from and 
dependent on the experimental data. The primary parameters, i.e. derived from the experimentally 
obtained secondary parameters and independent of some operational experimental conditions, are 
calculated in accordance with ECETOC [14]: the steady-state permeability coefficient (Kp, cm/h) was 
calculated as follows:  
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where Cd (μg/ml) is the concentration of pellitorine in the dose formulation. Furthermore, the 
apparent diffusion (Dm, cm²/h) and partition (Km) coefficients were determined using the following 
equations:  
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where d and tlag are the measured skin thickness (cm) and the lag time (h), respectively. Furthermore, 
the steady-state plasma concentration after topical application of pellitorine (ng/ml) was calculated 
using the following formula:  
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in which Cl is the plasma clearance (l/h), A is the skin surface (cm²) and Cd the concentration in the 
dose solution applied on the skin.     
 
3. RESULTS  
Identification and purity of pellitorine 
The purity of the Anacyclus pyrethrum extract and the purified pellitorine was determined by HPLC-
UV. Figure 2 shows the HPLC-UV chromatogram of the used extract. The main peak was pellitorine 
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(deca-2E,4E-dienoic acid isobutylamide or C14H25NO), identified by the protonated molecule m/z 
signal observed in MS1 (precursor ion m/z = 224) and complemented by the CID fragmentation data 
in MS2. The product ions (m/z) were 74, 83, 123, 133, 151 and 168; with fragment losses of 150, 141, 
101, 91, 73 and 56, respectively. Its normalized concentration, based on UV258nm peak area, was 
32.0%. The other peaks observed are other N-alkylamides, e.g. anacycline (tetradeca-2E,4E-diene-
8,10-diynoic acid isobutylamide).  
 
 
Figure 2. HPLC-UV (258 nm) chromatogram of Anacyclus pyrethrum extract. 
 
The isolated pellitorine had a normalised concentration of 93.3%, with only one additional N-
alkylamide peak observed at 67.0 minutes (Figure 3). MS1 and MS2 data confirmed the identity of 
both peaks. The minor peak observed at 67.0 minutes with a precursor ion of 336 m/z (C22H25NO2) 
resulting in product ions (m/z) of 121, 129, 171, 199 and 216 with fragment losses of 215, 207, 165, 
137 and 120, respectively, was identified as tetradeca-2E,4E-diene-8,10-diynoic acid 4-OH 
phenylethylamide. 
 
 
Figure 3. HPLC-UV (258 nm) chromatogram of purified pellitorine. 
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Franz diffusion cell transdermal results 
Our results showed that pellitorine was able to diffuse through human skin when applied in an 
EtOH:H2O solution. All individual runs confirmed the sink and steady-state conditions. A linear 
relationship of the individual cumulative amounts versus time was observed between time points 8 
and 24h (R² not less than 0.96). The mean percentage of pellitorine of the applied dose solution 
permeated through the skin versus time, is visually presented in Figure 4 for both the purified 
pellitorine and pellitorine in the Anacyclus pyrethrum extract. 
 
 
Figure 4. Percentage of the applied dose solution permeated through the skin versus time (mean ± SEM, with 
n=4 for purified pellitorine and n=6 for pellitorine in AP extract).   
 
During the first hours of the FDC experiment, the percentage of pellitorine permeated through the 
skin was very similar for both formulations up to 8h. From then on (8-24h), the percentage of 
pellitorine penetrating the skin was higher for pellitorine in the extract and an increase in difference 
between the two formulations was seen towards the end of the experiment (24h). The curve of the 
AP extract exhibited a higher slope than the slope of purified pellitorine.  
 
Linear regression on the linear sections of the individual curves, relating the cumulative amounts of 
pellitorine versus time, was performed to calculate the skin parameters. The values of the 
transdermal parameters, calculated on the individual linear trend lines, are given in Table 1. 
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Table 1. Transdermal parameters for pellitorine in different dose solutions (mean ± SEM, with n=4 for purified 
pellitorine and n=6 for pellitorine in AP extract).    
Dose solution 
Observed secondary parameters 
Jss (μg/cm2.h) 
Q1d (% of the applied 
dose solution) 
tlag (h) 
Pellitorine 0.089 ± 0.032 0.314 ± 0.123 2.445 ± 0.674 
Pellitorine in AP extract 0.071 ± 0.008 0.569 ± 0.065 5.050 ± 0.576 
Dose solution 
Apparent primary parameters 
Kp (10-4 · cm/h) Dm (10-5 · cm2/h) Km 
Pellitorine 1.096 ± 0.397 5.479 ± 1.738 0.067 ± 0.030 
Pellitorine in AP extract 2.253 ± 0.246 2.166 ± 0.207 0.265 ± 0.028 
 
The difference in the apparent primary skin parameter Kp between the two formulations was 
significant at the 0.05 significance level using an independent t-test (p < 0.05). The steady-state 
permeability coefficient of pellitorine in the Anacyclus pyrethrum extract was thus significantly higher 
than the Kp of the purified pellitorine.  
 
After separating the epidermis from the dermis at the end of the FDC experiment (24h), the 
remaining amounts of pellitorine present in the applied dose solution, in the epidermis and in the 
dermis were determined. Figure 5 presents an overview of the pellitorine concentrations in the 
different compartments (dose solution, epidermis, dermis, receptor fluid) obtained under our 
experimental conditions, applying dose solutions of 816 μg/ml pellitorine (as purified form) and 316 
μg/ml pellitorine (as AP root extract).  
 
 
Figure 5. Concentration of pellitorine after 24h (mean ± SEM, n=4-6). 
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Concentrations of pellitorine in the epidermis and dermis ranged between 282-730 μg/ml and 50-56 
μg/ml, respectively. Pellitorine in the purified preparation showed a decreasing concentration 
gradient from the dose solution over the epidermis and dermis to the receptor fluid, while pellitorine 
in the plant extract gave a different concentration distribution, with much higher concentrations in 
the epidermis (‘reservoir effect’), compared not only to the dose solution, but also to the purified 
formulation.  
 
4.  DISCUSSION  
Our findings demonstrate for the first time that the plant diene N-alkylamide pellitorine from an 
Anacyclus pyrethrum extract permeates the skin. This corroborates well with a previous study from 
our research group, demonstrating the skin permeability of the triene N-alkylamide spilanthol [10]. 
Spilanthol and pellitorine only differ in the place and the number of unsaturated bonds in the fatty 
acid chain. Spilanthol, having an extra double bond in the fatty acid chain, is slightly more hydrophilic 
than pellitorine. This is reflected in the logP values: spilanthol has a slightly lower logP value (3.39) 
than pellitorine (3.65) (calculated with Hyperchem professional 8.0 software). Both these logP values 
are acceptable values for skin penetrators, with the optimal target logP value currently proposed 
ranging between 1 and 3 [15]. Due to its slightly more optimal logP value, spilanthol is expected to 
penetrate the skin more. Indeed, spilanthol has higher Kp values (purified: 1.66·10-4 cm/h and in 
extract: 4.29·10-4 cm/h) compared to the Kp’s of pellitorine (purified: 1.10·10-4 cm/h and in extract: 
2.25·10-4 cm/h).  
 
In this study, two different forms were tested: purified pellitorine and pellitorine in Anacyclus 
pyrethrum extract. Upon comparison of the apparent permeability coefficients of pellitorine between 
the two formulations, a significant difference between the Kp’s of the purified pellitorine versus the 
AP extract was observed: a two times higher Kp was obtained for pellitorine in the extract. As a result 
of this, the percentage of pellitorine that had penetrated through the skin after 24h was significantly 
higher when the extract was used as dose solution. This can only be due to the other compounds 
present in the extract, which improved the penetration of pellitorine. The AP extract does indeed 
contain other N-alkylamides (Figure 2) [1], which can themselves function as skin penetration 
enhancers. This corroborates well with a previous study, where the NAA spilanthol was 
demonstrated to act as a compound dependent skin penetration enhancer [16]. The results of the 
current study with the pellitorine extract suggest that also other NAAs can exert a penetration 
enhancing effect. Furthermore, based upon these results, a similar study was undertaken comparing 
the Kp’s of purified spilanthol versus the Kp of spilanthol in Spilanthes acmella extract. A 2.6 times 
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higher Kp (4.29·10-4 cm/h) was obtained for the extract compared to purified spilanthol (1.66·10-4 
cm/h), confirming and generalizing our findings.   
 
In general, two processes have to be considered in skin permeation: (1) the partition of a compound 
from the dose solution (vehicle) into the SC and (2) the diffusion across the SC and subsequent 
layers. The first step is thus the partitioning of a compound into the SC, which can be quantified by a 
thermodynamic equilibrium constant between the concentration of the penetrant in the vehicle and 
the upper skin layer, i.e. the stratum corneum. Partitioning is important for skin absorption because 
it influences the amount of penetrant in the SC and subsequently this amount affects the 
thermodynamic gradient across the skin [17].  
The partition coefficient Km for pellitorine in the Anacyclus pyrethrum extract (0.265) was higher than 
the one of purified pellitorine (0.067). This can also be observed in the distribution graph, presented 
in Figure 5, in which the epidermis contained the highest concentration of pellitorine when the dose 
solution was the AP extract: the ratio C24h,epidermis/C24h,vehicle was 2.78 for the AP extract and 0.40 for 
purified pellitorine. The other N-alkylamides present in the extract will thus not only influence the 
pellitorine behaviour in the dose solution, but will also alter the chemical properties of the SC and 
hence the partition coefficient Km. 
The second stage in skin absorption is the diffusion of the penetrant within the upper skin layers, 
which depends upon a thermodynamic gradient. Factors that can affect the diffusion are the size, the 
shape of the penetrant and stickiness of the penetrant to compounds present in the skin (hydrogen 
bonding) [17]. Furthermore, it is recognized that solvents, such as ethanol, as used in our study, can 
enhance solubility, influence drug permeation and alter skin barrier properties. Ethanol is a 
frequently used solvent in topically applied medicines and is known to also have a penetration 
enhancing effect at lower concentrations with a change in this property observed at concentrations 
above 70%. At these higher ethanol levels, there is i.a. a dehydration of human skin resulting in a 
decrease of permeability of compounds dissolved in high ethanol formulations [10, 18, 19]. The co-
compounds in the extract apparently do not significantly influence the diffusion in the viable skin 
layers and thus once in the skin, there is almost no difference between the Dm of pellitorine in the 
two forms. 
 
As there are already some topical products on the market containing pellitorine, it is important to 
determine the biological relevance of the obtained local skin kinetics data of pellitorine. Until now, 
there are no integrated pharmacokinetic/pharmacodynamic (PK/PD) models available to characterise 
the effects of pellitorine. Consequently, for example, the required plasma concentration of 
pellitorine for having systemic effects is not yet known. Therefore, this information is taken from 
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another plant N-alkylamide, where PK/PD data are available. In the study of Guiotto et al. (2008), the 
apparent clearance of the N-alkylamide dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide from 
Echinacea purpurea was 137 l/h and this value was also used for our calculations with pellitorine 
[20]. With the obtained Kp values in this study (1.1·10-4 for purified pellitorine and 2.3·10-4 for 
pellitorine in the extract) and under the assumptions that the exposed skin surface is 20 cm² and the 
concentration in the dose solution is 1 mg/ml, the steady-state plasma concentration of pellitorine 
after topical application can thus be calculated: the resulting steady-state plasma concentrations for 
purified pellitorine and pellitorine in the Anacyclus pyrethrum extract were 1.6·10-2 ng/ml and    
3.2·10-2 ng/ml, respectively. When comparing these values with the steady-state plasma 
concentration of the Echinacea purpurea N-alkylamide (4.3·10-2 ng/ml) to have bioactivity, it is 
concluded that the pellitorine steady-state plasma concentrations are in the same order of 
magnitude as the bioactive Echinacea purpurea N-alkylamide, indicating pellitorine is able to elicit 
systemic effects after topical application [20]. Furthermore, the epidermis and dermis concentration 
of pellitorine obtained with a concentration of pellitorine in the dose solution of 816 μg/ml in the 
purified solution and 316 μg/ml in the extract solution, were between 282 μg/ml – 730 μg/ml and 50 
μg/ml – 56 μg/ml respectively. Seen the high skin concentrations of pellitorine, local effects are 
certainly expected, e.g. immune-modulating activity. A topical formulation of pellitorine can thus be 
interesting for systemic and/or local functionalities.  
 
This transdermal behaviour, coupled to its pharmacodynamic properties, can have consequences for 
the regulatory classification of products containing plant-based N-alkylamides like pellitorine [21-23]. 
This study clearly demonstrated that pellitorine was able to penetrate the skin and reach not only 
the viable cells of the skin in this study, but also the systemic circulation, recommending 
formulations containing reasonable concentrations of this plant N-alkylamide as a medicinal product. 
This will be further discussed in Chapter VII.        
 
5. CONCLUSION  
In this study, the N-alkylamide pellitorine was isolated from an ethanolic Anacyclus pyrethrum 
extract by means of semi-preparative HPLC. The purity was evaluated and was determined to be 93% 
using HPLC-UV. The transdermal behaviour of pellitorine was investigated with Franz diffusion cells 
and pellitorine was applied on human skin in two different forms: as purified pellitorine and as 
Anacyclus pyrethrum extract. The purity of pellitorine in the extract was 32%. In both dose solutions, 
pellitorine was able to cross the stratum corneum and subsequently reach the viable epidermis and 
dermis. A higher permeability coefficient was observed for pellitorine when administered as extract 
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(2.3·10-4 cm/h) than as purified pellitorine (1.1·10-4 cm/h). After 24h, concentration profiles of 
pellitorine were obtained in the remaining dose solution, the epidermis, the dermis and the receptor 
fluid. An increased partitioning of pellitorine from the dose solution into the stratum corneum was 
observed when using the extract, which is also reflected by the higher partition coefficient (0.265) 
compared to the Km value of the purified pellitorine (0.067). Other N-alkylamides present in the 
Anacyclus pyrethrum extract thus contribute to the skin penetration of pellitorine. To conclude, due 
to the high systemic and skin concentrations of pellitorine, local dermal and systemic biological 
effects are expected, recommending that topically applied N-alkylamides like pellitorine are generally 
better classified as a medicinal product instead of a cosmetic.  
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CHAPTER IV 
 
IMPLEMENTATION OF A 
SINGLE QUAD MS 
DETECTOR IN HIGH-
THROUGHPUT 
TRANSDERMAL RESEARCH 
OF PLANT EXTRACTS 
 
 
“Human science fragments everything in order to understand it, kills everything in order to 
examine it.”  
 
 
 Leo Tolstoy, War and Peace  
(°1828- †1910, Russian writer) 
 
 
 
 
 
 
Parts of this chapter were published: 
 
Veryser L, Taevernier L, Roche N, Blondeel P, De Spiegeleer B. Implementation of a single quad MS 
detector in high-throughput transdermal research of plant extracts. Journal of Pharmaceutical and 
Biomedical Analysis 2015;115:594-602. 
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ABSTRACT 
In this study, a new type of single quadrupole mass spectrometric detector was implemented in 
transdermal research. The local skin pharmacokinetic properties of the plant N-alkylamides (NAAs) 
pellitorine and anacycline, present in an Anacyclus pyrethrum extract, and spilanthol, present in 
Spilanthes acmella extract were investigated. This single quad MS detection method showed great 
advantages compared to the traditional UV detector. The NAAs could be identified and quantified in 
the samples with an ultra high performance liquid chromatography (UHPLC)-single quad MS 
detection system, even if they were not separated, which is a requirement when using an UV-
detector. Another advantage of the UHPLC-MS system is that lower limit of detection values could be 
obtained allowing a more accurate and precise determination of the experimental lag time in the in 
vitro skin permeation experiments. To conclude, this single quad MS detector coupled to UHPLC is a 
useful analytical tool with improved performance compared to high performance liquid 
chromatography (HPLC)-UV for biomedical-pharmaceutical purposes in transdermal research. 
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CHAPTER IV 
IMPLEMENTATION OF A SINGLE QUAD     
MS DETECTOR IN HIGH-THROUGHPUT 
TRANSDERMAL RESEARCH OF PLANT 
EXTRACTS 
Main focus in this chapter: 
 To evaluate the use of a single quad MS detector in transdermal research.   
 To compare the advantages of this technique with a traditional UV detector. 
 
1. INTRODUCTION  
There are some limitations concerning the use of liquid chromatography – ultraviolet/visible (LC-
UV/VIS) for the quantification of chemicals, as there is the possibility for compounds with a very 
similar structure to co-elute, as well as the relatively high limits of detection (LoD) for most 
compounds. Therefore, there is a need for a simple technique to overcome these separation 
problems and to obtain low LoD values. Currently, there is such simple technology available with a 
single quad MS detector, which is directly compatible with existing LC equipments and software, 
complying with GLP/GMP requirements. This detector is characterized by easy-to-use smooth lab-
integration, increased efficiency and acceptably low cost, providing additional detection possibilities 
over the traditional UV/VIS detectors. The productivity and information content of the analyses can 
thus be enhanced. With the single quad MS detector, it is not only possible to make a scan of a 
selected mass range, but selected ion monitoring (SIM) methods can be used as well, making it 
possible to look at selected compounds with a known molecular weight. Besides the confirmation of 
the identity of a compound using the m/z of the compound, it can thus also be used for the 
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quantification of compounds. Recently, this detector has been implemented in the routine QC 
analysis of some peptide drugs [1]. 
 
In this study, biologically active compounds in plant extracts are quantified. Plant extracts are 
complex mixtures, containing quite often many bioactive compounds. These plant extracts are 
frequently used in cosmetics for topical use. Investigation of the transdermal behaviour of bioactive 
compounds is not only important for cosmetics, but also in the development of medicinal 
compounds to characterize the clinical relevance as well as the toxicological effects of the 
compounds. A great number of mathematical models are described in the literature to calculate 
transdermal parameters from in vitro and in vivo studies. Local skin kinetics of active compounds are 
investigated in vitro using a Franz Diffusion Cell (FDC) set-up, studying permeation, penetration and 
partition of the absorbed compounds into the different skin layers. The OECD guideline number 428 
is widely accepted to perform skin absorption studies [2-4]. 
After topical application of a compound, the percutaneous absorption begins, but with a delay of 
entering the systemic circulation ranging from a few minutes to several hours and even days and this 
time is thus of clinical relevance. The delayed absorption is due to the penetration across the outer 
layer and main barrier of the skin, i.e. the stratum corneum (SC) and the partition into the different 
viable skin layers. The concept of lag time (tlag) is generally defined as the time it takes for a 
compound to penetrate the skin. Most therapeutic indications require a drug with a short lag time. 
The tlag is seldom used alone to describe the transdermal behaviour of a penetrant. Besides the lag 
time, the most relevant and commonly used transdermal parameters are the steady state (SS) flux 
(Jss) and the permeability coefficient (Kp,v) [4-9]. 
 
However, there exist different interpretations of the term lag time yielding different calculation 
approaches (Figure 1). The lag time most often used and calculated in in vitro experiments is 
obtained by the extrapolation to the x-axis of the linear part of the slope of the cumulative amount 
versus time plot and is called the “extrapolated” lag time. This approach is derived from a steady 
state mathematical model, based on Fick’s first law of diffusion and used in case of an infinite dose 
[2, 9, 10]. However, in most cases, a certain amount of the compound has already penetrated the 
skin before the extrapolated lag time is reached and this time point is called the “experimental” lag 
time [11].  
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Figure 1. Illustration of a cumulative amount versus time curve with different definitions of tlag.   
 
Another lag time approach is the “true” lag time, i.e. the time point when steady state conditions are 
reached, taking approximately three times the extrapolated lag time. This true lag time reflects the 
time it takes for the compound’s concentration gradient to become stabilized across the skin [12]. 
Before this true lag time, the permeation rate across the skin continually increases. It follows that SS-
flux and permeability coefficient values can only be calculated after three times the extrapolated lag 
time at SS conditions [5, 13]. After about 1.7 times the extrapolated lag time, there is less than 10% 
error on the estimation of the actual amount of compound penetrated through the skin at SS [4]. The 
time it takes to achieve steady state depends on several factors, such as the physicochemical 
properties of the compound and the permeability of the skin itself, related to the skin thickness on 
the site of application and the diffusion coefficient [9].  
 
In this study, the Anacyclus pyrethrum DC (AP) and the Spilanthes acmella (SA) plant extracts are 
used, containing various N-alkylamides (NAAs), showing interesting biological activities [14]. The 
single quad MS detector coupled to UHPLC was used for the quantification of pellitorine and 
anacycline present in the AP extract and spilanthol in the SA extract samples obtained during a FDC 
experiment.  
The implementation of the single quad MS detector in transdermal research, overcomes the 
resolution problems encountered with UV. Moreover, in transdermal research, low concentrations of 
the compound(s) of interest are often obtained in the FDC experiments. With the MS detector, lower 
LoD values can be obtained compared to UV. The lower the LoD values, the more accurate 
transdermal parameters such as the lag time, can be determined. 
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2. MATERIALS AND METHODS  
Chemicals and reagents 
The Anacyclus pyrethrum root extract came from a local supplier in Sagar (India) and was processed 
as previously described [14]. The analytical characterisation of the extract was reported earlier by 
Veryser et al. (2014) (see Chapter III) [15]. Spilanthol, supplied as a 30% w/w ethanolic Spilanthes 
acmella flower extract, was a generous gift of Robertet (Grasse, France). 
0.01 M phosphate buffered saline (PBS) was bought from Sigma-Aldrich. Absolute ethanol (EtOH, 
99.8% V/V) came from Fisher Scientific (Erembodegem, Belgium), while ULC-MS grade formic acid 
(FA, 99%), ULC-MS grade acetonitrile (ACN, 99%) and ULC-MS grade methanol (MeOH) were 
purchased from Biosolve (Valkenswaard, the Netherlands). Ultrapure water (18.2 MΩ.cm) was 
produced using an Arium 611 VF water purification system (Sartorius, Vilvoorde, Belgium). 
 
Preparations of Franz diffusion dose solution 
The Anacyclus pyrethrum extract was first dissolved in ethanol, vortexed, sonificated for 2h and 
centrifuged at 3220 × g at room temperature for 15 min. Then, a 30:70 H2O:EtOH (V/V) solution was 
prepared, centrifuged one more time and the supernatant was filtered using a 0.45 μm Whatman 
nylon HPLC filter. The experimentally determined concentrations of pellitorine (deca-2E,4E-dienoic 
acid isobutylamide or C14H25NO) and anacycline (tetradeca-2E,4E-diene-8,10-diynoic acid 
isobutylamide or C18H25NO) in the dose solution were 495 μg/ml and 96 μg/ml, respectively. The 
concentration of pellitorine in the AP extract dose solution was determined using purified pellitorine 
as reference standard [15].  
Spilanthol (deca-2E,6Z,8E-trienoic acid isobutylamide or C14H23NO) dose solutions of 1.335 mg/ml 
and 0.233 mg/ml (experimentally determined) in 30:70 H2O:EtOH (V/V) were prepared with the 
Spilanthes acmella extract. 
 
In vitro skin permeation study 
The skin penetration of pellitorine, anacycline and spilanthol was evaluated using static Franz 
diffusion cells (Logan Instruments Corp., New Jersey, USA) with an available diffusion area of 0.64 
cm². The receptor compartment was filled with 5 ml 0.01 M PBS, free of air bubbles. A randomized 
blocked design was applied and analyses were done in fivefold (pellitorine and anacycline) and in 
fourfold (spilanthol). Human skin of two healthy female patients of 62 ± 14 years old (mean ± SD) was 
obtained after aesthetic body contouring surgery, with confidential procedures and informed 
consent, from the Department of Plastic and Reconstructive Surgery of the University Hospital 
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(Ghent, Belgium). The skin was cleaned with 0.01 M PBS pH 7.4 immediately after the surgical 
procedure and the subcutaneous fat was removed. Subsequently, the skin was stored at −20°C for 
not longer than 6 months. Just before the start of the FDC experiments, the full-thickness skin was 
thawed, mounted on a template and sliced with an electrical powered dermatome to obtain split-
thickness human skin. An actual skin thickness of 492 ± 61.8 μm (mean ± SD, n=15) for donor 1 and 
402 ± 39.0 μm (mean ± SD, n=15) for donor 2 was experimentally determined with a micrometer 
(Mitutoyo, Tokyo, Japan) used for pellitorine and anacycline, while for spilanthol, an actual skin 
thickness of 530 ± 121 μm (mean ± SD, n = 10) and 377 ± 36.2 μm (mean ± SD, n = 10) were 
experimentally determined from the different patients. After visual inspection for skin damage, the 
intact skin pieces with the epidermis side upwards were mounted on the FDC between the donor and 
the receptor chambers ensuring that no air was present under the skin. During the whole 
experiment, the receptor fluid was mixed continuously using a Teflon coated magnetic stirring bar 
(400 rpm). The skin impedance was measured to check for skin integrity using an automatic micro-
processor controlled Tinsley LCR Impedance Bridge (Croydon, U.K.). Skin pieces displaying an 
impedance value below 10 kΩ were discarded and replaced by a new skin piece [16]. With a 
micropipette, 500 μl of the dose solutions were applied on the skin and afterwards covered with 
parafilm to prevent evaporation of solvents. Due to a water jacket, the receptor compartment was 
kept at 32°C. After 1h, 2h, 4h, 8h, 12h, 18h, 21h and 24h (pellitorine and anacycline) and after 15 
min, 30 min, 45 min, 1h 30, 2h, 2h 30, 3h, 3h 30, 4h, 4h 30, 5h, 6h (spilanthol), 200 μl samples of the 
receptor fluid were taken from the sample port and were immediately replaced by 200 μl fresh PBS 
solution. This was taken into account for the calculation of the cumulative permeated 
concentrations. At the end of the experiment using the AP extract, i.e. after 24h, the remaining dose 
formulation was removed by swabbing the skin surfaces with cotton wool. Afterwards, the epidermis 
and dermis were separated with forceps and pellitorine and anacycline were extracted from the skin 
layers with ethanol to construct a mass balance of pellitorine and anacycline. In addition, the ratio 
C24h,epidermis/C24h,vehicle was obtained. The concentration of pellitorine/anacycline in the (epi)dermis was 
obtained by dividing the amount of extracted NAA (experimentally determined) by the volume of the 
(epi)dermis (thickness of (epi)dermis (cm) x skin surface (0.64 cm²)). The thickness of the epidermis 
was assumed to be 50 μm, and the thickness of the dermis was the total measured skin thickness 
minus the thickness of the epidermis. The concentration of pellitorine/anacycline in the remaining 
dose solution after 24h was calculated by dividing the amount of pellitorine/anacycline in the dose 
solution left after 24h (experimentally determined) by the applied volume of the dose solution, i.e. 
500 μl”. 
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Analysis of the FDC samples using UHPLC-MS 
The UHPLC equipment consisted of an Acquity sample manager, an UPLC quaternary solvent 
manager, an UPLC PDA Acquity isocratic solvent manager (ISM) and a single quadrupole mass 
detector i.e. the Acquity QDa detector with Empower 3 FR 2 software for data acquisition (all Waters, 
Millford, USA). Positive electrospray ionisation (ESI+) was used for the ionisation. An Acquity UPLC 
C18 column (50 mm x 2.1 mm, 1.7 μm) (Waters, Milford, USA) with a suitable guard column was used 
and the injection volume was 2 μl. The column temperature was kept constant at 30°C, while the 
sample compartment was maintained at 5°C.  
For the AP extract, a gradient at a flow rate of 0.5 ml/min was used with mobile phase, consisting of 
0.1% FA in 30:70 H2O:MeOH (V/V) – 0.1% FA in MeOH (t=0-1.8 min= 100:0 (V/V), t=1.8-2.3 min= 
0:100 (V/V), t=2.3-3.55 min= 0:100 (V/V), t=3.55-4.05 min= 100:0 (V/V), t=4.05-6.55 min= 100:0 
(V/V)). The restrictor module in the ISM divides the post-column mobile phase (0.1% FA in 50:50 
MeOH:H2O (V/V)) at a flow of 0.5 ml/min from the column between the PDA detector and the single 
quad MS detector with a post-column PDA/MS split ratio of 10/1. The capillary voltage was 0.8 kV 
and the cone voltage and probe temperature were set at 15 V and 600°C, respectively. A SIM method 
was used for pellitorine (m/z = 224.36) and anacycline (m/z = 272.40). UV detection was performed 
at 258 nm. Analytical validation was performed and the LoD and LoQ of pellitorine, defined as the 
concentrations equivalent to a signal to noise value of 3 and 10, respectively, were determined to be 
0.17 ng/ml and 0.55 ng/ml, in case 100% of the mobile phase was going to the MS detector. 
Linearity, with determination coefficient R² = 0.9999, is assured in a working range of 5.52 ng/ml 
(LoQ) up to 2.48 μg/ml. The LoD and LoQ of anacycline were 0.02 ng/ml and 0.08 ng/ml, respectively, 
in case 100% of mobile phase was sent to the MS; while the linearity is assured in a working range of 
0.80 ng/ml up to 0.48 μg/ml (R² = 0.997). The LoD and LoQ of pellitorine were 3.57 ng/ml, and 11.90 
ng/ml, respectively, in case 100% of mobile phase was sent to the UV detector.  
For spilanthol, an isocratic method was used with as mobile phase 0.1% FA in ACN - 0.1% FA in H2O 
(55:45, V/V) at a flow rate of 0.5 ml/min. The capillary voltage was also 0.8 kV and the cone voltage 
and probe temperature were set at their optimized values, namely 12 V and 600°C, respectively. A 
full mass spectrum between m/z 50 and 600 was obtained at a sampling rate of 5.0 spectra/sec. In 
addition, a SIM method was used for spilanthol (m/z= 222.15). UV detection was performed at 237 
nm. Analytical validation was performed and the LoD and LoQ of spilanthol, defined as the 
concentrations equivalent to a signal to noise value of 3 and 10, respectively, were determined to be 
0.32 ng/ml and 1.07 ng/ml with MS. The LoD and LoQ of spilanthol, determined with UV were 7.10 
ng/ml, and 23.67 ng/ml, respectively.  
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Calculation of skin permeation parameters according to the ECETOC 
The cumulative amounts of the NAAs (in μg) permeated through human skin were plotted as a 
function of time (in hours) and the individual graphs were used for the calculations of the 
transdermal parameters. The observed secondary parameters are the steady state flux (Jss), the lag 
time and the Q1d (cumulative quantity, expressed as % of the effective dose applied, obtained after 1 
day). Several conditions must be fulfilled in order to apply this method, i.e. a constant compound 
concentration in the vehicle, sink conditions in the receptor compartment and initially a lack of 
compound in the SC. After a while, SS conditions will be achieved [8]. The formulas used to calculate 
the transdermal parameters are based on Fick’s first law [4]. Steady state flux (μg/(cm²·h)) was 
calculated from the slope of the linear portion of the cumulative amount versus time curve divided 
by 0.64 to correct for the exposed skin area (cm2). The lag time (h) was obtained by setting y = 0 in 
the individual linear regression equation. These parameters were directly obtained from and 
dependent on the experimental data. The permeability coefficient of the NAA in the vehicle 
(ethanol:water) (Kp,v, cm/h) [17], which is a primary parameter derived from the experimentally 
obtained secondary parameters and independent of some operational experimental conditions, was 
calculated in accordance with European Centre for Ecotoxicology and Toxicology of Chemicals 
(ECETOC) [9]. The permeability coefficient was calculated as follows: Kp,v = Jss/Cv, where Cv (μg/ml) is 
the concentration of pellitorine in the applied vehicle (dose formulation). 
 
3. RESULTS AND DISCUSSION  
Chromatograms of the N-alkylamides in the Anacyclus pyrethrum extract   
Figure 2A shows the UHPLC-UV chromatogram of the AP extract at 258 nm; no immediate 
identification and quantification of the major NAAs pellitorine and anacycline were possible.  
 
Therefore, for the separate quantification of pellitorine and anacycline, the single quad MS detector 
was used. The main peaks in Figure 2B and 2C are pellitorine and anacycline, respectively, identified 
by the protonated molecule m/z signal observed in MS1 (precursor ion m/z of pellitorine = 224; 
precursor ion m/z of anacycline = 272). Anacycline and pellitorine are eluting around the same time 
i.e. between 1 and 2 minutes. Contrary to the UV detector, it is thus not necessary that compounds 
are separated from each other at baseline to quantify them.    
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Figure 2. (A) UHPLC-UV (258 nm) chromatogram of Anacyclus pyrethrum extract, (B) MS ion chromatogram of 
AP extract for pellitorine (m/z 224), (C) MS ion chromatogram of AP extract for anacycline (m/z 272). 
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Transdermal results 
Using the single quadrupole mass detector as quantification technique, the transdermal behaviour of 
the NAAs was quantified. Steady state conditions were maintained during the experiment for 
pellitorine. The in-silico calculated aqueous solubility of pellitorine was 6.58 mg/l [18]; hence the 
concentration of pellitorine did not exceed 10% of the solubility in the receptor fluid, confirming sink 
conditions. Linear regression was performed on the individual cumulative amounts of pellitorine 
versus time curves from 8 to 24h (R² ≥ 0.95). The cumulative amount versus time curve of pellitorine 
is shown in Figure 3, as well as the mean cumulative amount of anacycline at 24h.  
 
 
Figure 3. Cumulative amount vs. time curves of pellitorine in the Anacyclus pyrethrum extract (n=5), mean 
cumulative amount of anacycline at 24h (mean ± SEM, n=4) and transdermal parameters of pellitorine (mean ± 
SEM, with n=5). 
 
A mean amount of 0.56 μg of pellitorine (n=5) permeated through the skin after 24h, which 
corresponds to 0.22% of the applied dose solution. For anacycline, no cumulative amount versus 
time curve could be constructed, as the concentration of anacycline in the receptor fluid samples 
before 24h were below the LoQ. The mean amount of anacycline after 24h is indicated in Figure 3 
and amounts 0.05 μg (n=4), corresponding to 0.10% of the applied dose. 
 
Skin parameters of pellitorine were calculated according to the ECETOC and are given in Figure 3. 
These values are in the same range as the results obtained in a previous study (see Chapter III) [15]. 
The permeability coefficient Kp,v of pellitorine is 0.915·10-4 cm/h. At the end of the experiment (i.e. 
24h), the concentration of pellitorine and anacycline in the dermis and epidermis were determined. 
The concentrations of pellitorine in the different compartments, after applying a dose solution of 
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pellitorine of 495 μg/ml in 30:70 H2O:EtOH (V/V), are visually shown in Figure 4, while the 
concentrations of anacycline in the different compartments, after applying a dose solution containing 
96 μg/ml anacycline, are graphically shown in Figure 5.  
  
 
Figure 4. Distribution of pellitorine (mean values ± SEM, n=5) in the different compartments after 24h: 
remaining dose, epidermis, dermis and receptor fluid. The amount of pellitorine in each compartment as a 
percentage of the applied dose is indicated above the bars. 
 
 
Figure 5. Distribution of anacycline (mean values ± SEM, n=4) in the different compartments after 24h: 
remaining dose, epidermis, dermis and receptor fluid. The amount of anacycline in each compartment as a 
percentage of the applied dose is indicated above the bars. 
 
For both pellitorine and anacycline, the concentrations found in the different compartments are in 
decreasing order: the epidermis < the remaining dose < the dermis < the receptor fluid, respectively. 
As the epidermis is more lipophilic than the dermis, lipophilic compounds like pellitorine and 
anacyline will remain there longer. The relative distribution of both NAAs in the different skin 
compartments is very similar. 
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Lag time determination  
As mentioned in the introduction, different definitions are ascribed to the word ‘lag time’. There is 
the “experimental”, the “extrapolated” and the “true” lag time (Figure 1). The real time for a 
compound needed to cross the skin, is mostly related to the “experimental” lag time and not to the 
“extrapolated” and “true” lag time, as there is already an amount of compound penetrated through 
the skin before both these lag times. However, the experimental lag time can be defined in different 
ways depending on its determination. Theoretically, it can be defined as the time it takes for one 
molecule of the compound to penetrate (through) the skin, however this is difficult to experimentally 
observe. Using a particular analytical method, the (highest) observable lag time is related to the LoD 
or LoQ of the method. Apart from this direct experimentally obtained (highest observable) lag time, 
mathematical models can be used for calculating the lag time from a discrete set of experimental 
data. One of the advantages of using these models is the ability to extrapolate from the observable 
high and method dependent lag time to a lower and method independent lag time.  
As this lag time is within the first part of the curve of the cumulative amount versus time curve, this is 
the non-steady state, transient part of the curve and thus a non-linear model must be used [19-23].  
 
Figure 6 gives the mean cumulative amount curve of pellitorine, quantified with UV (and hence co-
elution with anacycline), as well as with the MS detector. The two detection methods are compared 
here. From an analytical point of view, to determine the observable experimental lag time, the LoD 
and LoQ must be taken into account. The LoQ (μg) was calculated by multiplying the LoQ (μg/ml, 
corresponding to signal/noise=10) by the receptor fluid (i.e. 5 ml). 
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Figure 6. (A) Cumulative amount vs. time curves of pellitorine in the Anacyclus pyrethrum extract quantified 
using UHPLC-UV and UHPLC-MS (mean ± SEM, n=5), (B) Zoomed part of the curve. 
 
From the MS data, it appears that pellitorine already penetrated the skin after 2 hours and it can thus 
be assumed that pellitorine is present in the systemic blood circulation after 2h. Whereas when using 
UV, it seems likely that pellitorine penetrated the skin after a longer time, i.e. 8h. Significantly lower 
LoQ values (factor 22) were obtained with the single quad mass spectrometer, compared to UV.       
The initial transdermal behaviour of spilanthol, another important NAA [24-26], was also evaluated 
using UHPLC-MS. The in-silico calculated aqueous solubility of spilanthol was 18.63 mg/l [18]; hence 
sink conditions were maintained during the experiment. The cumulative amount curves of spilanthol 
versus time are shown in Figure 7.  
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Figure 7. Cumulative amount vs. time curves of spilanthol in the Spilanthes acmella extract (n=4) with (A) dose 
solution (DS) 0.233 mg/ml and (B) DS 1.34 mg/ml. 
 
With UV (237 nm), after 6h, spilanthol was still below the LoD (data not shown). The time after which 
a compound (in this case spilanthol) is above the LoQ also depends on the concentration used in the 
dose solution (a higher concentration in the DS results in higher cumulative amounts in the receptor 
fluid and the LoQ is achieved more quickly at lower time points). With the low concentration DS, 
spilanthol was above the LoQ after 3h, while already after 2h in case of the higher concentration DS.  
 
By using the single quad MS detector as application for the quantification of NAAs in transdermal 
research, it has been shown that more accurate lag times are obtained when using the single mass 
detector due to low LoQ values. Up till now, most researchers estimate the in vitro transdermal 
parameters (i.e. Jss, Kp,v, tlag) based upon visual determination of the linear part of the slope of the 
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graph of the cumulative absorbed dose and time, although other methods are possible to determine 
the permeability coefficient and lag time using non-linear regression [27]. However, as this “linear” 
method is subjective, large variations in time intercept are possible as a result of a minor variation in 
slope of SS. Moreover, if the concentration of the compound in the vehicle depletes in time or the 
concentration in the receptor compartment increases enormously (non-sink conditions) the slope 
method for the determination of the transdermal parameters will underestimate the permeability. In 
that case, more complex data analysis is needed. In addition, if the slope of the curve was used as a 
part of the curve in which SS conditions were not yet achieved, there will be an underestimation of 
permeability coefficient as well.  
In the literature, it is reported that permeability coefficient values obtained in vivo are larger than 
permeability coefficient values obtained in in vitro experiments. Moreover, the tlag, determined in in 
vitro experiments is not the same as the actual time needed to reach the systemic circulation in vivo. 
However, some caution is advised to simply adopt this, as there are often errors in in vitro 
experiments due to the visual determination of the slope and thus permeability coefficients are often 
underestimated [3, 8, 28].  
 
The previous described manner for the determination of the lag time in vitro is used to compare the 
transdermal behaviour of chemicals in vitro. In this way, it is possible to compare the time needed for 
compounds to penetrate the skin. As such, the compound which penetrated the skin the fastest can 
be selected. Compounds with the lowest lag time value are most desirable in therapeutics. However, 
there is no relevance between this in vitro determined lag time and the actual in vivo percutaneous 
absorption. The extrapolated lag time is simply an artificial derivation of the in vitro diffusion 
experimental test. In this study, another approach of the term ‘lag time’ was used and a more 
accurate lag time determination was possible, resembling more the in vivo percutaneous absorption 
time and thus of clinical relevance. Before steady state conditions, absorption of the compound has 
already started and hence the compound can already exert some biological functions in the human 
body. 
 
4. CONCLUSION  
This study has demonstrated the applicability of identifying and quantifying bioactive NAAs i.e. 
pellitorine, anacycline and spilanthol in complex plant extracts by using single quad MS detection. 
Besides calculation of skin parameters, information about the distribution in the skin was obtained 
by performing a FDC experiment with human skin. The single quad MS detector shows great 
advantages compared to the UV detector, as no baseline separation is necessary between the 
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compounds to be analyzed and lower LoD values are obtained. Additionally, a more accurate 
determination of the lag time can be achieved. In conclusion, UHPLC coupled to a single quad MS 
detector is a useful technique with additional advantages compared to traditional HPLC-UV in 
transdermal research of plant extracts. 
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CHAPTER V 
 
QUANTITATIVE IN VITRO 
AND IN VIVO EVALUATION 
OF INTESTINAL AND 
BLOOD-BRAIN BARRIER 
TRANSPORT KINETICS OF 
SPILANTHOL 
 
 “Try to learn something about everything and everything about something.”  
 
 
 Thomas Henry Huxley 
(°1825-†1895, English biologist) 
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Burvenich C, Risseeuw M, De Spiegeleer B. Mucosal and blood-brain barrier transport kinetics of 
the plant N-alkylamide spilanthol using in vitro and in vivo models. BMC Complementary and 
Alternative Medicine 2016;16:177.  
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ABSTRACT 
N-alkylamides (NAAs) are a large group of secondary metabolites occurring in more than 25 plant 
families which are often used in traditional medicine. A prominent active NAA is spilanthol. The 
general goal was to quantitatively investigate the gut mucosa and blood-brain barrier (BBB) 
permeability pharmacokinetic properties of spilanthol. Spilanthes acmella (L.) L. extracts, as well as 
purified spilanthol were used to investigate (1) the permeation of spilanthol through a Caco-2 cell 
monolayer in vitro, (2) the absorption from the intestinal lumen after oral administration to rats, and 
(3) the permeation through the BBB in mice after intravenous injection. Quantification of spilanthol 
was performed using a validated bio-analytical UHPLC-MS2 method. Spilanthol was able to cross the 
Caco-2 cell monolayer in vitro from the apical-to-basolateral side and from the basolateral-to-apical 
side with apparent permeability coefficients Papp between 5.2·10-5 and 10.2·10-5 cm/h. This in vitro 
permeability was confirmed by the in vivo intestinal absorption in rats after oral administration, 
where an elimination rate constant ke of 0.6 h-1 was obtained. Furthermore, once present in the 
systemic circulation, spilanthol rapidly penetrated the blood-brain barrier: a highly significant influx 
of spilanthol into the brains was observed with a unidirectional influx rate constant K1 of 796 
μl/(g·min). Spilanthol shows a high intestinal absorption from the gut into the systemic circulation, as 
well as a high BBB permeation rate from the blood into the brain.  
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CHAPTER V 
QUANTITATIVE IN VITRO AND IN VIVO 
EVALUATION OF INTESTINAL AND BLOOD-
BRAIN BARRIER TRANSPORT KINETICS OF 
SPILANTHOL 
Main focus in this chapter: 
 To explore the penetration behaviour of spilanthol through a Caco-2 cell monolayer and rat 
intestinal gut.  
 To evaluate the transport kinetics of spilanthol from blood-to-brain and from brain-to-blood.  
 
1. INTRODUCTION  
N-alkylamides (NAAs) are a large group of secondary metabolites occurring in more than 25 plant 
families, often used in traditional medicine and claimed to possess a diverse range of 
pharmacological activities such as antimicrobial, analgesic and anti-inflammatory properties [1-8]. 
The NAAs consist of a short-chain amine linked to an aliphatic chain of poly-unsaturated fatty acids 
through a central peptide amide bond. Spilanthol (affinin; deca-2E,6Z,8E-trienoic acid isobutylamide; 
F3M1 according to the FxMy classification of NAAs) is a highly abundant and biologically potent 
triene NAA found in Asteracea plants such as Spilanthes acmella. Traditionally, Spilanthes acmella 
plants are not only used as a food spice, in toothpastes and cosmetics, but have also been used in 
folk medicine for the treatment of toothaches, stomatitis, rheumatism, fever, fungal skin infections 
and diverse pain and neuropathic disorders [8]. The pharmacological central nervous system (CNS) 
activity and physiological mechanisms of spilanthol are only fragmentary documented. Chakraborty 
et al. (2004) and Barman et al. (2009) reported a central analgesic activity of a subcutaneously 
Spilanthes acmella extract in an in vivo rat tail flick experiment [9, 10]. Rios et al. (2007) showed that 
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a Heliopsis longipes extract, in which spilanthol was the main active compound, evoked cortical GABA 
(gamma-aminobutyric acid) release in an ex vivo in vitro mice brain-tissue study [11]. 
 
In order to exert these CNS effects, these compounds must be able to cross several physiological 
barriers in the human body. Using in vitro Franz diffusion cell (FDC) experiments, our group has 
already been shown that the N-alkylamide spilanthol can permeate the human skin and pig oral 
mucosa, reaching the systemic circulation after topical application. The permeability coefficient Kp,aq 
was 3.31·10-3 cm/h for human skin and 11.3·10-3 cm/h for the porcine buccal mucosa [12-14]. After 
oral administration, compounds must be able to pass through the intestinal barrier to reach the 
systemic circulation. Matthias et al. (2004) investigated the transport of mainly diene N-alkylamides 
from Echinacea (E. angustifolia and E. purpurea root) through a Caco-2 cell monolayer, which is a 
model of the intestinal barrier, and found that after 90 min, more than 50% of the NAAs permeated 
through the monolayer [15].    
 
Once present in the blood by passsage through the skin or mucosa, compounds can cross the blood-
brain barrier to exert central nervous system effects. This entry of compounds into the brain is 
strictly regulated and controlled: the BBB forms not only a physical barrier (tight junctions), but also a 
transport and metabolic barrier (enzymes) to maintain an adequate microenvironment of the 
neuronal cells [16]. A previous study indicated that tetraene NAAs from Echinacea appeared in the 
brains after a single oral dose of 2.5 mg/kg to rats [17].  
 
Up till now, there is no information about the transport kinetics of the 2,6,8-triene N-alkylamide 
spilanthol through the intestinal barrier after oral application and through the blood-brain barrier, 
once present in the blood. Therefore, the aim of this study was to quantitatively investigate the 
intestinal permeability (in vitro Caco-2 cell monolayer and in vivo oral gavage rat model) and the BBB 
transport kinetics (in vivo mice model) of spilanthol. Moreover, the distribution of spilanthol within 
the BBB, i.e. brain parenchyma versus endothelial cells, was investigated.  
 
2. MATERIALS AND METHODS  
Chemicals and reagents 
Ultrapure water (H2O) of 18.2 MΩ.cm quality was produced by an Arium 611 purification system 
(Sartorius, Göttingen, Germany). Vitamin E-TPGS, Hanks’ Balanced Salt Solution (HBSS), trypan blue, 
potassium chloride (KCl), dimethyl sulfoxide (DMSO), phosphate buffered saline (PBS), sodium 
chloride (NaCl), calcium chloride dehydrate (CaCl2.2H2O), sodium lactate, dichloromethane, sodium 
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hydrogen carbonate (NaHCO3), sodium sulphate (Na2SO4), sodium dihydrogen phosphate (NaH2PO4), 
hydrochloric acid (HCl) and urethane were purchased from Sigma-Aldrich (Diegem, Belgium), while 
bovine serum albumin (BSA), disodium hydrogen phosphate dehydrate (Na2HPO4.2H2O), sodium 
dihydrogen phosphate monohydrate (NaH2PO4.H2O), sodium hydrogen carbonate and absolute 
ethanol (≥ 99.9% V/V) were obtained from Merck KGaA (Darmstadt, Germany). Absolute ethanol 
(99.8% V/V), HPLC gradient grade methanol (MeOH) and acetonitrile (ACN) came from Fisher 
Scientific (Erembodegem, Belgium). Dextran was obtained from AppliChem GmbH (Darmstadt, 
Germany). UPLC-MS grade MeOH and ACN were bought from Biosolve (Valkenswaard, the 
Netherlands). Phosphoric acid (85%) (H3PO4) and dimethylacetamide were purchased from Jansen 
Chimica (Geel, Belgium). Trypsin-EDTA was obtained from Invitrogen (Ghent, Belgium). Calcium 
dichloride (CaCl2), LC-MS grade formic acid (FA), polyethylene glycol 400 (PEG 400), tween 80, D-
glucose, sodium hydroxide (NaOH) and HEPES were purchased at Fluka (Diegem, Belgium) while 
propylene glycol (PG) was bought from Riedel-de Haën (Seelze-Hannover, Germany). Triethylamine, 
decanoyl chloride and isobutylamine were purchased at Acros Organics (Geel, Belgium). The BBB-
positive control dermorphin was purchased at Bachem (Bubendorf, Switzerland). NMR solvents were 
bought from Eurisotop (Saint-Aubin, France). 
 
Products examined  
The ethanolic Spilanthes acmella (L.) L. flowers extract (batch 0001853516, 30% w/w spilanthol in 
ethanol) was obtained from Robertet (Grasse, France) and was used for the BBB transport assay. 
Spilanthes acmella (L.) L. is also known as Akarkara (local name) and Para Cress (English name). HPLC 
analysis confirmed the spilanthol content, as well as a small quantity (9%) of other NAAs [14]. The 
Spilanthes acmella (L.) L. extract (A. Vogel, label claim indicated 2% w/w dry residue of extracts in 
69% V/V ethanol; internal assay: 0.11% w/w spilanthol, purity >90%) came from Bioforce AG 
(Switzerland) and was used for the oral gavage experiment.   
Purified spilanthol was used for the Caco-2 cell permeability assay. Semi-preparative HPLC was used 
for its purification as follows: the Spilanthes acmella (L.) L. extract of Robertet was dissolved in 30:70 
(V/V) H2O:ethanol and filtered using a 0.45 μm nylon HPLC filter (Whatman). One ml of this solution 
was injected on a Vydac C18 monomeric semi-preparative column (Grace, 250 mm x 10 mm, 5 μm 
particle size, 300 Å pore size) using a Waters HPLC, equipped with a Waters 2487 Dual Absorbance 
Detector. The sample compartment and column temperature were maintained at room temperature. 
An isocratic elution mode was used with a 50:50 (V/V) A:B (A: 0.1% FA in H2O and B: 0.1% FA in 
MeOH) mobile phase. A flow rate of 6.0 ml/min was used and UV detection was performed at 237 
nm. Fractions between 16 and 32 min retention time were collected and lyophilized using a Christ 
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Gamma 1-16 LSC freeze-dryer (Q-lab, Vilvoorde, Belgium). The purity of the isolated spilanthol was 
determined by analytical HPLC-UV at 237 nm [12] and was 99.9%.  
As analytical internal standard (IS) in the bio-analytics, isobutyldecanamide was used and synthesised 
as described in Figure 1. The NMR spectra of this internal standard can be retrieved in the 
Supplementary information S1.  
 
 
Figure 1. Synthesis of isobutyldecanamide (analytical internal standard).  
 
Triethylamine (6.0 mmol, 608 mg, 837 μl) was added to a solution of isobutylamine (6.0 mmol, 439 
mg, 597 μl) in dichloromethane (30 ml). The mixture was cooled to 0°C using an ice bath. Decanoyl 
chloride (5.0 mmol, 954 mg, 1.0 ml) was slowly added to the solution. The mixture was stirred 
overnight, allowing the temperature to rise to room temperature. The reaction mixture was 
extracted with 50 ml dichloromethane which was washed successively with HCl (1.0 M aq.) and 
NaHCO3 (sat. aq.). The organic layer was dried on Na2SO4, filtered and concentrated in vacuo to yield 
the title compound (1.07 g, 4.7 mmol) as an off-white waxy solid. The compound was identified by 1H 
and 13C NMR recorded with a Varian Mercury-300BB (300/75 MHz) spectrometer. Chemical shifts are 
given relative to tetramethylsilane (0 ppm) 1H NMR (300 MHz, CDCl3): δ 5.47 (s, 1H), 3.07 (t, J = 6.45 
Hz, 2H), 2.16 (t, J = 7.44 Hz, 2H), 1.80-1.69 (m, 1H), 1.68-1.58 (m, 2H) 1.38-1.18 (m, 12H), 0.90 (d, J = 
6.90 Hz, 6H), 0.87 (t, J = 6.90 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 173.25, 46.92, 37.16, 32.00, 29.61, 
29.51, 29.47, 29.41, 28.67, 26.05, 22.80, 20.24, 14.24. 
 
In vitro permeation study in Caco-2 cell monolayers 
Cell culture  
Caco-2 cells, originating from a human colorectal carcinoma were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) at 95% humidity and 37°C in an atmosphere of 5% CO2, supplemented with 
10% (V/V) fetal bovine serum, 2 mM L-glutamine and 1% non-essential amino acids (100x), 100 U/ml 
penicillin and 100 μg/ml streptomycin (all from Invitrogen/GIBCO, Ghent, Belgium).   
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Caco-2 cell permeability assay    
The Caco-2 cell intestinal model was used as a model for the gut mucosa to investigate the 
permeation of spilanthol. Caco-2 cells were seeded at a density of 2.6·105 cells/cm² cells for each 
Transwell (Corning Costar, New York, USA) membrane insert filter (0.4 μm pore size, 12 mm filter 
diameter) and cultivated in the described supplemented DMEM, also containing 100 units/ml 
penicillin and 100 μg/ml streptomycin. The medium was changed every second day. The cells were 
allowed to grow and differentiate for 21-29 days until monolayers were formed. Intact 
membranes/integrity of the monolayers were checked via the measurement of transepithelial 
electrical resistance (TEER) of the monolayers using the Millicell-ERS system (Millipore Corp., 
Bedford, MA, USA) before and after transport experiments. The experiment was performed in 
duplicate for each dose solution. Transport experiments were carried out in the apical-to-basolateral 
(ab) direction and in the basolateral-to-apical (ba) direction in Hanks’ Balanced Salt solution, 
according to Hubatsch et al. (2007) [18]. Two dose solutions of purified spilanthol at 10 μg/ml were 
tested, differing in solvent: 0.5% ethanol (further indicated as DS1) and 0.5% of a mixture of vitamin 
E-TPGS (33.3%), ethanol (11.1%), PEG 400 (33.3%) and PG (22.2%) (further indicated as DS2) 
dissolved in HBSS.  
 
Final volumes of 0.4 ml apically and 1.2 ml basolaterally were used for 12-mm filter supports during 
the transport experiment. Samples were taken at 15, 30, 60, 90 and 120 min from the acceptor (= 
receiver) compartment (basolateral to apical transport: 100 μl; apical to basolateral transport: 300 
μl) and were immediately replaced by fresh HBSS. At the last time point, a sample from the donor 
compartment was taken as well, allowing to obtain the mass balance, which for spilanthol ranged 
between 104.7 and 120.9% total recovery. Atenolol (50 μM) and propranolol (20 μM) were used as 
the low- and high-permeability control, respectively, confirming the validity of the test [19]. 
Quantification of spilanthol was conducted using the ultra high performance liquid chromatography – 
tandem mass spectrometry (UHPLC-MS²) method as described below.  
 
The apparent permeability coefficient (Papp in cm/s) of spilanthol was calculated from a non-sink 
equation. From Fick’s first law: Jൌ െ ൈ ሾሺሻሿȀ (D is the diffusion coefficient, J is the flux or 
transfer rate along the donor-to-receptor side, x is the distance from the donor compartment and 
C(x) is the concentration in the barrier at the coordinate x in the barrier), the following differential 
equation is derived: ୰ሺሻȀ ൌ ୟ୮୮ ൈ  ൈ ሾୢሺሻ െ ୰ሺሻሿ, in which Mr is the amount of 
substance in the receiver chamber, Papp is the apparent permeability coefficient (a product of 
distribution coefficient with diffusion coefficient divided by the barrier thickness), A is the cross-
sectional area of the barrier, Cd is the donor concentration and Cr is the receiver concentration. This 
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differential equation is the basis to calculate Papp values of compounds requiring sink, as well as non-
sink conditions with different initial conditions to solve this equation. In the case of non-sink 
conditions, this resulted in the following solution [18-20]: 
୰ሺሻ ൌ ൤

ୢ ൅ ୰
൨ ൅ ൬୰ǡ୲ିଵ ൈ  െ ൤

ୢ ൅ ୰
൨൰ ൈ 
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ሻൈο୲ 
in which t is the time (s), Vd is the volume of the donor compartment (ml), Vr the volume of the 
receiver compartment (ml), A the area of the filter (= 1.12 cm²), M the total amount of spilanthol in 
the system at time t (μg), Cr,t-1 the concentration of spilanthol in the receiver compartment at the 
previous time point (μg/ml), f is the sample replacement dilution factor (1-Vs/Vr with Vs is the sample 
volume), 't is the time at time t minus the previous time point (s) and Cr(t) the concentration of 
spilanthol in the receiver compartment at time t (μg/ml). Non-linear curve fitting by minimisation of 
the sum of squared residuals (SSR) was used to obtain the Papp. The efflux ratio is calculated as 
Papp,ba/Papp,ab, while the uptake ratio is calculated as Papp,ab/Papp,ba. 
 
In vivo pharmacokinetic experiment with rats 
Animals    
The Wistar rats were bred in Bharat Serum and Vaccines pvt. Ltd, Thane, India (registration number 
103/99/CPCSEA) and kept for the experiments at C. U. Shah College of Pharmacy, SNDT Women’s 
University, Santacruz, Mumbai, India (registration number 39/99/CPCSEA). The half of the rats used 
in the experiment were female rats and the other half male rats. Rats of 7-8 weeks old, weighing 220 
g, and fasted overnight were used for the experiment.  
 
Pharmacokinetic experiment   
The pharmacokinetic oral gavage experiment was carried out at C. U. Shah College of Pharmacy, 
SNDT Women’s University, Santacruz, Mumbai, India. A spilanthol dose solution was prepared with 
the Spilanthes acmella (L.) L. extract (A.Vogel). 1.5 ml of a spilanthol dose solution of 0.73 mg 
spilanthol/g dose solution in 10:20:30:40 (w/w/w/w) ethanol:PG:vitamin E-TPGS:PEG400 was 
administered to the rats using a gavage needle made up of stainless steel (length 3 inches and 2.5 
mm internal diameter). A blank dose solution was used as well, containing ethanol, PG, vitamin E-
TPGS and PEG without spilanthol. For each dose solution, six rats were used of which three were 
females and three males. Blood was collected (1.5 ml) from the retro orbital vein at specified time 
points i.e. 1, 2, 3, 4, 6, and 8h after oral administration of the dose solution. The collected blood 
samples were centrifuged using a Remi R-24 centrifuge. At the end of the study, the animals were 
sacrificed by CO2 inhalation. All samples were immediately frozen at -80°C until bio-analysis. The 
elimination rate constant was calculated using a one compartmental model using GraphPad software 
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(La Jolla, USA), using the following equation: ሺሻ ൌ ଴ ൈ ି୩౛ൈ୲, in which t is time (h), C0 the 
concentration of spilanthol at time t=0 (ng/ml), C(t) the concentration of spilanthol at time t and ke 
the elimination rate constant (h-1). The elimination half-life (h) is computed as ln(2)/ke.  
 
In vivo blood-brain barrier experiment with mice 
Animals    
Female, Institute for Cancer Research, Caesarean Derived-1 (ICR-CD-1) mice (Harlan Laboratories, 
Venray, the Netherlands) of age 7-10 weeks and weighing 29-32 g, were used during the BBB 
transport experiments. All animal experiments were performed in accordance with the Ethical 
Committee principles of laboratory animal welfare as approved by our institute (Ghent University, 
Faculty of Veterinary Medicine, no. EC2012/157 and no. EC2014/128). 
 
Blood-to-brain transport 
An in vivo multiple time regression (MTR) analysis was performed to investigate if spilanthol was able 
to cross the BBB. A dose solution of spilanthol was prepared using the Spilanthes acmella (L.) L. 
extract (Robertet) with a final concentration of 4 mg/ml spilanthol dissolved in 7.0% ethanol, 2.5% 
dimethylacetamide, 0.6% tween 80 (all w/w) diluted in lactated Ringer’s solution containing 1% BSA. 
The ICR-CD-1 mice were anesthetized by intraperitoneal injection with a 40% (w/V) urethane solution 
(3 g/kg) and the jugular internalis vein and carotid artery were isolated, 20 μl of the spilanthol dose 
solution was injected into the jugular vein. Blood was obtained from the carotid artery at regular 
time points after injection (1, 3, 5, 10, 12.5 and 15 min, with start and end in duplicate), and the mice 
were immediately thereafter decapitated. After sacrificing the mice, the brains were collected. The 
collected blood from the carotid artery was centrifuged at 10 000 g for 15 min at 21°C, resulting in 
serum. In order to assure the validity of the MTR method, 125I-BSA and dermorphin diluted in lactated 
Ringer’s solution containing 1% BSA were used as the negative and positive control, respectively [21-
23]. Furthermore, to evaluate the functional BBB integrity under our experimental conditions, 125I-
BSA was also administered to the mice in a solution containing the same surfactant and co-solvents 
in equal concentrations as in the spilanthol dose solution. The serum profile of spilanthol was plotted 
against the time (expressed in min). The curve was fitted using the same one compartmental model 
as previously described in the pharmacokinetic section of the in vivo experiment using rats. In order 
to determine the BBB permeability of a compound, the ratio of the brain and serum concentration 
(μl/g) was plotted versus a derived time variable, i.e. the exposure time (Ʌ) of the Gjedde-Patlak plot 
[24, 25].  
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The exposure time is defined as the integral of the concentration of spilanthol in serum from start 
(t=0 min) to time T, divided by the concentration of spilanthol in serum at time T: 
Ʌ ൌ ׬ େ౩ሺ୲ሻήୢ୲େ౩ሺ୘ሻ
୘
଴ . The integral of the concentration of spilanthol in serum from zero to time T is the area 
under the curve until time T.                 
A biphasic model of blood-brain transfer was used to fit the uptake, as elaborated by Wong et al. 
(1986) [26]:  
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where K1 is the unidirectional clearance (μl/(g·min)), K is the net clearance (μl/(g·min)), Vg the tissue 
brain distribution volume (μl/g), and V0 the vascular brain distribution volume (μl/g). The negative 
control BSA has a low vascular distribution volume and this value (14.8 μl/g) is used as V0 to calculate 
the brain kinetic parameters of spilanthol. In the equation, Cbrain(T) is the concentration of spilanthol 
in the brain at time T (ng/g) and Cs(T) the concentration of spilanthol in serum at time T (ng/μl).  
 
Capillary depletion 
To investigate the distribution of spilanthol in the parenchyma and capillaries of the brain, a capillary 
depletion experiment was performed. By means of this experiment, it is possible to distinguish the 
transport of spilanthol into the brain (represented by the parenchyma) and part of spilanthol which is 
trapped by the endothelial cells of the brain (represented by the capillaries). The method of Triguero 
et al. (1990), as modified by Gutierrez et al. (1993), was used [27-29]. Briefly, after anesthetizing the 
mice intraperitoneally with 40% (w/V) urethane solution (3 g/kg), 20 μl of the 4 mg/ml spilanthol 
dose solution was injected into the jugular vein. Blood was collected from the abdominal aorta ten 
min after injection and serum was obtained by centrifuging the blood at 10 000 g during 15 min at 
21°C. Immediately after blood collection, the skin of the mice’s chest is removed to clamp the aorta 
and the jugular veins are severed. Immediately after clamping the aorta, the brain is perfused 
manually with 20 ml of Lactated Ringer’s solution. The mice are decapitated immediately after 
perfusion and brain is collected. The brains were put into an Eppendorf tube and weighed. 525 μl ice-
cold capillary buffer (10 mM HEPES, 141 mM NaCl, 4 mM KCl, 2.8 mM CaCl2, 1 mM MgSO4, 1 mM 
NaH2PO4 and 10 mM D-glucose adjusted to pH 7.4) was added and homogenized. Then, 1000 μl of 
26% ice-cold dextrane solution in capillary buffer was added and vortexed. The Eppendorf tube was 
centrifuged at 20 000 g for 60 min at 4°C. Pellet (capillaries) and supernatant (parenchyma and fat 
tissues) were separately collected into an Eppendorf tube and weighed. The sample preparation of 
the pellet is the same sample preparation method as used for the mice brains, while the sample 
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preparation for the supernatant is the same sample preparation method as used for mice serum, as 
further described in the section ‘bio-analytics’. 
 
The distribution was calculated as follows:  
	ሺΨሻ ൌ
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where Mtissue represents the amount of spilanthol in the capillaries, respectively parenchyma; 
Mcapillaries the amount of spilanthol in the capillaries and Mparenchyma the amount of spilanthol in the 
parenchyma.  
 
Brain-to-blood transport 
To evaluate the efflux of spilanthol out of the brain, an in vivo method previously described was used 
[27]. Briefly, after anesthetizing the ICR-CD-1 mice using a 40% (w/V) urethane solution (3 g/kg), the 
skin of the skull was removed. Thereafter, a hole was made into the lateral ventricle using a 22 G 
needle marked with tape at 2 mm at the following coordinates: 1 mm lateral and 0.34 mm posterior 
to the bregma. 1 μl of the 4 mg/ml spilanthol dose solution as used for the blood-to-brain influx 
experiment was injected intracerebroventriculary (ICV) using a syringe pump (KDS100, KR analytical, 
Cheshire, UK) at a speed of 360 μl/h for 10 s. At specified time points post-injection (1, 3, 5, 10, 12.5 
and 15 min), mice were decapitated. Prior to decapitation, blood was collected from the abdominal 
aorta. Serum was obtained by centrifuging the blood at 10 000 g during 15 min at 21°C and brains 
were collected. The efflux brain half-life (t1/2,brain) (min) was calculated from the linear regression of 
the natural logarithm of the spilanthol concentration in brain (ng/g) versus time as follows: t1/2,brain = 
ln(2)/kout, where kout (min-1) is defined as the efflux rate constant calculated as the negative value of 
the slope of the linear regression, applying first order kinetics. 
 
Bio-analytics  
Serum sample preparation 
60 μl of the serum samples, 60 μl of 4% (V/V) aqueous H3PO4 solution and 30 μl of the IS solution 
were transferred into a 0.5 ml (LoBind Eppendorf) tube and vortexed. Interfering compounds were 
removed by solid phase extraction using a positive pressure-96 processor (Waters). 100 μl (rat 
serum) or 125 μl (mice serum) of the previous sample solution was loaded on the HLB Oasis® 
μelution 96 well plate (Waters, Zellik, Belgium), which was preconditioned with 200 μl of MeOH and 
equilibrated using 200 μl of ultrapure water. After the loading step, the HLB Oasis® μelution plate 
was washed using 200 μl of 5% MeOH in H2O followed by 200 μl of 20% MeOH in H2O. Spilanthol was 
eluted using two times 25 μl ACN. To the eluate, 25 μl of a 80:20 (V/V) H2O:MeOH solution was 
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added and analysed with a UHPLC-MS² method, as described further in the section ‘UHPLC-MS² 
method’. 
 
A limited validation of the bio-analytical method for the quantification of spilanthol in serum was 
performed, based upon the EMA guideline on bio-analytical method validation 
(EMEA/CHMP/EWP/192217/2009), with limited replicates and concentration levels [30]. The limit of 
detection (LoD) (S/N=3) and limit of quantification (LoQ) (S/N=10) of spilanthol, determined on the 
reference standard, were calculated as 0.09 ng/ml and 0.31 ng/ml, respectively, which correspond to 
0.17 ng/ml and 0.58 ng/ml in rat serum, respectively. The LoD and LoQ of spilanthol in mouse serum 
were 0.048 ng/ml and 0.16 ng/ml, respectively. A matrix factor of 1.1 was observed for spilanthol in 
rat and mouse serum. The quantification of spilanthol in the rat serum samples was performed using 
a matrix spiked calibration curve (R²=0.9998). Linearity was assured in a working range from 0.31 
ng/ml up to 101 ng/ml, corresponding to 0.58 ng/ml to 189 ng/ml in rat serum. The quantification of 
spilanthol in the mouse serum samples was performed using a one-point calibration curve with a 
spilanthol standard in 40:33.33:26.67 (V/V/V) MeOH:ACN:H2O. The accuracy of the references used 
for the calibration curves with the pre-extracted spiked matrix samples and the QC reference pre-
extracted spiked matrix samples conformed to the specification limits (< 15% of the nominal value 
and for the lower limit of quantification (LLoQ) < 20% of the nominal value), except for the LLoQ used 
for the validation of spilanthol in mouse serum (> 20% of the nominal value). These values are slightly 
higher than the specification limits given by the EMA in their guidelines for formal bio-analytical 
method validation, but are still acceptable for our purposes in the discovery phase. Precision was 
expressed as the coefficient of variation (CV). The within-run CV value did not exceed 15% for the 
pre-extracted spiked matrix samples. Also the LLoQ did not exceed 20% and are thus all conform to 
the specification limits. The recovery in rat serum was 102.1% (18.8 ng/ml to 189 ng/ml in serum 
concentration range), calculated from the slopes of the pre-extracted and post-extracted spiked 
matrix samples. The recovery in mouse serum was 113.3% (3 to 257 ng/ml in serum concentration 
range). No significant carry-over was observed (< 20% of LLoQ spilanthol and < 5% for IS). The 
selectivity was conform to the specification limits (placebo rat serum < 20% of LLoQ spilanthol and < 
5% for IS). 
 
Brain sample preparation 
For the analysis of the mice brain samples, the weighed brains were transferred into a test tube and 
crushed. 1.0 ml of the IS solution in ACN was added, followed by shaking during 4h at 110 rpm at 
room temperature using an Eppendorf centrifuge 5810 (Eppendorf, Rotselaar, Belgium). The test 
tube was centrifuged at 250 g for 5 min and 800 μl of the supernatant was transferred into an 
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Eppendorf tube. Thereafter, a second centrifugation was performed at 20 000 g during 5 min at 
room temperature. 750 μl of the supernatant was evaporated to dryness under nitrogen and 175 μl 
90:10 (V/V) H2O:ACN was added to redissolve spilanthol. Thereafter, 160 μl of this solution was 
loaded on the HLB Oasis® μelution 96 well plate. The same washing and elution steps were used as 
for the serum samples.  
 
Again, a limited validation of the bio-analytical method for the quantification of spilanthol in brains 
was performed, based upon the EMA guideline on bio-analytical method validation 
(EMEA/CHMP/EWP/192217/2009), with limited replicates and concentration levels [29]. The LoD and 
LoQ of spilanthol were 6.30 pg/g in brain and 21.0 pg/g in brain, respectively. Ion enhancement 
(matrix factor = 1.38 > 1) was observed for the quantification of spilanthol in mice brains. Hence, 
quantification of spilanthol in the brain samples was performed using the matrix spiked calibration 
curve (R²=0.9986). Linearity was assured in a working range of 0.107 ng/ml to 175 ng/ml spilanthol, 
corresponding to 21.0 pg/g to 34.3 ng/g in brain. The accuracy of the references used for the 
calibration curves with the pre-extracted spiked matrix samples conformed to the specification limits 
(< 15% of the nominal value), except for the LLoQ used for the validation of spilanthol in brains (> 
20% of the nominal value), but was still acceptable for our purposes in the discovery phase. The 
within-run CV value did not exceed 15% for the pre-extracted spiked samples. Also the LLoQ did not 
exceed 20% and are thus all conform to the limits. The recovery in mouse brains was 72.7% (0.92 to 
98.10 ng/g brain concentration range). 
 
UHPLC-MS² method   
Quantification of spilanthol was performed using a UHPLC-MS² method, which was developed on an 
Acquity UPLC coupled to a Xevo™ TQ-S mass spectrometer (MS) (Waters, Zellik, Belgium) with 
electrospray ionisation source and a triple quadrupole mass analyser. An Acquity UPLC RP C18 
column (Waters, 50 x 2.1 mm, 1.7 μm) with a suitable guard column was used. The sample 
compartment was kept constant at 5°C, while the column temperature was maintained at 30°C. 2 μl 
of the sample was injected and the flow rate was set to 0.5 ml/min. A mobile phase was applied 
using solvent A (0.1% FA in 30:70 (V/V) H2O:MeOH) and solvent B (0.1% FA in MeOH) in gradient 
mode as follows: 0-1.6 min 100:0 (V/V) A:B, 1.6-2 min going from 100:0 (V/V) A:B to 0:100 (V/V) A:B, 
2-3 min 0:100 (V/V) A:B, 3-3.4 min going from 0:100 (V/V) A:B to 100:0 (V/V) A:B, 3.4-5 min 100:0 
(V/V) A:B. The needle wash solvent was 60:40 (V/V) DMSO:ACN. The MS was operated in the positive 
electrospray ionisation mode (ESI+), with an optimised capillary voltage of 3.0 kV, cone voltage of 50 
V and source offset of 60 V. Source and desolvation temperatures were set at 150°C and 500°C, 
respectively, while cone and desolvation gas (N2) flows were 180 and 1000 l/h, respectively. 
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Acquisition was performed in the multiple reaction monitoring (MRM) mode with m/z 222.15 to m/z 
80.96 transition. The applied collision energy was 20 eV (collision gas = argon). Data were acquired 
and analysed through MassLynx® software (V4.1 SCN 843, Waters).  
 
3. RESULTS  
Caco-2 cell permeability 
Propranolol was used as a positive control and a Papp,ab value of 19.1·10-6 cm/s was obtained, which is 
in good agreement with the values reported in literature [31]. Atenolol served as the negative 
control and a lower permeability was observed compared to propranolol. Spilanthol was able to 
diffuse through the Caco-2 cell monolayer from the apical-to-basolateral side, as well as from the 
basolateral-to-apical side. Figure 2 shows the percentages of spilanthol permeated through the Caco-
2 cells versus time plot with DS1 and DS2.  
 
 
Figure 2. The percentages of spilanthol from the applied dose solutions using dose solution 1 (DS1) and dose 
solution 2 (DS2) which permeated through the Caco-2 cells monolayer in the course of time. Apical-to-
basolateral transport and basolateral-to-apical transport experiments of spilanthol were performed in 
duplicate (individual results in the same figure). 
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The percentage of the applied spilanthol which permeated through the Caco-2 cells from the apical-
to-basolateral membrane after 120 min is 79.8% (or 3.20 μg spilanthol) with DS1 and 64.3% (or 2.47 
μg spilanthol) with DS2. In the opposite direction, the percentage of spilanthol which permeated 
through the Caco-2 cells from the basolateral-to-apical membrane after 120 min is 32.1% (or 3.86 μg 
spilanthol) with DS1 and 21.6% (or 2.49 μg spilanthol) with DS2.  
The apparent permeability coefficient (Papp) of spilanthol obtained with DS1 and DS2 from the apical-
to-basolateral side is 8.42 ± 0.59·10-5 cm/s (mean ± SD, n=2) and 5.61 ± 0.54·10-5 cm/s (mean ± SD, 
n=2), respectively. The Papp of spilanthol obtained with DS1 and DS2 was also determined from the 
basolateral-to-apical side and is 10.21 ± 0.46·10-5 cm/s (mean ± SD, n=2) and 5.20 ± 0.06·10-5 cm/s 
(mean ± SD, n=2), respectively. The efflux ratio for spilanthol with DS1 and DS2 is 1.21 and 0.93, 
respectively, while the uptake ratio for spilanthol with DS1 and DS2 is 0.82 and 1.08, respectively.  
 
Oral gavage experiment 
Figure 3 represents the rat serum data after oral gavage of spilanthol, fitting a one compartmental 
model with the mean concentration of spilanthol at each time point. These results of the in vivo 
experiment confirm the in vitro Caco-2 cell monolayer results of spilanthol. 
 
 
Figure 3. Concentration of spilanthol in rat serum (ng/ml) as a function of time (h) after oral gavage of 
spilanthol. Data are fitted according to a one compartmental model (n=3, mean, error bars: SEM). 
 
From these data, the elimination rate constant and the elimination half-life were calculated as 0.61  
h-1 and 1.13 h, respectively.  
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Blood-brain barrier transport kinetics of spilanthol 
The blood-to-brain transport of spilanthol was investigated. The negative and the positive control 
confirmed the validity of the BBB test. BSA is known to be a vascular marker, while dermorphin is 
regarded as the positive control as the BBB influx is higher compared to BSA. However, the brain 
influx of BSA can be explained by the fact that iodinated BSA showed nonspecific binding to cerebral 
capillaries compared to the tritiated from. Both controls are included in the experiment as a system 
suitability test [22, 23, 32]. The K1 value of BSA (negative control) was 0.12 μl/(g·min), while the K1 
value of the positive control dermorphin was 0.26 μl/(g·min), both consistent with previous data [27, 
33]. The multiple time regression data indicated that spilanthol crosses the blood-brain barrier. In 
Figure 4, the ratio of the concentration of spilanthol in brain and serum is plotted versus the 
exposure time. Furthermore, the kinetic influx data of 125I-BSA with or without the surfactant/so-
solvents were not significant different, indicating that the surfactant and co-solvents did not affect 
the BBB integrity (data not shown).    
 
 
Figure 4. Blood-to-brain transport (multiple time regression experiment) results of spilanthol, BSA and 
dermorphin in mice. The ratio of spilanthol concentration in brain versus serum (μl serum/g brain) is plotted 
versus the exposure time (min). Start and end point were performed in duplicate. The data were fitted using a 
biphasic model. 
 
The MTR data of spilanthol were fitted using a biphasic model, based on the modified Gjedde-Patlak 
equation according to Wong et al. (1986) [26]. A rapid but highly significant influx of spilanthol into 
the brains was observed with a unidirectional influx rate (K1) of 796 μl/(g·min). The tissue brain 
distribution volume (Vg) is 652 μl/g.  
The curve reached a plateau-phase after about 10 min exposure time and can be explained by efflux 
of spilanthol out of the brain.  
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At the same time, also the elimination kinetics of spilanthol in serum were evaluated in the mice 
model. The serum profile of spilanthol follows a one compartmental model. The concentration of 
spilanthol at time zero was 3.05 μg/ml and an elimination rate constant and elimination half-life of 
0.22 min-1 and 3.16 min were obtained. 
 
Capillary depletion 
The capillary depletion method was used to study the distribution of spilanthol i.e. the part that was 
taken up by the brain and the part which was trapped in the endothelial cells of the brain capillaries. 
A high brain penetration of spilanthol was found: about 98% of spilanthol (corresponding to 137.8 
μl/g) was found in the brain parenchyma and only about 2% of spilanthol (corresponding to 2.4 μl/g) 
that entered the brain remained in the brain capillaries. 
 
Brain-to-blood transport kinetics of spilanthol 
The efflux properties of spilanthol out of the brain were investigated by quantifying the 
concentration of spilanthol in the brain after intracerebroventricular injection of the dose solution. 
When evaluating the transport of spilanthol out of the brain into the blood, it is confirmed that there 
is also efflux of spilanthol (Figure 5), which can explain the rapid plateauing observed when 
evaluating the blood-to-brain kinetics during the influx experiment (Figure 4). The efflux transfer 
constant kout was derived from the absolute value of the slope of the natural logarithm of the 
concentration of spilanthol in the brain (ng/g) versus the experimental time curve (min). The kout 
calculated for spilanthol was 0.11 min-1, equal to a t1/2,brain of 6.4 min.  
 
 
Figure 5. Brain-to-blood transport results of spilanthol in mice. The natural logarithm of the concentration of 
spilanthol in the brain (ng/g) in function of the time (min) is given. 
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4. DISCUSSION  
In this study, the in vitro Caco-2 cell monolayer permeability of spilanthol, a 2,6,8-triene NAA, was 
investigated using two different dose solutions. The permeation level of spilanthol through Caco-2 
cells was the highest from the apical-to-basolateral side: 64-80% of the applied DS permeated 
through Caco-2 cells after 120 min (absorptive direction). Spilanthol, applied as DS2, did not appear 
to better permeate the Caco-2 cells compared to spilanthol applied as DS1, suggesting that co-
solvents (vitamin E-TPGS, PEG 400, PG) did not enhance the permeation of spilanthol through the cell 
monolayer. Both dose solutions did not contain more than 0.5% ethanol in buffer, as final ethanol 
concentrations above 2% can damage the Caco-2 cell monolayer. 
As mentioned earlier, Matthias et al. (2004) investigated a different type of NAA, namely the 
transport of 2-ene and 2,4-diene NAAs through the Caco-2 cell monolayer (dissolved in ethanol and 
diluted in HEPES buffer, final ethanol concentration did not exceed 2%) with Papp values ranging from 
3·10-6 to 3·10-4 cm/s. The diversity in Papp for the different N-alkylamides was correlated to structural 
variations, with saturation and N-terminal methylation contributing to lowered Papp values [15].  
The Papp values obtained for spilanthol in this study were all above 1·10-6 cm/s, indicating an almost 
complete intestinal absorption. Compounds with Papp values < 1·10-6 cm/s show a less readily 
absorption. The Papp values obtained for spilanthol in this study (5·10-5 to 10·10-5 cm/s) are thus 
consistent with the structural conclusions reported by Matthias et al. (2004) based on the mono- and 
diene-NAAs from Echinacea plant species [15].  
It has been reported that if there is a more than 2-fold difference in Papp values between the apical-
to-basolateral and the basolateral-to-apical direction, a high probability of active transport exists 
[34]. In this experiment, for both dose solutions of spilanthol, this difference was less than 2-fold, 
indicating that no active transport function can be readily assumed. Studies have proven a 
correlation between drug permeability coefficients obtained during a Caco-2 cell monolayer 
experiment and oral absorption in humans [31, 35, 36]. However, as no in vitro model can yet totally 
mimic the in vivo intestinal barrier, since many factors such as solubility, formulation, chemical 
composition, pH of the intestinal secretions, food composition, gastric emptying time, intestinal 
motility and blood flow play a role [34, 37, 38], an oral gavage experiment in rats was conducted to 
evaluate the intestinal barrier properties of spilanthol in vivo. Rats are one of the most common 
animals used in preclinical oral absorption studies and are generally considered as good animal 
models towards humans (e.g. F1 modifying factor in permitted daily exposure (PDE) toxicity 
evaluation is 5 for extrapolation from rats to humans) [37, 39]. Several studies have already shown 
that there is a good correlation between the absorption of compounds in rat and the absorption in 
humans [37, 38, 40]. Spilanthol was orally administered to rats in a liquid dose solution containing 
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the same solvents as used for DS2 of the Caco-2 cell permeability experiment, consisting of ethanol, 
PG, vitamin E-TPGS and PEG400. For the absorption rate, the formulation plays an important role and 
compounds solubilized in liquid generally absorb faster compared to solid forms. The elimination 
phase, on the contrary, is independent of the oral dosage form. Vitamin E-TPGS, an esterified vitamin 
E derivative, was added to the formulation because of its solubilizing and emulsifying properties to 
enhance the solubility and facilitate the absorption of spilanthol [41, 42]. In this in vivo study, 
spilanthol was clearly observed in the rat serum and hence, spilanthol was able to diffuse through 
the gut barrier into the systemic circulation, confirming the in vitro Caco-2 cell results. Spilanthol 
showed an elimination half-life of 1.13h (63 min), corresponding to similar values reported by 
Woelkart et al. (2009), who investigated the plasma concentration of dodeca-2E,4E,8E,10E/Z-
tetraenoic acid isobutylamides from Echinacea via oral gavage in rats, resulting in an elimination half-
life of 72 min [17].        
Besides the lipophilicity of the compound, its passive gut-blood permeability is dependent on the 
charge and molecular size of the compound. Considering the lipophilic LogP value of 3.39 of 
spilanthol and the molecular weight of 221.34 g/mol, it seems that transcellular transport is 
appropriate for spilanthol [43]. These findings were confirmed in the Caco-2 cell permeability 
experiment, which indicated that spilanthol diffused through the cells via passive diffusion. Once in 
the systemic circulation, the investigated compound can distribute to extravascular compartments 
such as the brain to exert CNS activity.  
 
Therefore, the present study investigated the blood-brain barrier transport properties of spilanthol in 
an in vivo mice experiment. In kinetic BBB research, one of the ‘golden’ methodologies is the MTR 
using mice for reasons of costs, handling and animal care. In PDE toxicity evaluation, the F1 
modifying factor is 12 for extrapolation from mice to humans [39]. Spilanthol was administered to 
the mice in a solution containing ethanol, dimethylacetamide and tween 80 in lactated Ringer’s 
solution containing BSA. Dimethylacetamide and ethanol are often used in injectable pharmaceutical 
formulations as co-solvents to solubilize poorly soluble compounds, while tween 80 is a traditional 
surfactant [44, 45]. It is known that tween 80 in high doses up to 30 mg/kg administered to mice 
causes blood-brain barrier disruption [46]. In this MTR study, a dose of 3 mg/kg tween 80 was used. 
Also ethanol, at a concentration of 1-4 g/kg, may cause disruption of the BBB as well [46]. However, 
in the current study, only 0.04 g ethanol/kg mice was administered. Although transient effects 
cannot be excluded, our data indicate that the solvents did not affect the BBB integrity. In addition, 
no toxicity was observed during the experiment. From our results, it is concluded that spilanthol was 
able to rapidly penetrate the BBB after intravenous administration with a unidirectional influx rate of 
796.2 μl/(g·min). This high K1 value indicates a high initial influx rate of spilanthol into the brain, 
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which is supported by the lipophilic character of this NAA. Moreover, 98% of spilanthol was found in 
the parenchyma of the brains, while only 2% was trapped in the capillaries, which makes it possible 
for NAAs to exert CNS effects. Furthermore, significant efflux out of the brain into the blood was also 
observed.    
It was already mentioned in the introduction that Spilanthes acmella extracts showed some central 
analgesic activities. In general, different central nervous pharmacodynamic activities are attributed 
to N-alkylamide containing plants. Psychotropic effects (anxiolytic effect) in animals were already 
found by using alkylamide Echinacea preparations, which was explained by their affinity for the CB 
receptors. Furthermore, similar to cannabinoids, alkylamides alter immune cell activity, which open 
perspectives for the treatment of neuroinflammatory diseases [17, 47]. In addition, capsaicin, the 
major NAA in hot peppers of the plant genus Capsicum interacts agonistically with the transient 
receptor potential vanilloid 1 receptor, predominantly expressed in primary afferent fibres and 
sensory neurones, playing a role in pain sensation [48, 49]. Another study reported an improvement 
of amyloid beta(1-42)-induced spatial memory impairment after administration of a 50 mg/kg and 
100 mg/kg methanolic extract of Piper nigrum fruits by gastric gavage to rats. The plant extract, 
containing piperine, which is a major alkylamide of black pepper, caused an attenuation of the 
oxidative stress in the rat hippocampus. Other studies demonstrated analgesic, anticonvulsant, 
antidepressant, anti-oxidant, anti-inflammatory, protection against neurodegeneration and cognitive 
enhancing effects of cognitive deficit-like condition of Alzheimer’s disease of piperine [50, 51].  
In addition, in some studies there is an indirect proof of blood-brain barrier influx of N-alkylamides. It 
has been shown that several N-alkylamide containing plants showed activity against epilepsy in 
animal models. Experiments with medicinal plants such as Anacyclus pyrethrum, Nigella sativa, 
Ferula gummosa and Pimpinalla anisum were performed to investigate their effect on seizures of 
epilepsy. It has been shown that the chloroform fraction of Anacyclus pyrethrum roots, 100-800 
mg/kg administered intraperitoneally to mice, possess neuropharmacological effects, such as 
antiseizure activity [52, 53]. Other studies demonstrated the myorelaxation and anticonvulsant 
activities in mice of the Anacyclus pyrethrum extract as well [52, 54]. Treatment with capsaicin 
resulted in a decrease in behavioral seizure activity and body temperature in a kainic acid induced 
epileptogenesis mice model. Furthermore, anti-oxidant activity in blood increased and the 
concentrations of IL-1β and TNF-α in the brain lowered [49].  
 
The majority of the studies reported in literature only look at the effects of in vivo or in vitro studies 
and no exposure data are available. Therefore, more detailed studies about exposure levels are 
required. In the current study, spilanthol concentrations in brains and serum were quantitatively 
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measured and we demonstrated a high influx of spilanthol into the brain, indicating a possible role in 
CNS diseases.      
 
5. CONCLUSION  
In this study, it is demonstrated that spilanthol is able to cross the Caco-2 cell monolayer in vitro and 
the intestinal membrane in vivo in rats after oral administration. After absorption and reaching the 
systemic circulation, spilanthol is able to rapidly and significantly cross the BBB in mice. Spilanthol 
also showed a significant efflux out of the brain, which explains partly the biphasic behaviour of the 
influx. These results suggest possible medicinal applications for spilanthol in central nervous system 
diseases from a pharmacokinetic point of view.  
 
  
CHAPTER V –QUANTITATIVE IN VITRO AND IN VIVO EVALUATION OF INTESTINAL AND BLOOD-BRAIN BARRIER TRANSPORT KINETICS OF SPILANTHOL 
  
 
134 
7. REFERENCES 
[1] Wu SH, Sun CR, Pei SF, Lu YB, Pan YJ. Preparative isolation and purification of amides from 
the fruits of Piper longum L. by upright counter-current chromatography and reversed-phase 
liquid chromatography. Journal of Chromatography A 2004;1040:193-204. 
[2] Barnes J, Anderson LA, Gibbons S, Phillipson JD. Echinacea species (Echinacea angustifolia 
(DC.) Hell., Echinacea pallida (Nutt.) Nutt., Echinacea purpurea (L.) Moench): a review of their 
chemistry, pharmacology and clinical properties. Journal of Pharmacy and Pharmacology 
2005;57:929-954. 
[3] Wang YL, Wang YC, McNeil B, Harvey LM. Maca: An Andean crop with multi-pharmacological 
functions. Food Research International 2007;40:783-792. 
[4] Yang XG. Aroma constituents and alkylamides of red and green huajiao (Zanthoxylum 
bungeanum and Zanthoxylum schinifolium). Journal of Agricultural and Food Chemistry 
2008;56:1689-1696. 
[5] Boonen J, Bronselaer A, Nielandt J, Veryser L, De Tre G, De Spiegeleer B. Alkamid database: 
Chemistry, occurrence and functionality of plant N-alkylamides. Journal of 
Ethnopharmacology 2012;142:563-590. 
[6] Coulon D, Faure L, Salmon M, Wattelet V, Bessoule JJ. N-Acylethanolamines and related 
compounds: Aspects of metabolism and functions. Plant Science 2012;184:129-140. 
[7] Sharma V, Boonen J, Chauhan NS, Thakur M, De Spiegeleer B, Dixit VK. Spilanthes acmella 
ethanolic flower extract: LC-MS alkylamide profiling and its effects on sexual behavior in 
male rats. Phytomedicine 2011;18:1161-1169. 
[8] Prachayasittikul V, Prachayasittikul S, Ruchirawat S, Prachayasittikul V. High Therapeutic 
Potential of Spilanthes Acmella: A Review. Experimental and Clinical Sciences Journal 
2013;12:291-312. 
[9] Chakraborty A, Devi RKB, Rita S, Sharatchandra K, Singh TI. Preliminary studies on 
antiinflammatory and analgesic activities of Spilanthes acmella in experimental animal 
models. Indian Journal of Pharmacology 2004;36:148-150. 
[10] Barman S, Sahu N, Deka S, Dutta S. Anti Inflamatory and Analgesic Activity of Leaves of 
Spilanthes Acmella (Elsa) in Experimental Animal Models. Pharmacologyonline 2009;1:1027-
1034. 
[11] Rios MY, Aguilar-Guadarrama AB, Gutierrez Mdel C. Analgesic activity of affinin, an alkamide 
from Heliopsis longipes (Compositae). Journal of Ethnopharmacology 2007;110:364-367. 
[12] Boonen J, Baert B, Burvenich C, Blondeel P, De Saeger S, De Spiegeleer B. LC-MS profiling of 
N-alkylamides in Spilanthes acmella extract and the transmucosal behaviour of its main bio-
active spilanthol. Journal of Pharmaceutical and Biomedical Analysis 2010;53:243-249. 
[13] Boonen J, Baert B, Roche N, Burvenich C, De Spiegeleer B. Transdermal behaviour of the N-
alkylamide spilanthol (affinin) from Spilanthes acmella (Compositae) extracts. Journal of 
Ethnopharmacology 2010;127:77-84. 
[14] De Spiegeleer B, Boonen J, Malysheva SV, Di Mavungu JD, De Saeger S, Roche N, Blondeel P, 
Taevernier L, Veryser L. Skin penetration enhancing properties of the plant N-alkylamide 
spilanthol. Journal of Ethnopharmacology 2013;148:117-125. 
[15] Matthias A, Blanchfield JT, Penman KG, Toth I, Lang CS, De Voss JJ, Lehmann RP. Permeability 
studies of alkylamides and caffeic acid conjugates from echinacea using a Caco-2 cell 
monolayer model. Journal of Clinical Pharmacy and Therapeutics 2004;29:7-13. 
[16] Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the 
blood-brain barrier. Neurobiology of Disease 2010;37:13-25. 
[17] Woelkart K, Frye RF, Derendorf H, Bauer R, Butterweck V. Pharmacokinetics and Tissue 
Distribution of Dodeca-2E,4E,8E,10E/Z-tetraenoic Acid Isobutylamides after Oral 
Administration in Rats. Planta Medica 2009;75:1306-1313. 
 CHAPTER V –QUANTITATIVE IN VITRO AND IN VIVO EVALUATION OF INTESTINAL AND BLOOD-BRAIN BARRIER TRANSPORT KINETICS OF SPILANTHOL 
  
 
135 
[18] Hubatsch I, Ragnarsson EGE, Artursson P. Determination of drug permeability and prediction 
of drug absorption in Caco-2 monolayers. Nature Protocols 2007;2:2111-2119. 
[19] Cattoor K, Bracke M, Deforce D, De Keukeleire D, Heyerick A. Transport of Hop Bitter Acids 
across Intestinal Caco-2 Cell Monolayers. Journal of Agricultural and Food Chemistry 
2010;58:4132-4140. 
[20] Tavelin S, Grasjo J, Taipalensuu J, Ocklind G, Artursson P. Applications of epithelial cell 
culture in studies of drug transport. Methods in Molecular Biology 2002;188:233-272. 
[21] Van Dorpe S, Bronselaer A, Nielandt J, Stalmans S, Wynendaele E, Audenaert K, Van De Wiele 
C, Burvenich C, Peremans K, Hsuchou H, De Tre G, De Spiegeleer B. Brainpeps: the blood-
brain barrier peptide database. Brain Structure & Function 2012;217:687-718. 
[22] Stalmans S, Gevaert B, Wynendaele E, Nielandt J, De Tre G, Peremans K, Burvenich C, De 
Spiegeleer B. Classification of Peptides According to their Blood-Brain Barrier Influx. Protein 
and Peptide Letters 2015;22:768-775. 
[23] Stalmans S, Bracke N, Wynendaele E, Gevaert B, Peremans K, Burvenich C, Polis I, De 
Spiegeleer B. Cell-Penetrating Peptides Selectively Cross the Blood-Brain Barrier In Vivo. Plos 
One 2015;10. 
[24] Gjedde A. High-Affinity and Low-Affinity Transport of D-Glucose from Blood to Brain. Journal 
of Neurochemistry 1981;36:1463-1471. 
[25] Patlak CS, Blasberg RG, Fenstermacher JD. Graphical Evaluation of Blood-to-Brain Transfer 
Constants from Multiple-Time Uptake Data. Journal of Cerebral Blood Flow and Metabolism 
1983;3:1-7. 
[26] Wong DF, Gjedde A, Wagner HN, Jr. Quantification of neuroreceptors in the living human 
brain. I. Irreversible binding of ligands. J Cereb Blood Flow Metab 1986;6:137-146. 
[27] Stalmans S, Wynendaele E, Bracke N, Knappe D, Hoffmann R, Peremans K, Polis I, Burvenich 
C, De Spiegeleer B. Blood-brain barrier transport of short proline-rich antimicrobial peptides. 
Protein and Peptide Letters 2014;21:399-406. 
[28] Triguero D, Buciak J, Pardridge WM. Capillary Depletion Method for Quantification of Blood-
Brain-Barrier Transport of Circulating Peptides and Plasma-Proteins. Journal of 
Neurochemistry 1990;54:1882-1888. 
[29] Gutierrez EG, Banks WA, Kastin AJ. Murine Tumor-Necrosis-Factor-Alpha Is Transported from 
Blood to Brain in the Mouse. Journal of Neuroimmunology 1993;47:169-176. 
[30] European Medicines Agency (EMA). Guideline on bio-analytical method validation. 
EMEA/CHMP/EWP/192217/2009. 
[31] Yazdanian M, Glynn SL, Wright JL, Hawi A. Correlating partitioning and Caco-2 cell 
permeability of structurally diverse small molecular weight compounds. Pharmaceutical 
Research 1998;15:1490-1494. 
[32] Pardridge WM, Eisenberg J, Cefalu WT. Absence of albumin receptor on brain capillaries in 
vivo or in vitro. American journal of physiology 1985;249:E264-267. 
[33] Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high 
doses. International Journal of Obesity 2003;27:313-318. 
[34] Heikkinen AT, Korjamo T, Monkkonen J. Modelling of Drug Disposition Kinetics in In Vitro 
Intestinal Absorption Cell Models. Basic & Clinical Pharmacology & Toxicology 2010;106:180-
188. 
[35] Artursson P, Karlsson J. Correlation between Oral-Drug Absorption in Humans and Apparent 
Drug Permeability Coefficients in Human Intestinal Epithelial (Caco-2) Cells. Biochemical and 
Biophysical Research Communications 1991;175:880-885. 
[36] Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR. MDCK (Madin-
Darby canine kidney) cells: A tool for membrane permeability screening. Journal of 
Pharmaceutical Sciences 1999;88:28-33. 
[37] Zhao YH, Abraham MH, Le J, Hersey A, Luscombe CN, Beck G, Sherborne B, Cooper I. 
Evaluation of rat intestinal absorption data and correlation with human intestinal absorption. 
European Journal of Medicinal Chemistry 2003;38:233-243. 
CHAPTER V –QUANTITATIVE IN VITRO AND IN VIVO EVALUATION OF INTESTINAL AND BLOOD-BRAIN BARRIER TRANSPORT KINETICS OF SPILANTHOL 
  
 
136 
[38] Cao XH, Gibbs ST, Fang LY, Miller HA, Landowski CP, Shin HC, Lennernas H, Zhong YQ, Amidon 
GL, Yu LX, Sun DX. Why is it challenging to predict intestinal drug absorption and oral 
bioavailability in human using rat model. Pharmaceutical Research 2006;23:1675-1686. 
[39] European Medicines Agency (EMA): CVMP/VICH/502/99. VICH topic GL18. Impurities: 
residual solvents. 2000. 
[40] Caldwell GW, Masucci JA, Yan ZY, Hageman W. Allometric scaling of pharmacokinetic 
parameters in drug discovery: Can human CL, V-SS and t(1/2) be predicted from in-vivo rat 
data? European Journal of Drug Metabolism and Pharmacokinetics 2004;29:133-143. 
[41] Li JJ, Yang B, Levons J, Pinnamaneni S, Raghavan K. Phase Behavior of TPGS-PEG400/1450 
Systems and Their Application to Liquid Formulation: A Formulation Platform Approach. 
Journal of Pharmaceutical Sciences 2011;100:4907-4921. 
[42] Guo YY, Luo J, Tan SW, Otieno BO, Zhang ZP. The applications of Vitamin E TPGS in drug 
delivery. European Journal of Pharmaceutical Sciences 2013;49:175-186. 
[43] Fan JH, de Lannoy IAM. Pharmacokinetics. Biochemical Pharmacology 2014;87:93-120. 
[44] Guest RT. Dimethylacetamide. In: Rowe RC, Sheskey PJ, Quinn ME, editors. Handbook of 
pharmaceutical excipients. Grayslake: Pharmaceutical Press, 2009. p. 241. 
[45] Pramanick S, Singodia D, Chandel V. Excipient selection in parenteral formulation 
development. Pharma Times 2013;45:65-77. 
[46] Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 
2005;2:3-14. 
[47] Hohmann J, Redei D, Forgo P, Szabo P, Freund TF, Haller J, Bojnik E, Benyhe S. Alkamides and 
a neolignan from Echinacea purpurea roots and the interaction of alkamides with G-protein-
coupled cannabinoid receptors. Phytochemistry 2011;72:1848-1853. 
[48] Alawi K, Keeble J. The paradoxical role of the transient receptor potential vanilloid 1 receptor 
in inflammation. Pharmacology & Therapeutics 2010;125:181-195. 
[49] Lee TH, Lee JG, Yon JM, Oh KW, Baek IJ, Nahm SS, Lee BJ, Yun YW, Nam SY. Capsaicin 
prevents kainic acid-induced epileptogenesis in mice. Neurochemistry International 
2011;58:634-640. 
[50] Hritcu L, Noumedem JA, Cioanca O, Hancianu M, Kuete V, Mihasan M. Methanolic extract of 
Piper nigrum fruits improves memory impairment by decreasing brain oxidative stress in 
amyloid beta(1-42) rat model of Alzheimer's disease. Cellular and Molecular Neurobiology 
2014;34:437-449. 
[51] Rasool M, Malik A, Qureshi MS, Manan A, Pushparaj PN, Asif M, Qazi MH, Qazi AM, Kamal 
MA, Gan SH, Sheikh IA. Recent updates in the treatment of neurodegenerative disorders 
using natural compounds. Evidence-Based Complementary and Alternative Medicine 
2014;2014:979730. 
[52] Abdollahi Fard M, Shojaii A. Efficacy of Iranian traditional medicine in the treatment of 
epilepsy. BioMed Research International 2013;2013:692751. 
[53] Zaidi SMA, Pathan SA, Singh S, Jamil S, Ahmad FJ, Khar RK. Anticonvulsant, Anxiolytic and 
Neurotoxicity Profile of Aqarqarha (Anacyclus pyrethrum) DC (Compositae) Root Ethanolic 
Extract. Journal of Pharmacy and Pharmacology 2013;4:535-541. 
[54] Gautam OP, Verma S, Jain SK. Anticonvulsant and myorelaxation activity of Anacyclus 
pyrethrum DC. (Akarkara) root extract. Pharmacologyonline 2011;1:121-125. 
 
  
 CHAPTER V –QUANTITATIVE IN VITRO AND IN VIVO EVALUATION OF INTESTINAL AND BLOOD-BRAIN BARRIER TRANSPORT KINETICS OF SPILANTHOL 
  
 
137 
SUPPLEMENTARY INFORMATION  
S1. NMR spectra of internal standard isobutyldecanamide. 
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S1. NMR spectra of internal standard isobutyldecanamide. 
 
N-Isobutyldecanamide 1H NMR (300 MHZ CDCl3) 
 
 
N-Isobutyldecanamide 13C NMR APT (75 MHZ CDCl3) 
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CHAPTER VI 
 
QUANTITATIVE IN VITRO 
AND IN VIVO EVALUATION 
OF INTESTINAL AND 
BLOOD-BRAIN BARRIER 
TRANSPORT KINETICS OF 
PELLITORINE 
 
 
“Discovery consists of looking at the same thing as everyone else and thinking something 
different.”  
 
 
Albert Szent-Györgyi   
(°1893-†1986, Hungarian physician, Nobel Prize winner in Medicine) 
 
 
 
 
 
 
Parts of this chapter were published: 
 
Veryser L, Bracke N, Wynendaele E, Joshi T, Tatke P, Taevernier L, De Spiegeleer B. Quantitative in 
vitro and in vivo evaluation of intestinal and blood-brain barrier transport kinetics of the plant N-
alkylamide pellitorine. BioMed Research International 2016;2016:5497402.   
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ABSTRACT 
The objective was to evaluate the gut mucosa and blood-brain barrier (BBB) pharmacokinetic 
permeability properties of the plant N-alkylamide pellitorine. Pure pellitorine and an Anacyclus 
pyrethrum extract were used to investigate the permeation of pellitorine through (1) a Caco-2 cell 
monolayer, (2) the rat gut after oral administration, and (3) the BBB in mice after intravenous and 
intracerebroventricular administration. A validated bio-analytical UHPLC-MS2 method was used to 
quantify pellitorine. Pellitorine was able to cross the Caco-2 cell monolayer from the apical-to-
basolateral and from the basolateral-to-apical side with apparent permeability coefficients between 
0.6·10-5 and 4.8·10-5 cm/h and between 0.3·10-5 and 5.8·10-5 cm/h, respectively. In rats, a serum 
elimination rate constant of 0.3 h-1 was obtained. Intravenous injection of pellitorine in mice resulted 
in a rapid and high permeation of pellitorine through the BBB with a unidirectional influx rate 
constant of 153 μl/(g·min). In particular, 97% of pellitorine reached the brain tissue, while only 3% 
remained in the brain capillaries. An efflux transfer constant of 0.05 min-1 was obtained. Pellitorine 
shows a good gut permeation and rapidly permeates the BBB once in the blood, indicating a possible 
role in the treatment of central nervous system diseases.   
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CHAPTER VI 
QUANTITATIVE IN VITRO AND IN VIVO 
EVALUATION OF INTESTINAL AND BLOOD-
BRAIN BARRIER TRANSPORT KINETICS OF 
PELLITORINE 
Main focus in this chapter: 
 To quantitatively investigate the Caco-2 cell monolayer and rat intestinal barrier permeability 
properties of pellitorine.   
 To evaluate the ability of pellitorine to cross the blood-brain barrier.  
 
1. INTRODUCTION  
Pellitorine (deca-2E,4E-dienoic acid isobutylamide; F3M1 according to the FxMy classification of N-
alkylamides (NAAs)) is a highly abundant and biologically potent diene NAA found in Asteracea plants 
such as Anacyclus pyrethrum (AP) [1]. Various pharmacological activities of pure pellitorine have 
already been reported, i.e. antiprotozoal, larvicide, antiseptic, antithrombotic, antituberculosis, 
antibacterial, anticancer, antiplatelet aggregation properties and vascular barrier protective effects 
[2-10]. It was also demonstrated that pellitorine reduces fatty acid uptake in vitro [11]. Central 
nervous system (CNS) activities of purified pellitorine are not yet described, while a limited number 
of CNS activities of Anacyclus pyrethrum extracts have been reported. Antiseizure activity was 
demonstrated after intraperitoneally administration of 100-800 mg/kg of the chloroform fraction of 
Anacyclus pyrethrum roots to mice. Other studies with the Anacyclus pyrethrum extract in mice 
showed anticonvulsant and myorelaxation activities [12]. Another study with an ethanolic AP root 
extract showed anticonvulsant effect against maximal electro shock (MES) induced convulsions in 
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mice [13]. Sujith et al. (2011) found that the AP root extract possesses antidepressant activity in 
albino Wister rats and improves the learning acquisition of rats [14].   
CNS effects of compounds require them to penetrate the blood-brain barrier in order to reach their 
brain target. Compounds can enter the systemic circulation after topical and oral administration, by 
crossing several physiological barriers (i.e. stratum corneum, intestinal barrier) and further reach the 
brain. A previous study of our research group demonstrated that pellitorine permeates human skin 
using an in vitro Franz diffusion cell (FDC) experiment (see Chapter III). The permeability coefficient 
Kp,v (with vehicle= 30:70 H2O:EtOH (V/V)) of pellitorine was 2.3·10-4 cm/h for the crude plant extract 
and 1.1·10-4 cm/h for purified pellitorine [15]. Moreover, the intestinal barrier and BBB transport 
kinetics of spilanthol were studied as well (see Chapter V) [16].  
 
Up till now, to our best knowledge, no information is available about the intestinal barrier and blood-
brain barrier transport kinetics of the 2,4-diene N-alkylamide pellitorine. Hence, the aim of this study 
was to quantitatively investigate this in vitro using a Caco-2 cell monolayer as well as in vivo with an 
oral gavage rat model and a BBB mice model.  
 
2. MATERIALS AND METHODS  
Chemicals and reagents 
Dextran was bought from AppliChem GmbH (Darmstadt, Germany), while trypsin-EDTA came from 
Invitrogen (Ghent, Belgium). UPLC-MS grade acetonitrile (ACN), methanol (MeOH) and trifluoroacetic 
acid (TFA) were purchased at Biosolve (Valkenswaard, the Netherlands). Dimethylacetamide and 
phosphoric acid (85%) (H3PO4) were obtained from Jansen Chimica (Geel, Belgium), while propylene 
glycol (PG) was bought from Riedel-de Haën (Seelze-Hannover, Germany). Disodium hydrogen 
phosphate dihydrate (Na2HPO4.2H2O), sodium hydrogen carbonate (NaHCO3), sodium dihydrogen 
phosphate monohydrate (NaH2PO4.H2O), acetic acid and absolute ethanol (EtOH, ≥ 99.9% V/V) were 
purchased at Merck KGaA (Darmstadt, Germany), while polyethylene glycol 400 (PEG 400), calcium 
dichloride (CaCl2), LC-MS grade formic acid (FA), tween 80, sodium hydroxide (NaOH), D-glucose, 
HEPES, Hanks’ Balanced Salt Solution (HBSS), vitamin E-TPGS, trypan blue, dimethyl sulfoxide 
(DMSO), sodium chloride (NaCl), potassium chloride (KCl), phosphate buffered saline (PBS), sodium 
hydrogen carbonate (NaHCO3), calcium chloride dehydrate (CaCl2.2H2O), sodium lactate, sodium 
dihydrogen phosphate (NaH2PO4), sodium sulphate (Na2SO4), urethane, Krebs-Henseleit buffer and 
hydrochloric acid (HCl) were bought from Sigma-Aldrich (Diegem, Belgium). HPLC gradient grade 
ACN, MeOH and absolute ethanol (99.8% V/V) were obtained from Fisher Scientific (Erembodegem, 
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Belgium). Ultrapure water (H2O) of 18.2 MΩ.cm quality was produced by an Arium 611 purification 
system (Sartorius, Göttingen, Germany).  
 
Products examined  
The ethanolic Anacyclus pyrethrum root extract was prepared and characterised as previously 
described [17]. The Anacyclus pyrethrum root extract (4.87% w/w NAAs of which pellitorine was the 
main NAA (1.55% w/w pellitorine)) was used for the oral gavage experiment and the Caco-2 cell 
permeability assay. Pellitorine was bought from Adipogen Life Sciences (99.8% purity determined by 
HPLC) and was used for the BBB transport assay. As analytical internal standard (IS), 
isobutyldecanamide was used, obtained from the Laboratory of Medicinal Chemistry (Ghent 
University). Dermorphin (> 95% purity determined by HPLC) was obtained from Bachem (Bubendorf, 
Switzerland) and bovine serum albumin (BSA) from Merck KGaA (Darmstadt, Germany); these 
compounds were used as positive and negative controls during BBB studies, respectively. 
 
In vitro permeation study in Caco-2 cell monolayers 
Cell culture  
The Caco-2 cell line originated from a human colorectal carcinoma and was maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) (95% humidity, 37°C, 5% CO2), supplemented with 10% (V/V) fetal 
bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin, 2 mM L-glutamine and 1% non-
essential amino acids (all from Invitrogen/GIBCO, Ghent, Belgium).   
 
Caco-2 cell permeability assay    
The Caco-2 cell intestinal model was used to investigate the gut mucosa permeation of pellitorine. 
On each Transwell (Corning Costar, New York, USA) membrane insert filter (0.4 μm pore size, 12 mm 
filter diameter), the cells were seeded at a density of 2.6·105 cells/cm² cells and cultivated in the 
described supplemented DMEM. Every second day, the medium was changed. During a period of 21-
29 days, the cells were grown and differentiated until monolayers were formed. The integrity of the 
monolayers was checked via the measurement of transepithelial electrical resistance (TEER) of the 
monolayers with a Millicell-ERS system (Millipore Corp., Bedford, MA, USA) before and after the 
transport experiments. The experiments were performed in duplicate for each dose solution. 
Transport experiments were carried out according to Hubatsch et al. (2007) in two directions, i.e. 
from the apical-to-basolateral (ab) direction and from the basolateral-to-apical (ba) direction in 
Hanks’ Balanced Salt solution [18]. Two dose solutions of pellitorine (in Anacyclus pyrethrum extract) 
of 1 μg/ml in 0.5% EtOH (further indicated as DS1) and of 56 μg/ml in 0.5% of a mixture of vitamin E-
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TPGS (33.3%), EtOH (11.1%), PEG 400 (33.3%) and PG (22.2%) (further indicated as DS2) dissolved in 
HBSS were tested.  
 
Final apical volumes of 0.4 ml and basolateral volumes of 1.2 ml were used for 12-mm filter supports 
during the transport experiment. After 15, 30, 60, 90 and 120 min, samples were taken from the 
receiver compartment (basolateral to apical transport: 100 μl; apical to basolateral transport: 300 μl) 
and immediately replaced by fresh HBSS. After 120 min, a sample from the donor compartment was 
taken as well and a mass balance was constructed for pellitorine, which ranged between 103.6 and 
132.4% total recovery. To confirm the validity of the test, atenolol (50 μM) and propranolol (20 μM) 
were used as the negative (low permeability) and positive (high permeability) control, respectively 
[19]. Pellitorine was quantified using an ultra high performance liquid chromatography – tandem 
mass spectrometry (UHPLC-MS²) method as described below.  
 
The apparent permeability coefficient (Papp in cm/s) of pellitorine in DS2 was calculated using a sink 
condition equation, while the Papp of pellitorine in DS1 was calculated using a non-sink equation. 
From Fick’s first law: Jൌ െൈ ሾሺሻሿȀ (J is the flux or transfer rate along the donor-to-receptor 
side, D is the diffusion coefficient, x is the distance from the donor compartment and C(x) is the 
concentration in the barrier at the coordinate x in the barrier), the following differential equation is 
derived: ୰ሺሻȀ ൌ ୟ୮୮ ൈ  ൈ ሾୢሺሻ െ ୰ሺሻሿ, in which Papp is the apparent permeability 
coefficient (a product of distribution coefficient with diffusion coefficient divided by the barrier 
thickness), Mr is the amount of substance in the receiver chamber, A is the cross-sectional area of the 
barrier, Cd is the donor concentration and Cr is the receiver concentration. This differential equation 
can be solved to calculate Papp using different initial conditions depending on sink or non-sink 
conditions. In case of sink conditions, the following equation was obtained from the amount of 
compound transported per time dMr(t)/dt with the receiver concentration set to zero [18, 20]: 
୰ሺሻ
ୢǡ଴
ൌ ୟ୮୮ ൈ  ൈ  ൅  
where Papp is the apparent permeability coefficient (cm/s), A is the surface area of the filter (1.12 
cm²), Cd,0 is the initial concentration in the donor chamber (μg/ml), t is the time (s) and c is a constant 
term which vanishes, since Mr is initially zero at t = 0. 
The donor concentration at each time point was calculated by taking into account the amount of 
compound which already permeated through the cell monolayer during that time interval. In this 
way, the reduction in donor concentration after every sampling was also taken into account.  
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The cumulative fraction transported FAcum (cm) is defined as   
	ୡ୳୫ ൌ
ͳ

ൈ෎
ሾ୰ሺ୩ሻ െ  ൈ ୰ሺ୩ିଵሻሿ ൈ ୰
ሾୢሺ୩ିଵሻ ൅ ୢሺ୩ሻሿȀʹ
୧
୩ୀଵ
ൌ ୟ୮୮ ൈ ୧ 
in which Vr is the volume of the receiver compartment (ml), f is the sample replacement dilution 
factor (1-Vs/Vr with Vs being the sample volume), ti (s) is the time at sampling i, tk (s) is the time at 
sampling k, Cr(tk) (μg/ml) is the experimentally determined concentration of pellitorine in the 
receiver compartment at sampling k and Cd(tk) (μg/ml) is the experimentally determined 
concentration of pellitorine in the donor compartment at sampling k. Cd is considered as constant 
and is obtained by taking the average of Cd of the start and the end of the time interval. Papp was 
calculated from the slope of the cumulative fraction versus time curve using a linear fit.  
In case of non-sink conditions, the differential equation resulted in the following solution [18, 20]: 
୰ሺሻ ൌ ൤

ୢ ൅ ୰
൨ ൅ ൬୰ǡ୲ିଵ ൈ  െ ൤

ୢ ൅ ୰
൨൰ ൈ 
ି୔౗౦౦ൈ୅ൈሺ
ଵ
୚ౚ
ା ଵ୚౨
ሻൈο୲ 
in which M (μg) is the total amount of pellitorine in the system at time t, Vd (ml) is the volume of the 
donor compartment, Cr,t-1 (μg/ml) the concentration of pellitorine in the receiver compartment at the 
previous time point, t the time (s), 't (s) is the time at time t minus the previous time point and Cr(t) 
(μg/ml) the concentration of pellitorine in the receiver compartment at time t. Minimisation of the 
sum of squared residuals (SSR) was used on the non-linear curve fitting to obtain the Papp. The uptake 
and efflux ratio are calculated as Papp,ab/Papp,ba and Papp,ba/Papp,ab, respectively. 
 
In vivo pharmacokinetic experiment with rats 
Animals    
Male and female Wistar rats weighing approximately 220 g were obtained from Bharat Serum and 
Vaccines pvt. Ltd, Thane, India (registration number 103/99/CPCSEA) and were housed at C. U. Shah 
College of Pharmacy, SNDT Women’s University, Santacruz, Mumbai, India (registration number 
39/99/CPCSEA) where the experiments were carried out. Rats of 7-8 weeks old were fasted overnight 
and used for the experiments.  
 
Pharmacokinetic experiment   
A pellitorine dose solution was prepared using the Anacyclus pyrethrum extract. To the rats, 1.5 ml of 
a 0.73 mg pellitorine/g dose solution in 10:20:30:40 (w/w/w/w) EtOH:PG:Vit E-TPGS:PEG 400 was 
administered using a gavage needle (stainless steel, length 3 inches and 2.5 mm internal diameter). 
As blank, a solution containing EtOH, PG, Vit E-TPGS and PEG without pellitorine was used. Each dose 
solution was orally administered to three female and three male rats. 1.5 ml blood was collected 
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from the retro orbital vein at 1, 2, 3, 4, 6, and 8h after administration of the dose solution and was 
centrifuged for 20 min at room temperature. Thereafter, the serum samples were immediately 
frozen at -80°C until bio-analysis. The animals were sacrificed at the end of the experiment by CO2 
inhalation. Using GraphPad software (La Jolla, USA), the elimination rate constant ke (h-1) is calculated 
using the following equation of a one compartmental model: ሺሻ ൌ ଴ ൈ ି୩౛ൈ୲, in which C(t) 
(ng/ml) is the concentration of pellitorine at time t (h) and C0 the concentration of pellitorine at time 
t=0 (ng/ml). The elimination half-life t1/2,e (h) is calculated as ln(2)/ke.  
 
In vivo blood-brain barrier experiment with mice 
Animals    
Seven to ten weeks old female, Institute for Cancer Research, Caesarean Derived-1 (ICR-CD-1) mice 
(Harlan Laboratories, Venray, Netherlands) weighing 29-32 g, were used for the BBB transport 
experiments. The experiments were performed according to the Ethical Committee principles of 
laboratory animal welfare as approved by Ghent University (Faculty of Veterinary Medicine, no. 
EC2014/128). 
 
Blood-to-brain transport 
An in vivo multiple time regression (MTR) analysis was performed in order to determine whether 
pellitorine could enter the brain. A dose solution of 1.8 mg/ml pure pellitorine dissolved in 6.9% 
EtOH, 2.5% dimethylacetamide, 0.5% tween 80 (all w/w) diluted in lactated Ringer’s solution 
containing 1% BSA was prepared. After anesthetizing the mice intraperitoneally with a 40% (w/V) 
urethane solution (3 g/kg), the jugular internalis vein and carotid artery were isolated and 20 μl of 
the pellitorine dose solution was injected into the jugular vein. After 1, 3, 5, 10, 12.5 and 15 min post 
injection (with start and end in duplicate), blood was collected from the carotid artery. Immediately 
thereafter, the mice were decapitated and the brains were isolated. Serum was obtained by 
centrifuging the collected blood at 10 000 g for 15 min at 21°C. As negative and positive control, I125- 
BSA and dermorphin were used, respectively, to assure the validity of the experiment [21-23]. The 
serum concentrations of pellitorine were plotted against the time (expressed in min). The curve was 
fitted using a first order kinetic, two-compartmental model: ሺሻ ൌ ଵ ൈ ି஑ൈ୲൅ଶ ൈ ିஒൈ୲, in 
which C is the concentration of pellitorine in serum at time t, D and E are hybrid constants, 
dependent on the rate constants ke (elimination rate constant), k1,2 (rate constant between central 
and peripheral tissue compartment), k2,1 (rate constant between peripheral tissue and central 
compartment), C1 is the concentration obtained after extrapolation of the distribution phase D to the 
Y axis and C2 is the concentration obtained after extrapolation of the elimination phase E to the Y 
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axis. The ratio of the pellitorine brain and serum concentration (μl/g) was plotted versus the 
exposure time (Ʌ), which is a derived time variable of the Gjedde-Patlak plot, to determine the BBB 
influx kinetics of pellitorine [24, 25].  
The exposure time is computed as Ʌ ൌ ׬ େ౩ሺ୲ሻήୢ୲େ౩ሺ୘ሻ
୘
଴  and is defined as the integral of the concentration 
of pellitorine in serum from start (t=0 min) to time T, divided by the concentration of pellitorine in 
serum at time T. The integral of the concentration of pellitorine in serum from zero to time T is the 
area under the curve until time T.                 
The brain uptake of pellitorine was fitted using a biphasic model, as elaborated by Wong et al. (1986) 
[26]:  
ୠ୰ୟ୧୬ሺሻ
ୱሺሻ
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in which Cbrain(T) is the concentration of pellitorine in the brain at time T (ng/g), Cs(T) the 
concentration of pellitorine in serum at time T (ng/μl), K the net clearance (μl/(g·min)), Vg the tissue 
brain distribution volume (μl/g), K1 is the unidirectional clearance from pellitorine from blood to 
brain (i.e. the unidirectional brain transfer coefficient, also referred to as influx rate) (μl/(g·min)) and 
V0 the vascular brain distribution volume (μl/g). The vascular distribution volume of the negative 
control BSA (14.8 μl/g) was used as V0 to calculate the brain kinetic parameters of pellitorine.  
 
Capillary depletion 
A capillary depletion experiment was performed to distinguish the transport of pellitorine into the 
brain, represented by the parenchyma, and part of pellitorine which is trapped by the endothelial 
cells of the brain, represented by the capillaries. A method of Triguero et al. (1990) was used, which 
was modified by Gutierrez et al (1993) [27-29]. The mice were anesthetized intraperitoneally with 
40% (w/V) urethane solution (3 g/kg). Thereafter, 20 μl of the 1.8 mg/ml pellitorine dose solution 
was injected into the jugular vein. Ten min after injection, blood was collected from the abdominal 
aorta and serum was obtained by centrifuging the blood at 10 000 g during 15 min at 21°C. Then, 
after removing the skin of the mice’s chest, the aorta is clamped, the jugular veins are severed and 
the brain is immediately perfused manually with 20 ml of Lactated Ringer’s solution. The mice are 
decapitated, the brains are isolated, weighed and put into (LoBind Eppendorf) tubes, to which 525 μl 
ice-cold capillary buffer (10 mM HEPES, 141 mM NaCl, 4 mM KCl, 2.8 mM CaCl2, 1 mM MgSO4, 1 mM 
NaH2PO4 and 10 mM D-glucose adjusted to pH 7.4) was added. The (LoBind Eppendorf) tubes were 
homogenized. Next, 1000 μl of 26% ice-cold dextrane solution in capillary buffer was added, vortexed 
and the tubes were subsequently centrifuged at 20 000 g for 60 min at 4°C. Parenchyma and fat 
tissue (supernatant) were transferred into separate (LoBind Eppendorf) tubes and weighed. The 
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capillaries (pellet) were kept in the original tube. The sample preparation of the pellet and the 
supernatant is the same sample preparation method as used for the mice brains and mice serum, 
respectively, as further described in the ‘bio-analytics’ section. 
The distribution in the brains was calculated as follows:  
	ሺΨሻ ൌ
୲୧ୱୱ୳ୣ
ୡୟ୮୧୪୪ୟ୰୧ୣୱ ൅ ୮ୟ୰ୣ୬ୡ୦୷୫ୟ
ൈ ͳͲͲ 
in which Mtissue is the amount of pellitorine in the capillaries and parenchyma; Mcapillaries the amount of 
pellitorine in the capillaries and Mparenchyma the amount of pellitorine in the parenchyma. The capillary 
depletion experiment was performed in duplicate and mean values are reported.   
 
Brain-to-blood transport 
To evaluate the efflux of pellitorine out of the brain into the blood, a previously described in vivo 
method was used [28]. Briefly, the ICR-CD-1 mice were anesthetized with 40% (w/V) urethane 
solution (3 g/kg). Then, the skin of the skull was removed and a hole was made into the lateral 
ventricle using a 22 G needle marked with tape at 2 mm at the following coordinates: 1 mm lateral 
and 0.34 mm posterior to the bregma. Using a syringe pump (KDS100, KR analytical, Cheshire, UK), 1 
μl of the 1.8 mg/ml pellitorine dose solution as used for the blood-to-brain influx experiment was 
injected intracerebroventriculary (ICV) at a speed of 360 μl/h for 10 s. The mice were decapitated 
after 1, 3, 5, 10, 12.5 and 15 min post-injection. Just before decapitation, blood was collected from 
the abdominal aorta and serum was obtained by centrifuging the blood at 10 000 g during 15 min at 
21°C. Thereafter, brains were collected. The natural logarithm of the pellitorine concentration in 
brain (ng/g) was plotted versus time. The efflux rate constant kout (min-1) is obtained from the 
negative value of the slope of the linear regression, applying first order kinetics. From the kout, the 
efflux brain half-life (t1/2,brain) (min) is calculated as follows: t1/2,brain = ln(2)/kout.  
 
In vitro metabolic stability of pellitorine   
The in vitro metabolic stability of pellitorine was evaluated in mouse brain and liver homogenates 
and mouse serum according to previously described protocols [22, 30]. Using the Pierce Modified 
Lowry Protein Assay method (Thermo Scientific), the protein content of each tissue homogenate was 
determined to prepare a stock solution containing a 0.6 mg/ml protein concentration in Krebs-
Henseleit buffer (pH 7.4). Briefly, 75 μl of a 0.25 mg/ml pellitorine solution dissolved in 2% (V/V) 
EtOH in Krebs-Henseleit buffer pH 7.4 containing 3% (m/V) BSA was incubated in 375 μl of 
serum/organ homogenate and 300 μl of Krebs-Henseleit buffer pH 7.4 while shaking at 750 rpm at 
37°C. After 0, 5, 7.5, 15, 60 and 120 min, aliquots of 100 μl were taken and transferred into 0.5 ml 
(LoBind Eppendorf) tubes containing 100 μl of 1% (V/V) TFA in water. Next, the samples were heated 
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at 95°C for 5 min and subsequently cooled for 30 min in ice. Thereafter, the samples were 
centrifuged (20 000 g for 30 min at 5°C) and 25 μl of the clear supernatant was injected and analysed 
using a HPLC-UV/MS method of 46 min which was previously described [15]. The HPLC–MS analysis 
was done on a HPLC system which consisted of a Spectra System SN4000 interface, a Spectra System 
SCM1000 degasser, a Spectra System P1000XR pump, a Spectra System AS3000 autosampler, and a 
Finnigan LCQ Classic ion trap mass spectrometer in positive ion mode (all Thermo, San José, CA, USA) 
equipped with a Waters 2487 Dual Absorbance detector and Xcalibur 2.0 software (Thermo) for data 
acquisition. Control solutions were also prepared but without pellitorine. Furthermore, control 
reference solutions were prepared as well with a prior heat inactivation or without tissue 
homogenate. 
 
Bio-analytics  
Serum sample preparation 
To 60 μl of 4% (V/V) aqueous H3PO4 solution and 30 μl of the IS solution, 60 μl of the serum samples 
was added into a 0.5 ml (LoBind Eppendorf) tube and vortexed. By means of solid phase extraction 
using a positive pressure-96 processor (Waters, Zellik, Belgium), interfering compounds were 
removed. The sorbent in each well of the HLB Oasis® μelution 96 well plate (Waters, Zellik, Belgium) 
was preconditioned with 200 μl of MeOH and equilibrated using 200 μl of ultrapure water. 
Thereafter, 100 μl of the previous serum sample solution was loaded, followed by two washing steps 
using 200 μl of 5% MeOH in H2O and 200 μl of 20% MeOH in H2O, respectively. Two times 25 μl ACN 
was used to elute pellitorine. 25 μl of a 80:20 (V/V) H2O:MeOH solution was added to the eluate and 
analysed with a UHPLC-MS² method, as described further in the section ‘UHPLC-MS² method’. 
 
The bio-analytical method for the quantification of pellitorine in serum was limited validated using 
rat serum, based upon the European Medicines Agency (EMA) guideline on bio-analytical method 
validation (EMEA/CHMP/EWP/192217/2009), with limited replicates and concentration levels [31]. 
The limit of detection (LoD) (S/N=3) and limit of quantification (LoQ) (S/N=10) of pellitorine, 
determined on the reference standard, were calculated as 0.19 ng/ml and 0.62 ng/ml, respectively, 
which correspond to 0.36 ng/ml and 1.16 ng/ml in serum, respectively. A matrix factor of 0.97 was 
observed for pellitorine in serum. The quantification of pellitorine in the mouse serum samples was 
performed using a calibration curve with pellitorine standards in 40:33.33:26.67 (V/V/V) 
MeOH:ACN:H2O. The quantification of pellitorine in the rat serum samples was performed using a 
pre-extracted spiked matrix calibration curve. Linearity was assured in a working range from 0.62 
ng/ml up to 101 ng/ml, corresponding to 1.16 ng/ml to 189 ng/ml in serum (R²=0.9997). 
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The accuracy of the references used for the calibration curves with pellitorine standards in 
40:33.33:26.67 (V/V/V) MeOH:ACN:H2O, the pre-extracted spiked matrix samples and the quality 
control (QC) samples conformed to the specifications, i.e. < 15% of the nominal value and for the 
lower limit of quantification (LLoQ) < 20% of the nominal value. Precision was expressed as the 
coefficient of variation (CV). The within-run CV value did not exceed 15% for the pre-extracted spiked 
matrix samples. Also the CV for the LLoQ sample did not exceed 20% and are thus all conform to the 
specification limits. The recovery in serum was 90.65% (18.8 ng/ml to 189 ng/ml in serum 
concentration range), calculated from the slopes of the pre-extracted and post-extracted spiked 
matrix samples. No significant carry-over was observed (< 20% of LLoQ pellitorine and < 5% for IS). 
The selectivity was conform to the specifications (placebo serum < 20% of LLoQ pellitorine and < 5% 
for IS).  
 
Brain sample preparation 
The weighed mice brains were transferred into test tubes, 1.0 ml of the IS solution in ACN was added 
and the brains were crushed. The brains were shaken for 4 h at 110 rpm at room temperature using 
an Eppendorf centrifuge 5810 (Eppendorf, Rotselaar, Belgium). Thereafter, the test tube was 
centrifuged at 250 g for 5 min and 800 μl of the supernatant was transferred into other (LoBind 
Eppendorf) tubes. Then, these test tubes were centrifuged again at 20 000 g during 5 min at room 
temperature and 750 μl of the supernatant was evaporated to dryness under nitrogen. Pellitorine 
was redissolved in 175 μl 90:10 (V/V) H2O:ACN and 160 μl of this solution was loaded on the HLB 
Oasis® μelution 96 well plate. The same washing and elution steps were applied as for the serum 
samples.  
 
Again, a limited validation of the bio-analytical method for the quantification of pellitorine in brains 
was performed. The LoD and LoQ of pellitorine were 41.2 pg/g and 135 pg/g in brain, respectively. A 
matrix factor of 0.98 was observed for pellitorine in mice brains. Quantification of pellitorine in the 
brain samples was performed using the pre-extracted spiked matrix calibration curve (R²=0.9982). 
Linearity was demonstrated in a working range of 0.69 ng/ml to 100 ng/ml pellitorine, corresponding 
to 135 pg/g to 19.6 ng/g in brain. The accuracy of the references used for the calibration curves and 
the QC samples with the pre-extracted spiked matrix samples conformed to the specification limits (< 
15% of the nominal value; LLoQ < 20% of the nominal value), except for one QC reference pre-
extracted spiked matrix sample (17% of the nominal value instead of < 15%), but was still acceptable 
for our purposes. The within-run CV value did not exceed 15% for the pre-extracted spiked samples. 
Also the LLoQ did not exceed 20% and are thus all conform to the limits. The recovery in mouse 
brains was 115.5% (0.98 to 19.6 ng/g brain concentration range). 
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UHPLC-MS² method   
A UHPLC-MS² method using an Acquity UPLC RP C18 column (50 x 2.1 mm, 1.7 μm, Waters, Zellik, 
Belgium) with a suitable guard column was used for the quantification of pellitorine, developed on an 
Acquity UPLC chromatograph coupled to a Xevo™ TQ-S mass spectrometer (MS) (Waters, Zellik, 
Belgium) equipped with a triple quadrupole mass analyser and an electrospray ionisation (ESI) 
source. The column temperature was kept at 30°C, while the sample compartment remained 
constant at 5°C. The injection volume was 2 μl and the flow rate was set to 0.5 ml/min. A mobile 
phase was applied consisting of solvent A (0.1% FA in 30:70 (V/V) H2O:MeOH) and solvent B (0.1% FA 
in MeOH) in gradient mode as follows: 0-1.6 min 100:0 (V/V) A:B, 1.6-2 min going from 100:0 (V/V) 
A:B to 0:100 (V/V) A:B, 2-3 min 0:100 (V/V) A:B, 3-3.4 min going from 0:100 (V/V) A:B to 100:0 (V/V) 
A:B, 3.4-5 min 100:0 (V/V) A:B. A needle wash solvent of 60:40 (V/V) DMSO:ACN was used. The MS 
operated in ESI+ mode with an optimised cone voltage of 50 V, a capillary voltage of 3.0 kV and a 
source offset of 60 V. Cone and desolvation gas (N2) flows were 180 and 1000 l/h, respectively, while 
desolvation and source temperatures were set at 500°C and 150°C and, respectively. Acquisition was 
performed in the multiple reaction monitoring (MRM) mode with m/z 224.11 to m/z 80.84 transition. 
The collision gas was argon and the applied collision energy was 26 eV. By means of MassLynx® 
software (V4.1 SCN 843, Waters, Zellik, Belgium), data were acquired and analysed.  
 
3. RESULTS  
Caco-2 cell permeability 
Our results demonstrated that pellitorine was able to permeate the Caco-2 cell monolayer in both 
directions, i.e. from the apical-to-basolateral side, as well as from the basolateral-to-apical side. The 
percentages of pellitorine from the applied dose solutions (DS1 and DS2) which permeated through 
the Caco-2 cells in the course of time are shown in Figure 1. After 120 min, 56.7% (or 0.31 μg 
pellitorine) of the applied pellitorine with DS1 and 9.98% (or 2.24 μg pellitorine) of the applied 
pellitorine with DS2 permeated the Caco-2 cell monolayer in the apical-to-basolateral direction. In 
the basolateral-to-apical direction, the percentage of pellitorine which permeated through the Caco-
2 cells after 120 min is 23.7% (or 0.39 μg pellitorine) with DS1 and 1.84% (or 1.24 μg pellitorine) with 
DS2. The Papp,ab of the positive control propranolol resulted in 19.1·10-6 cm/s and similar values are 
documented in literature [32]. The negative control atenolol showed a lower permeability compared 
to propranolol. 
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Figure 1. The percentages of pellitorine from the applied dose solutions using dose solution 1 (DS1) and dose 
solution 2 (DS2) which permeated through the Caco-2 cells monolayer in the course of time. Apical-to-
basolateral transport and basolateral-to-apical transport experiments of pellitorine were performed in 
duplicate (individual results in the same figure). 
 
Apparent permeability coefficients of pellitorine of 48.08 ± 0.08·10-6 cm/s (mean ± SD, n=2) and 5.50 
± 0.06·10-6 cm/s (mean ± SD, n=2) in case of DS1 and DS2, respectively, were calculated for the 
apical-to-basolateral transport. For the opposite direction (basolateral-to-apical), Papp values of 
pellitorine obtained with DS1 and DS2 are 57.49 ± 6.20·10-6 cm/s (mean ± SD, n=2) and 2.80 ± 
0.09·10-6 cm/s (mean ± SD, n=2), respectively. Uptake ratios of 0.84 and 1.96 using DS1 respectively 
DS2 are obtained. 
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Oral gavage experiment 
The pellitorine serum concentrations after oral gavage are plotted against time (Figure 2). Pellitorine 
was able to permeate the intestinal barrier in vivo.    
 
 
Figure 2. Concentration of pellitorine in rat serum (ng/ml) as a function of time (h) after oral gavage of 
pellitorine (5 mg pellitorine/kg body weight). Data are fitted according to a one compartmental model (n=2-3, 
mean, error bars: SEM). 
 
The curve was fitted according to a one compartmental model. An elimination rate constant and half-
life of 0.28 h-1 and 2.46 h were obtained.  
 
Blood-brain barrier transport kinetics of pellitorine 
Using the MTR method, pellitorine showed a significant influx into the mouse brain. In Figure 3, the 
ratio of the concentration of pellitorine in brain and serum is plotted versus the exposure time. The 
data were fitted using a biphasic model, based on the modified Gjedde-Patlak equation according to 
Wong et al.(1986) [26]. Pellitorine showed a very high and rapid influx into the brains and a K1 of 153 
μl/(g·min) was determined. Moreover, the tissue brain distribution volume (Vg) is 792 μl/g. After 
about 10 min exposure time, a plateau was observed, which is consistent with the efflux of 
pellitorine out of the brain.   
Dermorphin (positive control) clearly showed an influx with a calculated unidirectional influx rate of 
0.26 μl/(g·min). The negative control BSA gave a very small, almost negligible brain influx, with a K1 of 
0.12 μl/(g·min). Both controls thus indicated a good performance of the test and are in compliance 
with those previously reported [28, 33]. 
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Figure 3. Blood-to-brain transport (multiple time regression experiment) results of pellitorine in mice. The ratio 
of pellitorine concentration in brain versus serum (μl serum/g brain) is plotted versus the exposure time (min). 
Start and end point were performed in duplicate. The data were fitted using a biphasic model. 
 
The MTR data allowed us to evaluate the elimination kinetics of pellitorine in serum as well. The 
serum profile of pellitorine followed a two compartmental model. C1 was 7.02 μg/ml and C2 was 0.44 
μg/ml. The distribution rate constant D was 1.56 min-1, while the elimination rate constant E was 
0.15 min-1 and an elimination half-life of 4.48 min was obtained. 
 
Capillary depletion 
The fraction of pellitorine that was taken up by the brain parenchyma and the fraction of pellitorine 
which was trapped in the endothelial cells of the brain capillaries was investigated. 97% of pellitorine 
(corresponding to 347.3 μl/g) transferred effectively into the brain parenchyma, versus a low 
percentage of pellitorine remaining in the brain capillaries: 3% (corresponding to 10.0 μl/g). The high 
absolute values in the brain parenchyma are consistent with the MTR results.  
 
Brain-to-blood transport kinetics of pellitorine 
A significant efflux of pellitorine out of the brain into the blood was observed after 
intracerebroventricular injection of the dose solution (Figure 4). The efflux behaviour can explain the 
rapid plateauing observed during the brain influx experiment. The efflux transfer constant kout was 
calculated as 0.05 min-1, equal to a t1/2,brain of 13.8 min.  
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Figure 4. Brain-to-blood transport results of pellitorine in mice. The natural logarithm of the concentration of 
pellitorine in the brain (ng/g) in function of the time (min) is given. 
 
In vitro metabolic stability of pellitorine   
The stability of pellitorine was determined in mouse serum, mouse brain homogenate and mouse 
liver homogenate. The results of this study indicate that pellitorine was stable during one hour in 
serum, in brain as well as in liver (91% - 105% recovery).   
 
4. DISCUSSION  
To characterize the intestinal absorption of pellitorine, the permeability of pellitorine through Caco-2 
cells was investigated using two different dose solutions. The ethanol percentage in both dose 
solutions was less than 0.5%. The permeation level of pellitorine through Caco-2 cells was higher 
from the absorptive apical-to-basolateral side (10-57%), compared to the permeation from the 
basolateral-to-apical side (2-24%). Pellitorine, applied as DS1 better permeated the Caco-2 cells 
monolayer compared to pellitorine applied as DS2 in both directions, indicating that co-solvents 
(vitamin E-TPGS, PEG 400, PG) did not influence the permeation level through the cells in a positive 
way. However, the esterified vitamin E derivative, vitamin E-TPGS, was added to increase the 
solubility and facilitate the permeation of pellitorine [34, 35]. The Papp values obtained for pellitorine 
(0.3·10-5 to 5.8·10-5 cm/s) were all above 1·10-6 cm/s, suggesting an almost complete intestinal 
absorption and are similar to values reported by Matthias et al. (2004) of the mono- and diene-NAAs 
from Echinacea plant species [36]. Given the physicochemical properties of pellitorine (logP=3.65, 
MW=223.36 g/mol), transcellular passive diffusion seems favourable for pellitorine [37]. This was 
confirmed in our study, as for both dose solutions containing pellitorine, the ratio of Papp values 
between the apical-to-basolateral and the basolateral-to-apical direction or vice versa was ≤ 2, 
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indicating that no active transport was involved [38]. As the efflux ratios were not greater than two, 
there is no efflux of pellitorine. Next to this in vitro evaluation of the intestinal barrier properties of 
pellitorine, a confirmatory in vivo oral gavage experiment in rats was performed. A liquid dose 
solution of pellitorine also containing EtOH, PG, Vit E-TPGS and PEG 400, was orally administered to 
rats. Pellitorine diffused through the gut barrier and was observable in rat serum. These results 
confirm the outcome of the initial in vitro Caco-2 cell permeability study. The elimination half-life of 
pellitorine was 2.46 h, which is in the same range as the elimination half-life of 1.20 h, obtained by 
Woelkart et al. (2009), who investigated the plasma concentration of dodeca-2E,4E,8E,10E/Z-
tetraenoic acid isobutylamides from Echinacea via oral gavage in rats [39].  
 
Once in the blood, pellitorine can distribute to extravascular compartments in order to exert a 
biological function. In the present study, the blood-brain barrier transport characteristics of 
pellitorine were explored in an in vivo mice experiment. Pellitorine was intravenously injected to the 
mice in a solution containing EtOH and dimethylacetamide, which are both frequently used as co-
solvents in injectable pharmaceutical formulations; and tween 80, which is a traditional surfactant, 
and diluted in lactated Ringer’s solution containing BSA [40, 41]. In our study, no toxicity was 
observed when performing the experiment and it is likely that the solvents did not have an influence 
on the BBB integrity, as lower doses are used than doses reported in literature which can cause 
blood-brain barrier disruption. A dose of tween 80 up to 30 mg/kg and 1-4 g/kg ethanol can disrupt 
the BBB, while in this study only 3 mg/kg tween 80 and 0.04 g EtOH/kg body weight were 
administered [42]. In the current study, a high initial unidirectional influx rate of 153 μl/(g·min) was 
observed, indicating that pellitorine rapidly penetrated the BBB after administration, which is 
consistent with the lipophilicity of pellitorine. In addition, pellitorine was distributed in the brains as 
follows: 97% in the parenchyma and only 3% in the capillaries, making it plausible to exert CNS 
effects. Badhe et al. (2010) already showed antidepressant activity of a hydroalcoholic Anacyclus 
pyrethrum root extract (50, 100, 200 mg/kg, p.o.) in albino mice [43]. Another study demonstrated 
the anticonvulsant and myorelaxation activity of an ethanolic AP root extract in albino mice. A dose 
dependent effect was observed against maximum electroshock test and rotarod test after 
intraperitoneal administration of the extract in doses of 200, 400 and 600 mg/kg [44]. Sujith et al. 
(2011) evaluated neuropharmacological activity of an ethanolic AP root extract (50, 100, 200 mg/kg, 
p.o.) in albino Wistar rats. Nootropic activity was observed in rats in a dose dependent way using the 
elevated plus maze (EPM) test. Furthermore, the extract also showed antidepressant activity in a 
forced swim test [14]. Another study showed the anticonvulsant activity against pentylenetetrazole 
(PTZ) of a hydroalcoholic root extract of AP after oral administration of 50, 100, 250 and 500 mg/kg 
to Wistar rats. The observed effect was dose dependent. In addition, protection against MES induced 
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seizures was observed in a dose dependent way after administration of the extract in doses of 250, 
500 and 1000 mg/kg. Furthermore, the extract prevented seizure induced oxidative stress and 
showed protective effects against cognitive impairment in rats in a dose dependent manner [45]. 
Sujith et al. (2012) showed a dose dependent cognitive improvement of an ethanolic root extract of 
AP (50, 100, 200 mg/kg) after oral administration to albino Wistar rats in an EPM test and passive 
avoidance paradigms. Moreover, the extract enhanced short-term social memory in a social 
recognition task [46]. Zaidi et al. (2013) showed anticonvulsant activity against PTZ in a dose 
dependent manner in mice after administration of a chloroform AP root extract in a concentration of 
100, 200, 400 and 800 mg/kg. Also against bicuculline, the 800 mg/kg AP extract showed 
anticonvulsant activity. Furthermore, anxiolytic behaviour was also observed in an EPM model after 
administration of 800 mg/kg AP extract. Administration of 1600 mg/kg AP extract showed impaired 
motor coordination in a rotarod test [47]. Another study showed that pretreatment of albino mice 
with 100, 250 and 500 mg/kg (p.o.) hydroalcoholic root AP extract increased myoclonic jerk latency 
and delay in the development of kindling. Protection against memory deficit was observed after 
pretreatment of the AP extract in doses of 100, 250, 500 mg/kg (p.o.) in PTZ kindled mice by 
decreasing oxidative stress and ROCK II expression [48]. Other research demonstrated the 
anticonvulsant activity of an ethanolic root extract of Anacyclus pyrethrum (200, 400 mg/kg, p.o.) in a 
MES model in albino mice. 400 mg/kg AP extract was protective against PTZ model [13].       
In the previously described effect-studies, the AP extract was administered to rats or mice in doses 
ranging between 50 and 1600 mg extract/kg body weight. Assuming that the concentration of 
pellitorine is 1.55% w/w (determined on the ethanolic AP extract used in this study), the pellitorine 
dose ranges between 0.8-24 mg/kg. Since our study showed a maximum serum concentration of 26 
ng/ml pellitorine after oral administration of 5 mg pellitorine/kg to rats (Figure 2), and assuming 
pellitorine follows a linear kinetic, the maximum serum concentration of pellitorine in the previously 
described effect-studies is between 4.0 and 129.0 ng/ml. Our BBB data (Figure 3) showed a 
brain/serum concentration ratio of 792 μl/g at equilibrium, so that the brain concentrations of 
pellitorine in the previous effect-studies correspond to 3.2 to 102.1 ng pellitorine/g brain. Looking at 
compounds used for the treatment of CNS diseases (e.g. multiple sclerosis, experimental 
autoimmune encephalomyelitis, epilepsy), administered at efficacious doses, drug concentrations in 
the brain ranging between 15 and 620 ng/g brain were found [49-51]. Hence, our BBB study 
corroborates well with the previously described effect studies using the AP extract and the brain 
concentrations of other CNS-active drugs.  
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5. CONCLUSION  
In the current study, the intestinal barrier properties of pellitorine were investigated in vitro and in 
vivo. It was shown that pellitorine was able to cross the Caco-2 cell monolayer and the rat gut after 
oral administration. Furthermore, it was demonstrated that after intravenously administration of 
pellitorine to mice, pellitorine significantly and rapidly penetrated the BBB reaching the brain 
parenchyma. The biphasic course of the influx can partly be explained by an observed significant 
efflux of pellitorine out of the brain. These pharmacokinetic findings support the observed activities 
using the Anacyclus pyrethrum extract in the treatment of CNS diseases.    
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REGULATORY STATUS OF   
N-ALKYLAMIDE 
CONTAINING HEALTH 
PRODUCTS 
 
 
 
 
 
 “You can avoid reality, but you cannot avoid the consequences of avoiding reality.”  
 
  Ayn Rand (°1905-†1982, American novelist, philosopher) 
 
 
 
 
 
 
 
 
Parts of this chapter originate from: 
 
De Spiegeleer B, Gevaert B, Wynendaele E, Janssens Y, Suleman S, Cattoor S, Saunders JH, Veryser 
L. Regulatory status of N-alkylamide containing health products. Submitted. 
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ABSTRACT 
N-alkylamides (NAAs) are secondary metabolites occurring in more than 25 plant families. Plants 
containing NAAs are traditionally used in food for flavouring, tingling, pungent and saliva-enhancing 
properties but also to treat various diseases. NAA containing products are abundantly available on 
the market as food, cosmetics, medical devices and medicinal products. However, no unambiguous 
legal product classification is applied for these products. In this study, the different health product 
classes from a European viewpoint are discussed in relation to the pharmacokinetic and 
pharmacodynamic properties of the NAAs, their applied dosage and claimed usage.   
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CHAPTER VII 
REGULATORY STATUS OF N-ALKYLAMIDE 
CONTAINING HEALTH PRODUCTS 
Main focus in this chapter: 
 To give an overview of the classification of health products containing plant(extract)s. 
 To discuss the regulatory status of health products containing N-alkylamides on the market. 
 
1. N-ALKYLAMIDES 
Introduction  
N-alkylamides (NAAs) are an important group of secondary metabolites in plants, attracting attention 
because of their numerous reported bioactivities. NAAs, available in more than 25 plant families (e.g. 
Asteraceae, Piperaceae, Lauraceae, Solanaceae), possess i.a. antimicrobial, insecticidal, antifungal, 
anti-inflammatory, immune-modulating and analgesic effects. Well-known, traditionally and 
medically important plants containing NAAs are Anacyclus pyrethrum, Spilanthes acmella, Achillea 
millefolium and Echinacea species, all belonging to the Asteraceae family. Furthermore, Capsicum 
annuum (Solanaceae) and Piper species (Piperaceae) are also plants rich in NAAs.  
NAAs consist of a fatty acid chain which is linked to an amide part through a peptide bond. Because 
of the structural diversity in these two parts, they can be classified based on the combination of the 
fatty acid chain (F, from 1 to 13) and amide part (M, from 1 to 13). More than 400 NAAs are already 
discovered and their chemical name, occurrence, physicochemical properties and reported 
functionalities are gathered in the online database Alkamid® [1].  
NAAs are mainly found in plants and their related plant extracts, purified to different extent, or 
chemically synthesised. Examples of synthesised molecules are the geometric isomers of the plant 
NAA N-(2-methylpropyl)-2,6,8-decatrienamide (‘synthetic spilanthol’) and the mammalian 
palmitoylethanolamide (PEA) [2]. PEA is a mammalian signaling molecule originating from N-
palmitoylethanolamine-phospholipids in the lipid bilayer [3].  
In most countries, NAA containing plants have not only been used in food, but also for therapeutic 
purposes. Ethnopharmacological studies investigate these plant medicines in particular ethnic 
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populations. This is generally grouped in the term ‘traditional medicine’ which is defined by the 
World Health Organisation (WHO) as “the total of knowledge, skills, and practices based on the 
theories, beliefs and experiences indigenous to different cultures, whether explicable or not, used in 
the maintenance of health as well as in the prevention, diagnosis, improvement or treatment of 
physical and mental illness” [4]. Sometimes, traditional medicines are considered synonyms for 
complementary alternative medicines (CAM). Well-known traditional medicines include the 
Ayurveda and traditional Chinese medicine (TCM), both encompassing NAA containing plants. 
Products containing NAAs are widely available on the market as i.a. food supplements, medicinal 
products, cosmetics and medical devices. Using the European regulatory-legal frame, the legal status 
of these NAA containing health products will be discussed. 
 
Traditional use of plants containing N-alkylamides 
Food  
Plants are traditionally used in food, as spices and for their fragrance properties. For example, the 
fruits of Piper nigrum L. (black pepper) are well-known used for their flavouring properties [5]. 
Moreover, plants containing NAAs often give additional tingling and pungent sensations and/or 
increased salivation [6, 7]. Due to these remarkable and directly observable characteristics, NAA 
containing plants and extracts are globally used as tonic, to stimulate the appetite, or for its local 
mouth-cooling properties. In Iran, fruits of Piper longum L., Piper nigrum L. and Capsicum annuum L. 
are traditionally used as tonic, while in Cameroon, the fruits of Capsicum annuum are traditionally 
added to food [5, 8]. In Japan, Serbia, and Iran, Spilanthes acmella L., Achillea millefolium L. and the 
fruits of Piper nigrum L., respectively, have been used to stimulate the appetite [5, 9, 10].  
 
The possibilities of this particular use are also reflected in patents, demonstrating the industrial-
commercial interest (patents and patent applications: Ley et al. (US 2007/0202188), Hatasa et al. (US 
3,720,762), Lombardo et al. (US 8,741,958), Langer et al. (US 8,828,469), Gatfield et al. (US 
8,063,107), Kenichi et al. (WO/2016/088638)) [11-16]. Several use-patents related to N-alkylamides 
(alkene carboxylic acid N-alkylamides, spilanthol and isomers, trans-pellitorine) exist, covering the 
aromatic and flavouring properties (piquant, tingling, pungent, saltiness enhancing properties). In the 
patent claims, these NAAs are used in food and nutrition (e.g. bread, cereal products, chocolate, 
meat products, alcoholic and non-alcoholic drinks, eggs, salad dressings) and also to mask the 
unpleasant flavour of other components/products. Furthermore, applications are given in products 
for oral hygiene (e.g. tooth paste/gel, tooth powder, mouth washes) for their cooling and local 
anesthetic effect and their relief of pain in case of toothache. Next to these claimed properties, they 
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are also added to food for their saliva stimulating effects which in turn stimulates the appetite. 
Another purpose of these saliva-enhancing components is to improve oral hygiene for the treatment 
of a dry mouth and their usages are described in products like breath fresheners, chewing gum, 
mentholated cigarettes, food, cough drops, therapeutic compositions, pharmaceuticals and 
nutraceuticals. Use protection in these patents is also described for their heat-generated effects on 
the mucosa and skin. Some patents also include a synthesis process to produce these N-alkylamides. 
 
Ethnopharmacological use 
A selection of plant examples of the Solanaceae (genus Capsicum), Piperaceae (genus Piper) and 
Asteraceae (genus Spilanthes, Anacyclus, Echineacea, Achillea) plant families, frequently used as 
traditional medicine, exemplifies the traditional healing properties (Tables 1-4). The treatment of 
toothache is a common ethnopharmacological indication of Spilanthes acmella, Anacyclus 
pyrethrum, Echinacea purpurea and Achillea millefolium [17-23]. 
Fruits of Capsicum annuum L. (common name: chilli pepper) are used as a stimulant, aphrodisiac, to 
treat and prevent malaria, to treat osteoarthritis and female infertility [5, 24-26]. Another plant 
frequently used is Achillea millefolium L., known to treat toothache, stomach disorders, menstrual 
complaints, cough and cramps, fever, lung cancer, migraine, gynaecological disorders, rheumatism, 
cardiopathy, headache and dizziness [10, 22, 27]. Piper longum L. has been used to treat asthma and 
tuberculosis, to improve food digestion and hence to relieve flatulence, while the fruits of Piper 
nigrum L. are also used as a stimulant [5, 19].  
      
Especially in India, Spilanthes acmella is traditionally applied in the Ayurveda system to treat 
toothache, oral lesions, gum inflammation, throat problems, cough, paralysis, epilepsy, leucorrhoea 
and a poisonous sting [18, 19, 28-33]. An overview of the plants, local names, the country where the 
survey was conducted, the used plant parts, the form and medicinal uses, is given in Table 3. Because 
of its frequent use in the treatment of toothache, the plant is also called the toothache plant [34].  
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Another member of the Asteracea family with strong ethnopharmacological properties is Anacyclus 
pyrethrum (Table 4). This plant is employed not only in the treatment of chest pain, stomach 
problems, dental problems (tooth infection, toothache), bad breath, rheumatism, blood anemia, 
neuralgia, sore throat, respiratory, urinary and genital diseases, hair, diabetic and dermatological 
disorders, but also as an anaesthetic, aphrodisiac, pesticide and astringent agent [5, 20, 21, 36-40]. 
Ethnopharmacological uses of Echinacea, also belonging to the Asteraceae family, are summarised in 
Table 2. Field surveys revealed that the roots of Echinacea spp. are used for diarrhea, while a tincture 
of Echinacea angustifolia DC. is used to strength a weakened immune system. Furthermore, the 
leaves and the stem of Echinacea purpurea are used in a paste to treat oral cancer, toothache and 
sinusitis [10, 17, 35]. 
 
Pharmacological effects of N-alkylamides 
NAAs obtained from synthesis or plants after extraction and/or purification were studied towards 
their pharmacodynamic (PD) and pharmacokinetic (PK) properties. Due to their high/ubiquitous 
abundance in frequently used medicinal plants, the pharmacological properties of typical NAAs such 
as spilanthol, pellitorine, NAAs isolated from Echinacea species and synthetic derivatives like 
palmitoylethanolamide, are being explored in more depth.  
 
Spilanthol is known to cause a very strong tingling and saliva stimulation effect [7]. It appears that 
mechanosensitive neurons are involved in this tingling effect by blocking two-pore potassium 
channels [41, 42]. Furthermore, spilanthol induced the GABA release in mice cortical brain slices, 
indicative for an analgesic activity [43]. Déciga-Campos et al. (2010) also studied the analgesic 
properties of spilanthol in pain models and dose-dependent analgesic effects were observed after 
intraperitoneal administration of spilanthol to capsaicin and acetic acid treated mice. Capsaicin 
activates transient receptor potential vanilloid 1 (TRPV1). There was a reduction of the number of 
abdominal writhes and the time of the mouse licking its injured paw, respectively [44]. In a formalin 
induced rat pain model, the analgesic effect of spilanthol was demonstrated. Spilanthol also showed 
anti-anxiety behaviour, anti-convulsant effects and hypnotic potention in mice [45]. Furthermore, 
spilanthol inhibited the nitric oxide (NO) production in a dose dependent manner (20% NO 
production at 360 μM spilanthol, compared to 100% of the control LPS) in murine macrophage-like 
RAW 264.7 cells. This anti-inflammatory effect was due to suppression of the production of nitric 
oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) enzymes at transcriptional and translational 
levels. In LPS-treated RAW 264.7 cells, spilanthol was able to reduce the production of the 
proinflammatory cytokines interleukin (IL)-1E, IL-6 and tumor necrosis factor-D (TNF-D). 
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Furthermore, it was shown that spilanthol inactivated nuclear factor-NB (NF-NB) and hence reduced 
the transcription of proinflammatory mediators [46]. Anti-inflammatory effects were also in vivo 
demonstrated by Hernandez et al. (2009) for spilanthol on arachidonic acid - and phorbol myristate 
acetate-induced oedema in mouse ears [47]. Furthermore, antimutagenic properties of spilanthol 
were shown by reducing oxidative DNA damage induced by norfloxacin and reducing mutations 
caused by 2-aminoanthracene [48]. 
Molina-Torres et al. (1994, 2004) demonstrated the fungistatic (100% growth inhibition relative to 
control against Sclerotium rolfsii, Sclerotium cepivorum, Phytophthora infestans, Rhizoctonia solani at 
150 μg/ml) and bacteriostatic (100% growth inhibition relative to control against Escherichia coli at 
75 μg/ml and Bacillus subtilis at 150 μg/ml and Pseudomonas solanacearum at 150 μg/ml and 95% 
growth inhibition against Saccharomyces cerevisiae at 75 μg/ml) activities of spilanthol [49, 50]. 
In addition, a 1:1 mixture of spilanthol and undeca-2E,7Z,9E-trienoic acid isobutylamide is also active 
against the larvae of the yellow fever mosquito Aedes aegypti (50% mortality with 6.25 μg/ml) and 
the neonates of the moth Helicoverpa zea (corn earworm) (66% weight reduction with 250 μg/ml 
after 6 days) [51]. Another study demonstrated that spilanthol had ovicidal, larvicidal and pupicidal 
activity against the mosquitos Anopheles culicifacies, Culex quinquefaciatus and Aedes aegypti [52]. 
Spelman et al. (2011) demonstrated antimalarial activity of spilanthol. IC50 values of 16.5 μg/ml and 
5.8 μg/ml were obtained against Plasmodium falciparum strain PFB (compared to positive control 
chloroquine: IC50=0.009 μg/ml) and the chloroquine resistant P. falciparum K1 strain (compared to 
positive control chloroquine: IC50=0.032 ng/ml), respectively [53]. Furthermore, insecticidal activity of 
spilanthol against the moth Tuta absoluta was shown, with a LD50 value of 0.13 μg/mg compared to 
0.71 μg/mg of the positive control permethrin [54].  
Pharmacokinetically, spilanthol is able to permeate oral mucosa and human skin. In Chapter V, it was 
demonstrated that spilanthol crossed the intestinal barrier and via the blood circulation penetrated 
the blood-brain barrier. Hence, spilanthol is rapidly and extensively absorbed into the systemic 
circulation via different exposure routes, and distributed towards other organs including the 
relatively impermeable brain [55-57].     
 
The saliva-enhancing properties of spilanthol were also observed with pellitorine [7]. Ku et al. (2013) 
demonstrated the antithrombotic properties of pellitorine, i.e. 10 μM pellitorine increased the 
activated partial thromboplastin time (aPTT) (41 s) compared to the negative control saline (31 s) in 
human plasma; with 10 μM pellitorine, the prothrombin time (PT) was higher (23 s) compared to 
saline (14 s) and, after administration of 4.5 μg pellitorine to mice, there was a higher tail bleeding 
time (58 s) compared to the control saline (42 s) [58]. Furthermore, pellitorine showed antiseptic 
properties. The release of high mobility group box 1 (HMGB1) was inhibited, which is a late mediator 
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of septic conditions in LPS-induced human umbilical vein endothelial cells (HUVECs) and cecal ligation 
and puncture (CLP)-treated mice. Furthermore, pellitorine down-regulated HMGB1-dependent 
inflammatory responses in HUVECs. Pellitorine was also able to inhibit LPS-induced barrier disruption 
of HUVECs and the expression of cell adhesion molecules (CAMs). In addition, the production of the 
proinflammatory cytokines TNF-Dand IL-6 was reduced in LPS-treated HUVECs after incubation with 
pellitorine. Leukocytes migration was also inhibited by pellitorine in mice [59, 60].  
In another study, carried out by Ee et al. (2010), anticancer properties of pellitorine were 
demonstrated. It was found that pellitorine had an IC50 value of 1.8 μg/ml against the MCF-7 cell line 
(breast cancer) and an IC50 of 13.0 μg/ml against HL60 cell-line (human promyelocytic leukemia cells), 
meaning that pellitorine is toxic against these cell lines [61]. At a concentration of 100 μM, trans-
pellitorine was also able to reduce fatty acid uptake for 14% in Caco-2 cells, compared to non-treated 
control cells [62]. Furthermore, pellitorine is shown to be an inhibitor of acyl-CoA: cholesterol 
acyltransferase (ACAT) and, by preventing cholesterol esterification, it can potentially be used in 
pharmaceutical compositions or health food to prevent and treat hypercholesterolemia vascular 
diseases [63].   
Pellitorine possesses antifungal properties against Cladosporium cladosporioides and the minimum 
amount required for the inhibition of fungal growth was 5 μg, compared to 0.5 μg of the positive 
controls nystatin and miconazole [64]. Insecticidal properties of pellitorine against Sitophilus oryzae 
and Rhyzopertha dominica have been observed: 80% insect mortality at 200 mg/ml pellitorine [65]. 
In addition, pellitorine showed antiprotozoal properties against Plasmodium falciparum, Leishmania 
donovani, Trypanosoma cruzi, Trypanosoma brucei rhodesiense with IC50 values of 3.26 μg/ml 
(positive control chloroquine K1 strain: 0.080 μg/ml), 5.96 μg/ml (positive control miltefosine: 0.127 
μg/ml), 8.45 μg/ml (positive control benznidazole: 0.439 μg/ml) and 5.35 μg/ml (positive control 
melarsoprol: 0.003 μg/ml), respectively [66]. No experiments were carried out with purified 
pellitorine regarding the systemic effects.  
Furthermore, in Chapters III and VI, the pharmacokinetic properties of pellitorine were investigated 
and it was demonstrated that pellitorine was able to penetrate human skin, thereby reaching the 
blood circulation. Moreover, pellitorine was able to cross Caco-2 cell monolayers in vitro, which was 
in vivo confirmed in an oral gavage experiment using rats. Once present in the blood, pellitorine 
rapidly crossed the blood-brain barrier [67, 68]. These mucosal/skin and BBB permeation studies of 
NAAs corroborate well with the traditional use of NAA containing plants, e.g. the Asari Radix and 
Rhizoma use in TCM to treat brain diseases [69]. 
 
Echinacea plants are well-known for their anti-inflammatory and immune-modulating properties. 
NAAs isolated from different species of Echinacea have shown to increase the phagocytic activity of 
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alveolar macrophages in rats and to potently modulate the expression of TNF-D in human monocytes 
[70, 71]. Furthermore, alkylamides were able to suppress the production of TNF-D in LPS and H1N1 
influenza A stimulated RAW 264.7 macrophage-like cells. NO and NF-NB concentrations were also 
decreased after NAA treatment in LPS stimulated RAW 264.7 cells, while prostaglandin E2 (PGE2) 
production was reduced in H1N1 influenza A infected RAW 264.7 cells [72, 73]. Other studies showed 
that N-alkylamides from Echinacea modulated the NF-NB expression in LPS stimulated Jurkat cells (a 
human T cell line) and that the NAAs dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide and dodeca-
2E,4E-dienoic acid isobutylamide were able to decrease the expression of IL-1E, IL12p70 and TNF-D 
in human blood stimulated with LPS [74, 75]. Some anti-inflammatory effects of NAAs are indicated 
in Figure 1. In addition, NAAs from Echinacea showed binding affinity for the mouse as well as for the 
human cannabinoid (CB)2-receptor [75-77]. Other NAAs also interact with the endocannabinoid 
system. Anandamide or N-arachidonoylethanolamine (AEA) is an endocannabinoid, produced in 
mammalians and metabolically degraded by fatty acid amide hydrolase (FAAH). N-benzyl-(9Z,12Z)-
octadecadienamide, isolated from Lepidium meyenii, showed binding affinity for the CB1-receptor, 
inhibited FAAH and inhibited anandamide cellular uptake [78].   
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Figure 1. Anti-inflammatory effects of N-alkylamides. 
(Abbreviations= NAA: N-alkylamides like 2E-N-isobutylundeca-2-ene-8,10-diynamide, PEA: 
palmitoylethanolamide, LPS: lipopolysaccharide, TLR: Toll-like receptor, PPARD: peroxisome proliferator-
activated receptor D, NF-NB: nuclear factor-NB, IκB: inhibitor of κB, MD2: myeloid differentiation protein-2, 
TRIF: TIR domain-containing adapter-inducing interferon-β, MyD88: myeloid differentiation factor 88, CD14: 
cluster of differentiation antigen 14, JNK: c-Jun-N-terminal kinase, AP-1: activator protein 1, IKK: IκB kinase, 
iNOS: inducible nitric oxide synthase, COX-2: cyclooxygenase 2, IL: interleukin, TNF-D: tumor necrosis factor D, 
NO: nitric oxide, PGE2: prostaglandin E2).  
 
Pharmacological effects such as immune-modulating, anti-inflammatory and analgesic properties are 
also reported for PEA. In models of neuropathic and chronic inflammation, it has been shown that 
PEA was able to reduce pain and endoneural oedema. Furthermore, at the injury site, there was a 
reduction of mast cells and proinflammatory mediators [3]. Many molecular mechanisms have been 
suggested for the pleiotropic effects of PEA. It has been shown that pharmacological effects of PEA 
are mediated by activation of the main molecular target peroxisome proliferator-activated receptor 
(PPAR)-D. This type of receptors switch off the NF-NB signalling cascade which results in an anti-
inflammatory effect [79]. Other mechanisms of action are also reported such as the interaction with 
uncharacterised CB2-like receptors. Furthermore, PEA displays an ‘entourage effect’: it enhances the 
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analgesic effect of anandamide by inhibition of FAAH resulting in higher tissue levels of the 
endogenous anandamide [80].  
 
2. CLASSIFICATION OF HEALTH PRODUCTS 
The legal, regulatory classification, and hence the requirements for placing these NAA products on 
the market, is an important aspect for the patient/consumer, the manufacturer/distributor and for 
the competent authorities in an attempt to acquire correct information, create added value and 
protect the different stakeholders of the society at large. This ‘classification’ system should be 
considered as a tempo-spatial characteristic, i.e. changing in time and dependent on the 
country/region. Currently, however, the guiding principles in product classification are globally 
relatively similar. For the sake of transparency and focus, we will use the European legal and 
regulatory frame to elaborate the different health product classifications possibly applicable to NAAs. 
A schematic overview is given in Figure 2. 
 
 
Figure 2. Product classification. 
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Medicinal products  
To clarify the terms used in the text below, some terms will first be defined. A medicinal product 
(MP) is defined as “(a) any substance or combination of substances presented as having properties 
for treating or preventing disease in human beings; or (b) any substance or combination of 
substances which may be used in or administered to human beings either with a view to restoring, 
correcting or modifying physiological functions by exerting a pharmacological, immunological or 
metabolic action, or to making a medical diagnosis.” Hence, there are two “classes” of medicinal 
products: (a) by presentation or (b) by function. Herbal medicinal products (HMP) are defined as “any 
medicinal product, exclusively containing as active ingredients one or more herbal substances or one 
or more herbal preparations, or one or more such herbal substances in combination with one or 
more such herbal preparations”. Furthermore, herbal substances are defined as “ whole, fragmented 
or cut plants, plant parts, algae, fungi, lichen in an unprocessed, usually dried form, but sometimes 
fresh. Certain exudates that have not been subjected to a specific treatment are also considered to 
be herbal substances. Herbal substances are precisely defined by the plant part used and the 
botanical name according to the binomial system (genus, species, variety and author)”, while herbal 
preparations are “preparations obtained by subjecting herbal substances to treatments such as 
extraction, distillation, expression, fractionation, purification, concentration or fermentation. These 
include comminuted or powdered herbal substances, tinctures, extracts, essential oils, expressed 
juices and processed exudates” [81]. Next to the conventional medicines, also non-conventional 
medicines exist, i.e. complementary and alternative medicines (CAM), of which homeopathic 
medicines are part of it, but will not be further discussed in this work.  
 
Herbal medicinal products are licensed and marketed in Europe according to Directive 2004/24/EC, 
which amends Directive 2001/83/EC related to medicinal products for human use [82]. Individual 
herbal medicinal products are nationally licensed by Member States (MS). Due to Directive 
2004/24/EC, the licence of herbal substances and preparations became more harmonised across the 
EU. Furthermore, in Directive 2004/24/EC, a subcategory of HMPs is introduced, namely the 
traditional herbal medicinal products (THMPs). Herbal medicinal products can reach the market in 
the European Union (EU) as (a) a traditional use HMP (simplified registration procedure by a Member 
State) and (b) a well-established use (WE) HMP (marketing authorisation by MS or European 
Medicines Agency (EMA)). In case of WE HMP, the active substances are in use in the EU for at least 
10 years and enough safety and efficacy data must be available. No proof of clinical efficacy is 
needed for THMPs as this efficacy is plausible due to their traditional long-standing use. Registration 
as THMP is only possible if the product has been used for more than 30 years of which at least 15 
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years in at least one country of the EU [83-85]. Independent of the type of registration procedure, 
the quality of the HMP must always be guaranteed. The Committee on Herbal Medicinal Products 
(HMPC), one of the seven scientific committees of the EMA prepares the EU herbal monographs, 
consisting of the scientific opinion of the HMPC on efficacy and safety data of a herbal substance or 
preparations for medicinal use. These monographs consist of two parts: a well-established use and a 
traditional use part. Monographs include important information about the composition, 
pharmaceutical form, therapeutic indications, posology and method of administration, 
contraindications, special warnings and precautions for use, interactions with other medicinal 
products, information in case of pregnancy and lactation, ability to drive and use machines, 
undesirable effects, overdose information, pharmacokinetic (PK) and pharmacodynamic (PD) 
properties and preclinical safety data. The final monographs are published by the EMA and are used 
as a reference by a traditional use registration applicant (traditional use part) or by a marketing 
authorisation applicant (WE use part). The MS can consult these monographs for the examination of 
an application, however monographs have no legally binding character. But to favour the 
harmonisation, and avoid discrimination and unfair competition, if there is a deviation from the 
monographs, an appropriate justification is needed. Besides the monographs, there exist also list 
entries: “the EU list of herbal substances, preparations and combinations thereof for use in THMP”, 
which is legally binding and is published by the European Commission (EC) [83, 85]. 
 
Food 
The purpose of the implementation of the general food law, Regulation (EC) No. 178/2002, was to 
provide assurances of high level protection for consumers of all kinds of foods e.g. dietetic foods, 
food supplements, ‘functional foods’ and ‘nutraceuticals’ [86]. Food (or foodstuff) is defined as “any 
substance or product, whether processed, partially processed or unprocessed, intended to be, or 
reasonably expected to be ingested by humans. ‘Food’ includes drink, chewing gum and any 
substance, including water, intentionally incorporated into the food during its manufacture, 
preparation or treatment.” Food does not include “feed; live animals unless they are prepared for 
placing on the market for human consumption; plants prior to harvesting; medicinal products within 
the meaning of Council Directives 65/65EEC and 92/73/EEC; cosmetics within the meaning of Council 
Directive 76/768/EEC” [87]. The European Food Safety Authority (EFSA) was implemented in 
Regulation (EC) No. 178/2002 and provides scientific advice for the Community’s legislation. MS 
collaborate with EFSA to follow up the missions of the EFSA. Herbal products can be seen as food as 
they comply with the applicable food law Regulation (EC) No. 178/2002 and if they do not comply 
with the definition of medicinal products. EFSA discusses which type of botanical ingredients may be 
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used and which health claims are allowed [84]. Several subtypes of food are legally defined, which 
are discussed hereafter. 
 
Food supplements  
Since Directive 2002/46/EC, food supplements have been harmonised in the EU. Food supplements 
are defined as: “foodstuffs with the purpose to supplement the normal diet and which are 
concentrated sources of nutrients or other substances with a nutritional or physiological effect, alone 
or in combination, marketed in dose form, namely forms such as capsules, pastilles, tablets, pills and 
other similar forms, sachets of powder, ampoules of liquids, drop dispensing bottles, and other 
similar forms of liquids and powders designed to be taken in measured small unit quantities”. Food 
supplements thus contain substances with a nutritional or physiological effect such as nutrients 
(minerals and vitamins), essential fatty acids, amino acids and fibers. Specific rules are set up for 
vitamins and minerals and there is a positive list of vitamins and minerals that may be used in food 
supplements [88]. For other substances than vitamins and minerals with a nutritional or physiological 
character, there is little harmonisation across the EU and national rules of the MS are applicable. 
Belgium has its own unique Royal Decree on the manufacture and trade of foods composed of or 
containing plants or plant preparations. This Royal Decree can be an example for other countries in 
Europe how to deal with food composed of plants. In this Royal Decree, three lists are included with 
information about (1) the dangerous plants that may not be used in food, (2) edible mushrooms and 
(3) plants that needs to be notified if in dose form [89]. Food supplements must meet Directive 
2000/13/EC in which rules for food stuffs are described considering the labelling, presentation and 
advertising [90]. 
 
At the moment, no EU legislation for botanicals and derived preparations as food ingredients exists 
and therefore the general food law Regulation (EC) No. 178/2002 is applicable. These products must 
also comply with Regulation 1924/2006 on nutrition and health claims made on foods [87]. Nothing 
is mentioned in the Regulation about the assessment of the safety of botanicals and botanical 
preparations in food. Therefore, the scientific committee of the EFSA issued a living document, “the 
Compendium of botanicals reported to contain naturally occurring substances of possible concern for 
human health when used in food and food supplements” [91]. In the current list, Anacyclus 
pyrethrum is included, with N-alkylamides (for example pellitorine) indicated as chemicals of concern 
in the plant. 
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Functional foods   
There is currently no single legislative definition of ‘functional foods’. First used in the 1980’s in 
Japan, it means that this food can improve the health status of the body and decrease the risk of 
diseases. Products with a FOod for Specified Health Uses (FOSHU) symbol were seen in Japan as food 
where the function is superior to the taste. In contrast to Japan, in Europe, functional food is not 
considered as a separate food category, but it is more seen as a concept. The following definition of 
functional foods was given by the European Commission’s Concerted Action on Functional Food 
Science in Europe (FuFoSE): “a food product can only be considered functional if together with the 
basic nutritional impact it has beneficial effects on one or more functions of the human organism, 
thus either improving the general and physical conditions or/and decreasing the risk of the evolution 
of diseases. The amount of intake and form of the functional food should be as it is normally 
expected for dietary purposes. Therefore, it could not be in the form of pill or capsule” [92]. The USA-
based Functional Food Center (Dallas, TX) suggested that a functional food definition should be 
harmonised and proposed a new definition: “natural or processed foods that contain known or 
unknown biologically-active compounds, which, in defined, effective non-toxic amounts, provide a 
clinically proven and documented health benefit for the prevention, management or treatment of 
chronic disease” [93]. Different types of functional foods have been defined: probiotics (live 
microorganisms if consumed in adequate numbers conferring a health benefit on the host), 
prebiotics (non-digestible food ingredients that beneficially affect the host by stimulating the growth 
and/or activity of one or a limited number of bacteria in the colon, thus improving host health), 
functional drinks, functional cereals, bakery products, spreads, functional meat and functional eggs 
[92]. To regulate some aspects of functional foods, the general food law Regulation (EC) No. 
178/2002 and Regulation (EC) No. 1924/2006 on nutrition and health claims made on foods are 
applicable [87, 94].  
 
Products on the market must be safe and appropriately labeled and Regulation (EC) No. 1924/2006 
came into force to harmonise rules between MS on the use of nutrition and health claims on foods. 
Prior to the authorisation of health claims or foods in the Community, EFSA carries out a scientific 
assessment. Different kind of claims can be used for functional foods: (1) nutrition claim, (2) health 
claim and (3) reduction of disease risk claim. A nutrient claim is defined as “any claim which states, 
suggests or implies that a food has particular beneficial nutritional properties due to (a) the energy 
(calorific value) it provides/provides at a reduced or increased rate /does not provide, and/or (b) the 
nutrients or other substance it contains/contains in reduced or increased proportions/does not 
contain” (e.g. low energy, low sugar, fat-free), while a health claim means “any claim that states, 
suggests or implies that a relationship exists between a food category, a food or one of its 
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constituents and health” (e.g. helps maintaining acceptable cholesterol levels). A reduction of 
disease risk claim is defined as “any health claim that states, suggests or implies that the 
consumption of a food category, a food or one of its constituents significantly reduces a risk factor in 
the development of a human disease” (e.g. reduces cholesterol) [94]. It is due to this Regulation that 
debatably, foods can have claims with the name of a disease in it. Only nutrition claims mentioned in 
Annex of the Regulation may be used and they must comply to the conditions of the Regulation. 
Foods with claims must comply to Directive 90/496/EC considering general nutrition labelling for 
foodstuffs [84, 95, 96].  
 
‘Nutraceuticals’ is another term frequently used which has no regulatory framework and is not 
considered as a specific food category [86]. The term nutraceutical is a combination of ‘nutrition’ and 
‘pharmaceutical’. It is often defined as a food or parts of food providing medical or health benefits, 
including the prevention and treatment of a disease [97, 98]. Nutraceuticals can be functional foods 
or food supplements [99].  
 
Novel foods   
Foods and food ingredients belong to ‘novel foods’ if they have not been used to a significant degree 
for human consumption in the EU before 15 May 1997. Different categories of novel foods exist: “(1) 
foods and food ingredients with a new or intentionally modified primary molecular structure; (2) 
foods and food ingredients consisting of or isolated from micro-organisms, fungi or algae; (3) foods 
and food ingredients consisting of or isolated from plants and food ingredients isolated from animals, 
except for foods and food ingredients obtained by traditional propagating or breeding practices and 
having a history of safe food use; (4) foods and food ingredients to which has been applied a 
production process not currently used, where that process gives rise to significant changes in the 
composition or structure of the foods or food ingredients which affect their nutritional value, 
metabolism or level of undesirable substances” [100]. The use of genetically modified organisms 
(GMOs) in food or feed is separately regulated by Regulation (EC) 1829/2003 [101]. 
 
PARNUTS foods  
Foodstuffs for particular nutritional uses (PARNUTS or dietetic foods) are defined as “foodstuffs 
which, owing to their special composition or manufacturing process, are clearly distinguishable from 
foodstuffs for normal consumption, which are suitable for their claimed nutritional purpose and 
which are marketed in such a way as to indicate such suitability” [102]. ‘Particular nutritional use’ 
means that particular nutritional requirements must be fulfilled for infants or young children in good 
health, people with disturbed digestive processes or disturbed metabolism or people having special 
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physiological conditions. These products are intended to be consumed by a small part of the 
population. Specific directives are described covering infant formulae and follow-on formulae 
(Directive 2006/141/EC), processed cereal-based foods and baby foods for infants and young 
children (Directive 2006/125/EC), food intended for use in energy-restricted diets for weight 
reduction (Directive 96/8/EC), dietary foods for special medical purposes (Directive 1999/21/EC) and 
foods intended to meet the expenditure of intense muscular effort, especially for sportsmen 
(Directive 89/398/EEC) [103-107]. In Commission Regulation (EC) No. 953/2009 of 13 October 2009 
on substances that may be added for specific nutritional purposes in foods for particular nutritional 
uses, a list of substances (vitamins, minerals, amino acids, carnitine and taurine, nucleotides, choline 
and inositol) allowed to be added for specific nutritional purposes in foodstuffs for particular 
nutritional uses, is described [108]. For other substances which are not listed like botanicals and fatty 
acids, there are no harmonised EU rules and their use as PARNUTS food is considered at a national 
level [98]. 
 
Fortified foods  
A list of vitamins and minerals which may be added to foods are described and specific rules are 
given [109]. There is a harmonisation between MS considering the addition of vitamins and minerals 
and of certain other substances. The rules in Regulation (EC) No. 1925/2006 for vitamins and 
minerals are not applicable for food supplements covered by Directive 2002/46/EC. This Regulation is 
applicable for foods for particular nutritional use, novel foods and novel foods ingredients, food 
additives and flavourings, genetically modified food and authorised oenological practices and 
processes. 
 
Flavouring substances in food 
Flavourings and food ingredients with flavouring properties must fulfill the criteria laid down in 
Regulation (EC) No. 1334/2008 of the European Parliament and of the Council of 16 December 2008 
on flavourings and certain food ingredients with flavouring properties for use in foods and amending 
Council Regulation (EEC) No. 1604, Regulations (EC) No. 2232/96 and (EC) No. 110/2008 and 
Directive 2000/13/EC. Flavouring products are “not intended to be consumed as such, which are 
added to food in order to impart or modify odour and/or taste; made or consisting of the following 
categories: flavouring substances, flavouring preparations, thermal process flavourings, smoke 
flavourings, flavour precursors or other flavourings or mixtures thereof.” However, this Regulation 
does not apply to “non-compound foods and mixtures such as, but not exclusively, fresh, dried or 
frozen spices and/or herbs, mixtures of tea and mixtures for infusion as such as long as they have not 
been used as food ingredients” [110]. 
CHAPTER VII – REGULATORY STATUS OF N-ALKYLAMIDE CONTAINING HEALTH PRODUCTS 
  
 
182  
Cosmetics 
A cosmetic product is defined as “any substance or mixture intended to be placed in contact with the 
external parts of the human body (epidermis, hair system, nails, lips and external genital organs) or 
with the teeth and the mucous membranes of the oral cavity with a view exclusively or mainly to 
cleaning them, perfuming them, changing their appearance, protecting them, keeping them in good 
condition or correcting body odours” [111]. In annex II of Directive 76/768/EEC, a list is summarised 
of substances prohibited in cosmetic products, while annex III contains a list of substances which may 
not be included in cosmetic products, except if they are subject to the restrictions mentioned in 
annex III [112]. Commission Regulation (EU) No. 655/2013 is about common criteria for the 
justification of claims used in relation to cosmetic products [113].  
 
A term frequently used in the cosmetic industry for marketing purposes is ‘cosmeceuticals’ and is a 
combination of ‘cosmetics’ and ‘pharmaceuticals’. It bears no legally defined definition. These are 
cosmetics having medicinal product-like properties, but are not considered as a separate product 
class. Ingredients of these products can affect the biological skin function [114]. A product in the 
borderline section between food (nutrient), cosmetics and medicinal products can be classified as 
‘cosmenutraceuticals’, which is again not legally defined. These are products intended to be placed in 
contact with the external parts, of the human body or with the teeth and the mucous membranes of 
the oral cavity, providing systemic health benefits, including the prevention and treatment of a 
disease. 
 
Medical devices 
A medical device is “any instrument, apparatus, appliance, software, material or other article, 
whether used alone or in combination, including the software intended by its manufacturer to be 
used specifically for diagnostic and/or therapeutic purposes and necessary for its proper application, 
intended by the manufacturer to be used for human beings for the purpose of: diagnosis, prevention, 
monitoring, treatment or alleviation of disease; diagnosis, monitoring, treatment, alleviation of or 
compensation for an injury or handicap; investigation, replacement or modification of the anatomy 
or of a physiological process; control of conception; and which does not achieve its principal 
intended action in or on the human body by pharmacological, immunological or metabolic means, 
but which may be assisted in its function by such means” [115]. Some medical devices look like 
medicinal products or cosmetics. Examples of medical devices in this area are Kamillosan ocean nose 
spray (moistens and cleans the nasal cavity), Sensodyne Rapid toothpaste (rapid pain relief in case of 
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sensitive teeth), Flamigel (to treat minor wounds), Bepanthen cream (against itching) and Angifyt 
Naturactive throat spray (softens and cleanses the throat).   
 
Biocidal products  
Currently, biocides are regulated by the biocidal product Regulation (EC) No. 528/2012. Seen the 
ethnopharmacological use and insecticidal pharmacological properties of NAAs, a classification as 
biocide would not be unexpected. A biocidal product is defined as “any substance or mixture, in the 
form in which it is supplied to the user, consisting of, containing or generating one or more active 
substances, with the intention of destroying, deterring, rendering harmless, preventing the action of, 
or otherwise exerting a controlling effect on, any harmful organism by any means other than mere 
physical or mechanical action; any substance or mixture, generated from substances or mixtures 
which do not themselves fall under the first indent, to be used with the intention of destroying, 
deterring, rendering harmless, preventing the action of, or otherwise exerting a controlling effect on, 
any harmful organism by any means other than mere physical or mechanical action”. Germs and 
pests are examples of such harmful organisms. Biocidal products include preservatives, disinfectants 
and pest control products. Product-type 18 and 19, insecticides and repellents, respectively, are both 
product types belonging to the pest control products [116]. 
 
3. N-ALKYLAMIDE CONTAINING PRODUCTS ON THE MARKET  
Currently, NAA containing products are abundantly available on the market. However, the 
composition and quality of these products are often not well defined or uncontrolled. NAA 
containing products are presented under different forms by different companies with different 
health-related claims: gel (e.g. Buccaldol by A.B.S, contains i.a. Spilanthes, analgesic and prevents 
inflammation of the mouth mucus membrane), cream (e.g. Pea by RScience, contains 
palmitoylethanolamide, for sensitive skin and based on nutrient and protecting ingredients), 
ointment (e.g. Musculus Liniment by The Herbs, contains i.a. Achillea millefolium extract, Capsicum 
annuum extract and Echinacea angustifolia extract, cooling for the skin around the muscles), 
capsules (e.g. Cayenne, Capsicum annuum by Nature’s answer, contains i.a. fruits of Capsicum 
annuum), chewable tablet (e.g. Echinaforce chewable tablets forte + vit C by A. Vogel, contains i.a. 
Echinacea purpurea, supports immune system), powder (e.g. Natural herb powder by Evaidyaiji, 
contains Anacyclus pyrethrum, aphrodisiac and improves physical strength and supports the immune 
system), liquid (e.g. Dentaforce by A. Vogel, containing i.a. Spilanthes oleracea extract, supports oral 
hygiene and freshens breath), tincture (e.g. Spilanthes paracress drops by A. Vogel, contains 
Spilanthes oleracea), syrup (e.g. Thyme and Echinacea syrop by Unipharma, containing i.a. Echinacea 
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tincture, beneficial and soothing for the throat), pastilles (e.g. Echinacea bonbons by A. Vogel, 
contains i.a. Echinacea, refreshing and soothing for the throat), effervescent tablets (e.g. EchinaCold 
by Schwabe, contains dried juice of Echinacea purpurea herb, relieves symptoms of a common cold 
and influenza), tea (e.g. Echinacea Plus tea by Traditional Medicinals, contains Echinacea purpurea 
and Echinacea angustifolia, supports the immune system), toothpaste (e.g. Parodontax gel fluor + 
Echinacea by Paradontax, contains i.a. Echinacea purpurea, for a complete oral hygiene, Echinacea 
supports the immune system), throat spray (e.g. Echinacea throat spray by A. Vogel, contains i.a. 
Echinacea purpurea, relieves discomfort of the throat) and lip balm (e.g. Echinaforce lip balm by A. 
Vogel, contains i.a. Echinacea concentrate, caring and protective). A non-exhaustive list of typical 
products are exemplified in Table 5.  
The health-related claims of these products are very diverse, while no unambiguous and consistent 
product classification is applied. While some products explicitly claim the NAA (containing plant) as 
active ingredient, others present it as inactive excipient. They are sold as medicinal products (e.g. 
Echinacin liquid by Madaus, contains i.a. Echinacea purpurea, antiseptic properties in case of upper 
respiratory infections), food supplements (e.g. Anabeta by PES, containing i.a. Anacyclus pyrethrum 
DC root extract, muscle transformation agent), medical devices (e.g. Indolphar gel by I.D.Phar, 
contains i.a. spilanthol as aroma, reduces pain in case of mouth ulcers) or cosmetics (e.g. Parodontax 
gel fluor + Echinacea by Paradontax). 
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4. DISCUSSION OF THE CLASSIFICATION OF N-ALKYLAMIDE 
CONTAINING PRODUCTS 
Each health-related product class has its benefits and disadvantages for the manufacturers on the 
one hand and the consumers/patients on the other hand, with the competent authorities as the go-
between arbitrator protecting the society. Manufactures often want to avoid a medicinal product 
classification, as this requires the most stringent, time-consuming and expensive development and 
authorisation process. On the other hand, public health concerns ask for sufficient safety and 
information measures being installed before certain products are launched.  
The classification decision falls within the competence of individual countries, and hence differences 
may exist for example among different Member States in Europe. In case of doubt, the Court of 
Justice of the European Union (CJEU) clarifies the interpretation of the different product 
classifications. In article 2 of Directive 2004/27/EC, amending Directive 2001/83/EC, it is also 
explicitly mentioned that in cases of a borderline product, which can be considered as a medicinal 
product but also as another product type, the medicinal product classification shall be applicable 
[117]. Decisions must be taken for the whole product, taking into account all its characteristics and 
not for only one ingredient of it. The same ingredient can be used in e.g. food supplements as well as 
in medicinal products, depending on its use [95].  
 
Most N-alkylamide containing plants are marketed as a food supplement or cosmetic, and only very 
seldomly as a medicinal product. For the plants used in the medicinal products, community herbal 
monographs exist i.e. for Echinacea purpurea (L.) Moench, Echinacea pallida (Nutt.) Nutt., radix, 
Echinacea angustifolia DC., radix and Achillea millefolium L., herba [118-121]. Echinacin liquid is an 
example of such herbal medicinal product on the market. For the marketing authorisation of this 
product, it was possible for the applicant to rely on the community herbal monograph of Echinacea 
purpurea (L.) Moench, radix [118]. The therapeutic indication mentioned in the community herbal 
monographs of Echinacea pallida (Nutt.) Nutt. and Echinacea angustifolia, is the supportive 
treatment of a common cold, while Achillea millefolium is used for temporary loss of appetite, the 
symptomatic treatment of mild, spasmodic gastro-intestinal complaints including bloating, and 
flatulence, the symptomatic treatment of minor spasm associated with menstrual periods and for the 
treatment of small superficial wounds [119-121].  
Interactions with other drugs are increasingly becoming important due to i.a. polypharmacy in aging 
population [122]. Therefore, it is vital to consider the theoretically possible interactions from the 
mechanism of action and pursue further studies. Some studies have investigated the 
pharmacokinetic interactions of Echinacea preparations and other drugs [123]. However, for other 
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NAA containing products, no information is available. As an example, the well-known tingling effect 
of N-alkylamides is caused by blocking the two-pore potassium channels occurring in cells 
widespread over the body. The function of the two-pore potassium channels is to control the 
excitability of the cells by leaking potassium and these potassium channels are activated by some 
anesthetic drugs [124]. When two or more drugs are taken at the same time e.g. a medicinal product 
containing NAAs causing tingling effects and an anesthetic drug acting on the two-pore potassium 
channels, an interaction is theoretically not excluded, and its clinical relevance depends on dosing 
and pharmacokinetic considerations. Another example is related to the demonstrated interaction of 
NAAs with the endocannabinoid system. NAAs have shown to inhibit FAAH, thereby enhancing levels 
of the endogenous CB receptor agonist anandamide [78]. It has been demonstrated that FAAH 
inhibitors may impair the working memory in rats [125]. Hence, as FAAH inhibitors influence some 
regions in the brain, it is not without any risk to take such substances. However, more human derived 
data are needed to evaluate the clinical relevance of the information obtained from in vitro and 
animal studies.        
 
Besides the possibility to regulate NAA or acylethanolamide (e.g. PEA) containing products as 
medicinal products, they can also be registered as food supplements, governed by the food law. 
Currently, the list of the EU Register on nutrition and health claims includes no N-alkylamides or 
NAA-containing products. Food supplements have physiological and nutritional effects with the 
function to maintain health, while medicinal products exert pharmacological, immunological or 
metabolic properties and treat or prevent a disease [81, 88]. The borderline between a medicinal 
product and a food supplement is sometimes subject to interpretation, confounded by the fact that 
the form of a food supplement closely resembles that of medicinal products, for example capsules, 
tablets or powder sachets. To comply with the definition of a food supplement, the nutrients or 
‘other substances’ must have only a nutritional or physiological effect. While NAAs and PEA refer to 
‘other substances’ in the food supplement definition, it has been demonstrated that these NAAs and 
PEA possess several pharmacological effects with different molecular targets already described. Even 
when a product is not presented as a medicinal product (presentation criterion), their mechanism of 
action applies to the second part of the definition of a medicinal product (functionality criterion), 
which is confirmed by the community herbal monographs of Echinacea species and Achillea 
millefolium, plants consisting of mixtures of NAAs. Often, a product is considered as a medicine if 
they potentially have an effect on the human body and affect the metabolism. However, this part of 
the definition alone cannot be the only reason to classify a product as a medicinal product. It is also 
important to consider the dose of the active substance(s). If the dose is below the dose able to 
restore, correct or modify a physiological function as established by the current state of scientific 
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knowledge, then it is not a medicinal product. This has been elaborated/explicated by CJEU 
judgments: the argument that there is a human health risk at a lower (but sub-therapeutic) dose is 
on itself not sufficient to consider a product as a medicine; hence remaining its status as a food 
supplement [126]. Furthermore, the claims and presentation of the substances are also important to 
take into account for classification issues. Products resembling medicinal products as well as food 
supplements are often named nutraceuticals, although this is not a legally defined term. Besides food 
supplements, it should also be possible to consider NAA containing plants as functional foods, since 
these plants contain bioactive NAAs and have already shown beneficial effects on human body; they 
are able to reduce the risk of the evolution of a disease as well [1]. To present substances as 
functional food, it is important that the appearance of the product looks like ‘normal food’ and not in 
the form of capsules or pills [92]. Although no NAA plant is currently included in the EU register on 
nutrition and health claims, this may change in the future [127].     
 
The classification of products containing NAAs as a medical device should also be questioned. In 
some countries, medical devices which have the appearance of a medicinal product, are sold in 
selected distribution channels like the pharmacy [128]. Although medical devices may closely 
resemble medicinal products (‘borderline products’), there is a difference between the two product 
classes [129]. The principal intended action of a medical device is obtained by physical means. For 
example, Virumed is a medical device as its main action is to block the UV rays, hence eliminating 
one of the factors eliciting cold sore caused by active Herpes simplex virus. The other components 
like Echinacea purpurea extract only assist in the functionality of the product by supporting the 
resistance [130]. Medical devices may thus contain medicinal substances having an ancillary action. 
The pharmacological action of these ancillary medicinal substances are subordinate to the physical 
action of the medical device [131]. Some of these medical devices are clearly very close to medicinal 
products. 
 
There are also NAA containing products on the market as cosmetics. Often, cosmetic products are 
closely related to medicinal products and borderline issues are judged by the European Court. An 
example of such ‘cosmeceutical’ issue was the discussion about the meaning of ‘pharmacological 
action’ in the definition of a medicinal product of Directive 2001/83/EC [81]. The European Court 
decided that the definition explained in the Guidance Document on the demarcation between 
cosmetic products and medicinal products [132] can be used, which states that for a medicinal 
product, there must be “an interaction between the molecules of the substance in question and a 
cellular constituent, usually referred to as a receptor, which either results in a direct response or 
blocks the response of another agent”. Furthermore, the Court ruled that the ‘cellular constituent’ in 
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the definition does not mean cellular constituents of the user’s body, but it can also be cellular 
constituents of e.g. bacteria present in human body [133]. From the pharmacological effects of NAAs 
described previously, the interaction between NAAs and cellular constituents is beyond any doubt. 
The classification of NAA containing products as cosmetics can be similarly treated. Studies have 
shown that the N-alkylamides spilanthol and pellitorine, after topical administration were able to 
penetrate the different cell layers (stratum corneum and viable cell layers) and reach the systemic 
blood circulation. These compounds then exert a pharmacological effect, i.e. they interact with cells. 
As previously listed in Table 5, there are products on the market containing Spilanthes acmella 
(contains spilanthol) and Anacyclus pyrethrum (contains pellitorine) in the form of a cream or gel. 
This raises the question if such products, marketed as cosmetics, still can be considered as such, 
because when topically applied, the viable cells in the skin and the blood circulation below these cells 
are clearly reached, resulting in a systemic exposure with rapid tissue distribution. Depending on the 
amount that reaches the blood and the corresponding pharmacological effect, classification of such 
borderline products, informally called cosme(nutra)ceuticals, should be reconsidered.  
 
In conclusion, from their pharmacokinetic properties, i.e. absorbed in the systemic circulation and 
distributed, combined with their pharmacological activities, i.e. different molecular targets have 
been identified, the NAAs and their originating plant materials plausibly show beneficial health 
effects, supported by the ethnopharmacodynamic use, but also possess inherent risks (side effects, 
overdose, interactions, contraindications). Therefore, their use, and its related dose-rate, influencing 
the biological positive as well as negative functionalities, is a critical determinant for their legal-
regulatory classification.  
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BROADER INTERNATIONAL CONTEXT, 
RELEVANCE & FUTURE PERSPECTIVES 
 
1. BROADER INTERNATIONAL CONTEXT AND RELEVANCE 
Plant derived products are worldwide mainstream health preparations. For a full understanding of 
their health properties and a justified exploitation, analytical and biofunctional characterisations as 
well as regulatory positioning are required. This Ph.D. research is a contribution to our knowledge 
and current understanding in this field. 
 
N-alkylamides as a new class of medicines   
Medicinal plants containing N-alkylamides (NAAs) are widespread in nature. A well-known example 
of such plant is Echinacea purpurea. It is a popular flowering plant in gardens attracting bees and 
butterflies, but many people who have this easy-to-grow plant in their garden don’t know that it has 
medicinal properties due to its NAAs. The same is also true for Achillea plants like Achillea millefolium 
(common name: yarrow). 
 
Previously, it was demonstrated that spilanthol can penetrate human skin, and now a key finding of 
the presented study is that also pellitorine is able to penetrate human skin and reach the systemic 
blood circulation. Systemic concentrations of NAAs were found in a concentration range able to exert 
bioactive effects. In addition, high concentrations of NAAs were also achieved in the skin layers [1, 2]. 
Moreover, after oral administration, spilanthol and pellitorine reached the blood circulation. Another 
important observation of the presented study is that these NAAs were able to penetrate the blood-
brain barrier (BBB) [3, 4]. In combination with the findings of Woelkart et al. (2009), who 
demonstrated that dodeca-2E,4E,8Z,10E/Z tetraenoic acid isobutylamides from Echinacea species 
rapidly crossed the BBB after oral administration to rats, our results suggest that the BBB is indeed 
permeable for certain NAAs [5]. This is a major observation, given that this barrier, which separates 
the blood from the brain, is characterised by tight junctions between the endothelial cells, 
preventing most molecules to penetrate this highly impermeable barrier [6]. It can be expected that 
next to spilanthol and pellitorine, also other NAAs can enter the brain as well. Due to their many 
pharmacological actions described in the literature and their good bioavailability from our research, 
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N-alkylamides are important lead compounds for drugs [7]. These findings stimulate further 
investigation towards the central nervous system (CNS) pharmacodynamic properties of these 
compounds and will be of interest in the search of new CNS drugs, where the BBB is usually a 
hampering factor. NAAs are also incorporated in topical formulations to exert not only local but also 
systemic functionalities. However, the pharmacological effects and good bioavailability not only offer 
perspectives, but also regulatory challenges.   
 
In Chapter VII, some medicinal products containing NAAs are already mentioned, such as Echinaforce 
(A. Vogel) or Echinacin (Madaus), derived from Echinacea purpurea. Not only in plants, also other 
synthetic compounds have an N-alkylamide-like structure and are registered as medicines, such as 
lidocaine (local anesthetic), captopril (angiotensin-converting enzyme (ACE) inhibitor) and 
acetazolamide (diuretic). They can also be classified according to the FxMy classification system and 
are shown in Table 1 [7-10].  
 
Table 1: Structures of lidocaine, captopril, phenacemide and acetozalomide.   
Name Lidocaine Captopril Acetazolamide 
Structure
   
Classification F2M12 F2M6 F1M8 
 
N-alkylamides are structurally related to the endocannabinoid anandamide. Both NAAs and 
endocannabinoids consist of an amide bond, which resembles the peptide bond in peptides and 
proteins. Endogenous agonists for the cannabinoid receptors (CB1R and CB2R), like anandamide, are 
being explored as they are pleiotropic, also activating other receptors such as transient receptor 
potential cation channel subfamily V member 1 (TRPV1) and peroxisome proliferator-activated 
receptors (PPARs). Pepcans are such a family of peptides, shown to be ligands for the CB1R [11].   
 
Awaiting novel, more efficient synthetic pathways for NAAs, isolation from plants is still required for 
further exploration of the medicinal use of these compounds. We succeeded in isolating spilanthol 
and pellitorine from the raw plant extracts Spilanthes acmella and Anacyclus pyrethrum, respectively, 
allowing further pharmacodynamic experiments being executed using these isolated NAAs. This is 
important, as at present most pharmacodynamic investigations are carried out with the whole plant 
extract, often uncharacterised, instead of the isolated NAAs. 
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Phytotherapy  
Phytotherapy or herbal medicine is based on the use of plant derived medicines. Phytotherapy is a 
kind of complementary and alternative medicine (CAM) and is often not evidence-based according to 
our current paradigms. Other CAM systems include Ayurveda, Chinese traditional medicine, 
homeopathy and Unani [12]. The production of herbal preparations requires some additional steps 
compared to single substances, such as the collection and cultivation of the plants and extract 
characterisation [13]. Isolated active compounds from plants may be less active than the whole 
plant. This is the case if multiple compounds are responsible for the observed pharmacological effect 
of the plant or if the pharmacokinetics is mutually influenced [14-16]. 
 
In this research the practical use of medicinal plants was clearly demonstrated, suggesting that 
sufficient academic attention should be devoted to the medicinal properties of plants. After all, 
plants are an important source in the search for new medicines and still a major part of synthetic 
drugs have plant precursors. In this context, it is important to bear in mind that a substantial 
knowledge of medical properties of plants can be found in indigenous cultures. In these cultures, 
plant knowledge is of vital economic and health importance. This ethnopharmacological knowledge 
is traditionally passed on via (1) vertical transmission, i.e. from parents to children; (2) horizontal 
transmission, i.e. between individuals of the same generation and (3) oblique transmission, i.e. from 
adults (other than parents, e.g. teacher) to children. Traditional healers play a pivotal role in this 
transmission. A common method for the discovery of drugs derived from plants, is to study the use 
of plant preparations in the folk medicine of indigenous cultures. This way of discovering drugs is 
opposite to Western drug research, in which clinical data are the end point instead of the start point. 
Studying these cultures can result in information about pharmacologically active plants, their 
extraction method, routes of administration, formulations and the dosages used. Hence, less 
research must be spent on these aspects and the cost of research can be reduced. At present 
however, the described ethnopharmacological knowledge is on the verge of extinction, as the access 
to modern medicine, the globalisation of cultures and the ongoing deforestation are threatening 
traditional habits. It is in our view of utmost importance for current and future generations that the 
existing knowledge is studied and documented. This is especially important for African traditional 
medicine where ethnopharmacological knowledge is passed on only orally and is not documented. 
This is in contrast to the Chinese traditional medicine and the Ayurveda, Unani and Sithda, where this 
knowledge is documented [14, 15, 17-20]. An efficient way to document medicinal knowledge about 
plants is constructing databases. To document the knowledge of N-alkylamides, there is the Alkamid® 
database, containing 439 N-alkylamides [7]. It is important that databases are updated on a regular 
basis, in order that always the latest and newest information is available online.  
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There is the belief of many people that what is natural is safe. However, natural products cannot be 
regarded automatically as safe. The unsafety of plants can have different causes, e.g. insufficient 
knowledge of plants, plants containing toxic compounds or contaminated plants. In the past, there 
have been serious health problems after consuming Chinese herbals. It has been demonstrated that 
health problems related to the use of herbal products were mainly due to mislabeling of the package 
and not mentioning all plant species. Plants from the Aristolochia species caused nephropathy, also 
named “Chinese herbs nephropathy”. Aristolochic acid was the toxic compound present in the plants 
[21]. If fungi grow on plants, this is the cause of a lack of quality control (QC). Quality control is a 
common problem with herbal medicines, but also their proper use information to the patient will 
influence the safety profile [22].  
   
People who live in developing countries have not always access to Western medicine. Therefore, 
they still use plants in primary health care. And even when they have access to it, Western medicine 
(active compounds isolated and purified from plants or synthetised) is often too expensive for them 
[13]. If the knowledge of traditional medicines can be improved and their safety and effectiveness 
can be assured, then it should be possible to include herbal preparations in local healthcare systems 
in an affordable way. On the other side, phytotherapy will only be accepted in Western medicine if 
the safety, efficacy and quality of the plants or plant derived products can be properly controlled, 
using similar criteria as used for synthetic compounds. Efforts have been made for standardising 
herbal medicines, which is a considerable challenge due to plant composition variability [15, 23, 24].  
 
Of the many herbal products available, only for few of them, clinical trials have been conducted. 
Often, there is a poor quality of the clinical studies, e.g. too small sample size, inadequate controls 
and the study duration is too short. Many herbal medicines are not evaluated for their adverse 
reactions in clinical trials, as this is much more complicated compared to Western medicine (no 
standardisation, lack of quality systems). In order to compare clinical studies, exactly the same 
extract must be used. For clinical trials, the extract must be well characterised. A lot of in vitro and in 
vivo studies were performed with herbal medicines, supporting the healing properties of the herbal 
medicines used in traditional medicine. However, this is not always that simple to translate these 
effects to humans. And there is still the question/discussion if costly clinical trials will actually deliver 
added value for herbal medicines based on traditional medicine, as they have shown their efficacy in 
indigenous cultures [25]. 
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Improvement of analytical techniques  
Identification of all active compounds present in plants or plant extracts is not always easy, as plants 
are often complex mixtures. Currently, sensitive and selective analyses can be performed using gas 
chromatography (GC) or high performance liquid chromatography (HPLC) coupled to MS. These 
techniques can provide detailed information about the composition of multicomponent products 
[23]. In this work, we characterised the N-alkylamide content in two plant extracts belonging to the 
Asteracea family, i.e. Achillea millefolium and Achillea ptarmica. Two different analytical techniques 
were used: HPLC-MS and GC-MS. Especially using GC-MS, up till now, scarce analytical NAA profiling 
was performed. Furthermore, additional NAAs were identified in Achillea millefolium using GC-MS 
compared to HPLC-MS. Our data supplement the current existing information about the NAA content 
of the two plants, as we have elucidated new NAAs, never previously reported in Achillea millefolium 
and Achillea ptarmica [26-30]. In addition, these analytical methods can be further used for the 
identification of NAAs in other plants too. The progress in analytical techniques is very important as 
still a lot of plants have not yet been investigated for their medicinal effects or for a detailed 
compound profiling [15].     
 
Another analytical technique that can be used in plant research is UHPLC coupled to a single 
quadrupole MS detector. It was shown that the use of a single quad mass detector has several 
selectivity and sensitivity advantages compared to traditional ultraviolet (UV) detectors. We have 
demonstrated the applicability of this detector in transdermal research, in which bioactive N-
alkylamides that are present in complex plant extracts, were identified and quantified with UHPLC-
single quad MS. Using this detector, no baseline separation between compounds was needed for 
their quantification. It was also possible to quantify low concentrations of NAAs. Moreover, this type 
of detector has other applications too, such as its use in the quality control of peptides [31]. It is to 
be expected that this type of detector will be used in the near future more often for e.g. routine 
analyses and QC of drugs, and that it will be incorporated as a standard technique in pharmacopoeial 
monographs.  
 
Legal and regulatory framework of N-alkylamide containing plants  
Lastly, N-alkylamides are used worldwide due to their various biofunctionalities and have a vast 
range of applications in the food industry, as well as in the pharmaceutical and cosmetic industries. 
The interest in these compounds is also reflected in a number of patents related to the synthesis 
and/or the bioactive properties of NAAs and their application in food, food supplements, cosmetics, 
nutraceuticals and medicinal products [32-38]. In Chapter VII, it was the purpose to draw the 
attention to the legal status of these NAA containing products. Products on the market containing 
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NAAs are poorly or not regulated and we conclude that the legal and regulatory framework of NAA 
containing products should be strengthened. A system of objective, preferably quantitative, efficacy-
risk balance should be developed to allow a more consistent classification. 
 
2. FUTURE PERSPECTIVES  
In this work, some pharmacokinetic properties of spilanthol and pellitorine have been characterised. 
The next logical aspects to further investigate are the skin and brain pharmacodynamic properties of 
these NAAs. Plants containing NAAs are ethnopharmacologically used in topical applications, such as 
the plant Anacyclus pyrethrum in Morocco [39]. Nowadays, topical products containing these plants 
are available on the market, used to treat a variety of health problems. We have shown that 
spilanthol and pellitorine were able to penetrate the stratum corneum (the outerlayer of the skin) 
and NAA concentrations were found locally in the epidermis and dermis and in the systemic blood 
circulation [1, 2, 40]. However, the mechanism of action of NAAs regarding their dermatological use 
is not yet elucidated. As NAAs can penetrate the skin and since they have in vitro proven to possess 
anti-inflammatory properties, they can possibly play an important role in the treatment of various 
inflammatory related skin diseases [41-46]. In certain skin diseases, such as contact allergy and 
cutaneous inflammation, skin cancer, and pruritus, the endocannabinoid system is involved, in which 
the cannabinoid receptor 1 (CB1R) and CB2R are main receptors and are i.a. distributed in the skin 
[47]. Raduner et al. (2006) demonstrated already the ability of Echinacea NAAs to interact with both 
cannabinoid receptors [48]. However, no data are yet reported about the binding affinity of 
spilanthol and pellitorine towards the CBRs. Therefore, the investigation of more fundamental 
pharmacodynamic parameters including the binding affinity of different NAAs to various targets is a 
future research objective.  
 
A second aspect in need of further research is the question which effects NAAs cause in the brain. 
This study demonstrated that spilanthol and pellitorine are able to cross not only the stratum 
corneum, but also the blood-brain barrier [3, 4]. Although this is a major finding, in order to be 
correlated with the ethnopharmacological use and drug development, the effects of these NAAs in 
the brain have to be assessed thoroughly. As previously mentioned in Chapter I, CB1 receptors are 
expressed in the CNS. Hence, investigating the binding affinity of NAAs towards the cannabinoid 
receptors, is not only of importance in the treatment for skin related diseases, but also for CNS 
related disorders. Initial in vitro pilot experiments were performed in our laboratory using BV2-cells, 
murine microglial cells, which play a role in immunological reactions and occur in the CNS (data not 
yet reported). Microglia produce proinflammatory mediators in response to i.a. neurodegenerative 
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diseases (e.g. Alzheimer disease and Parkinson’s disease) and infection [49-51]. The influence of 
different concentrations of spilanthol and pellitorine on the production of proinflammatory cytokines 
was evaluated and compared to the positive control lipopolysaccharide (LPS). Our pilot data indicate 
that pellitorine and spilanthol have no influence on tumor necrosis factor-D (TNF-D)and nitric oxide 
(NO) production compared to the negative control, indicating that these NAAs cause no 
inflammatory reaction. However, also the anti-inflammatory properties of spilanthol and pellitorine 
are under investigation, with promising first results which should stimulate further investigations. In 
addition, initial tests are also on-going with spilanthol and pellitorine on a pheochromocytoma 
(PC12)-cell line, which is an in vitro model for studying neuronal functions. These cells respond to 
neurite outgrowth if the neurotrophin nerve growth factor (NGF) binds with the tropomyosin 
receptor kinase A (TrkA) receptor and cell protective properties are then obtained [52]. Neurite 
formation stimulants are important compounds in the treatment of neurodegenerative disorders, 
such as Alzheimer’s disease in which neurotrophin levels are altered [53]. Two types of tests are 
being performed, namely the effect of the NAAs after stimulating the cells with NGF and the effect of 
NAAs on untreated cells. From the initial in vitro pilot tests, it appears that both spilanthol and 
pellitorine had no effect on neurite outgrowth. Further investigations, including other brain cell 
types, are required to confirm these results and validate these pilot conclusions. Besides the 
distribution of spilanthol and pellitorine into the brain, further research should ideally also focus on 
the distribution of the NAAs within the different brain regions. As the brain uptake might not be 
homogeneous, this might lead to different concentrations in the different brain regions. Next to the 
brain, the distribution of these NAAs towards other tissues deserves further investigation as well, as 
these compounds can exert functional effects in these tissues. 
 
More academic attention should in the third place also be devoted to the structure-activity 
relationship (SAR) regarding the anti-inflammatory and immune-modulating activities described for 
NAAs [41-46]. Only few studies document the structure-activity relationship. A study of Moazami et 
al. (2015) investigated the SAR of selected NAAs on the suppression of TNF-D production in LPS 
stimulated RAW 264.7 cells (murine macrophage-like cell line). It appears that the double bounds in 
the fatty acid chain of the N-alkylamide are not critical to exert an effect. The suppression of TNF-D 
production was dependent on the fatty acid chain length i.e. minimum 11 carbons are required if 
there is no saturation in the fatty acid chain of the molecule to have an effect [54]. However, from 
the Alkamid® database, it appears that N-alkylamides have various structural diversities in the fatty 
acid part, as well as in the amide part [7]. SAR studies with NAAs using totally different structures are 
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currently lacking and should be further investigated in the future. Besides the TNF-D production, 
other immunological responses deserve further investigation as well.     
 
As medicinal products consisting of NAA containing plants are registered as traditional use herbal 
medicinal products via a simplified registration procedure, no pharmacokinetic/pharmacodynamic 
(PK/PD) and preclinical safety data need to be reported [55]. However, it is still important to 
investigate the interactions between these NAAs or NAA containing plants/products and drugs. It is 
after all not unlikely that the efficacy of drugs can be affected by NAAs, when taken simultaneously 
due to potential interactions between them. Because of interactions between the bioactive NAAs 
and drugs, the action of a particular drug may be altered, i.e. the drug can be less or more effective 
or an antagonistic effect can take place or side effects can occur [56]. Furthermore, NAAs can 
enhance the bioavailability of other drugs. These bio-enhancing properties have already been 
demonstrated for piperine, the main bioactive NAA in Piper longum and Piper nigrum. Piperine 
combined with other drugs or nutrients increased the bioavailability of these drugs/nutrients e.g. 
rifampicin, vitamin B6, theophylline, nimesulfide, pentobarbitone, and beta-carotene [57]. As 
interactions with NAAs like spilanthol and pellitorine with other drugs are not yet established, it is 
therefore important to further explore this. If bio-enhancing properties can be proven, it would have 
clear benefits for the application of drugs, given that in this scenario the dose of drugs could be 
lowered in combination with the NAA.   
 
Finally, also the relationship between the human microbiome and the intake of NAAs, under 
whatever form or via whatever route, is a hot topic for future investigations. It is known that diet, 
nutrition habits, age, health status and geographical location influence the human microbiome. Many 
studies have shown that the microbiome plays a role in the well-being of humans and the 
development of diseases such as the irritable bowel syndrome (IBS) [58, 59]. As NAAs or plants 
containing NAAs can be part of food, e.g. as spices, they can possibly alter the gut microbiome 
composition. Hence, it seems crucial to study whether manipulating the human microbiome – of 
which the composition can be determined by investigating the feces – by NAAs can have positive 
effects on the development of specific diseases.            
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SUMMARY & GENERAL CONCLUSIONS 
This research project aimed to analytically characterise two plant extracts and to demonstrate some 
pharmacokinetic properties of two N-alkylamides (NAAs) spilanthol and pellitorine. In Chapter I, 
NAAs were described as secondary metabolites occurring in more than 25 plant families. Their wide 
structural diversity is reflected in an online database Alkamid®. The database is kept up to date and 
gathers information about NAAs and their structural, botanical, physicochemical properties and 
functionalities. Plants containing NAAs have been used ethnopharmacologically for decades for their 
medicinal properties and are often used in food. In this thesis, two specific bioactive NAAs were 
focused on, namely the triene NAA spilanthol (deca-2E,6Z,8E-trienoic acid isobutylamide) and the 
diene NAA pellitorine (deca-2E,4E-dienoic acid isobutylamide). These NAAs are most abundantly 
present in respectively the plants Spilanthes acmella and Anacyclus pyrethrum, both belonging to the 
Asteracea family.  
In Chapter II, two other plants of the Asteracea family were analytically characterised: Achillea 
ptarmica and Achillea millefolium. NAAs were assigned in ethanolic extracts of these plants (roots, 
leaves, stems, flowers) using two different analytical methods: HPLC-ESI-MS and GC-EI-MS, allowing 
tentative structural assignments. By using both techniques, 14 NAAs were reported in Achillea 
ptarmica: 6 NAAs with an isobutylamide group, 3 NAAs with a piperide group, 1 NAA having a 
piperideide group, 2 NAAs with a N-methyl isobutylamide group, 1 NAA with a phenylethylamide 
group and 1 NAA with a N-methyl isobutylamide group. In the Achillea millefolium extract, 15 NAAs 
were reported: 6 NAAs with an isobutylamide group, 1 NAA with a tyramide group, 1 NAA having a 2-
methylbutylamide group, 2 NAAs having a piperidide group, 4 NAAs having a piperideide group and 1 
NAA with a 4-methoxy phenylethylamide group. In both plant extracts, new NAAs were reported: 
deca-2E,6Z,8E-trienoic acid 2-methylbutylamide (homospilanthol) or a related isomeric compound 
was assigned for the first time in both extracts, while another new NAA was assigned in Achillea 
ptarmica: deca-2E,4E-dienoic acid N-methyl isobutylamide. In both extracts, the roots contained the 
highest number of NAAs.  
In Chapter III, the transdermal properties of pellitorine were investigated for the first time. It was 
demonstrated that pellitorine was able to penetrate human skin in a Franz diffusion cell set-up. The 
permeability kinetics were investigated of (1) purified pellitorine (isolated from Anacyclus pyrethrum) 
and of (2) pellitorine, present in the Anacyclus pyrethrum extract. Samples were analysed using 
(U)HPLC-UV. The permeability coefficient (Kp) of purified pellitorine proved to be lower (Kp = 1.1·10-4 
cm/h) than the Kp of pellitorine in the extract (Kp = 2.3·10-4 cm/h), which can be explained by the fact 
that other NAAs in the extract can enhance the penetration properties of pellitorine. Pellitorine 
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concentrations were calculated in the epidermis, dermis and the receptor fluid, indicating that 
pellitorine is able to reach the systemic blood circulation. Hence, after topical administration of 
pellitorine, local and/or systemic effects are possible. As it is difficult to accurately quantify not 
baseline separated compounds with UV, the transdermal kinetics of NAAs in complex plant extracts 
were investigated again using another type of detector, i.e. UHPLC coupled to a single quadrupole 
mass spectrometric detector. The applicability of this new type of single quad MS detector in 
transdermal research is described in Chapter IV. Several advantages were demonstrated compared 
to the UV detector, such as a gain in selectivity as well as a lower limit of detection. It was possible to 
quantify two N-alkylamides pellitorine and anacycline, present in the Anacyclus pyrethrum extract, in 
transdermal samples, without a baseline separation. The local skin pharmacokinetic properties of 
spilanthol, present in Spilanthes acmella, were also investigated and transdermal samples were 
quantified with UHPLC-single quad MS. An additional advantage of this type of detector is that the 
lag time of compounds can be more accurately and precisely determined in transdermal research. In 
conclusion, the “single quad MS” detector has proven to be useful for biomedical-pharmaceutical 
purposes in transdermal research and development. 
In Chapter V, the intestinal barrier and blood-brain barrier (BBB) permeability properties of 
spilanthol were explored. In order to analyse all these biological samples with a bio-analytical UHPLC-
MS² method, a sample preparation method was developed using solid phase extraction (SPE). In an 
in vitro Caco-2 cell monolayer experiment, spilanthol was able to penetrate the Caco-2 cell 
monolayer from the apical to basolateral direction (absorptive direction) and from the basolateral to 
apical direction. Apparent permeability coefficients Papp between 5.2·10-5 and 10.2·10-5 cm/h were 
obtained. These results were confirmed in vivo in Wistar rats. In an oral gavage experiment, 
spilanthol concentrations were detected and quantified in the blood. Moreover, for the first time the 
blood-brain barrier characteristics of spilanthol were studied in the gold-standard in vivo mice model. 
Spilanthol was able to rapidly penetrate the BBB after intravenous injection with a high unidirectional 
influx rate constant K1 of 796 μl/(g·min). These results were further explored and 98% of spilanthol 
was found in the brain parenchyma with only remaining 2% in the brain capillaries. In addition, also 
efflux from the brain into the blood was observed with an efflux transfer constant kout of 0.11 min-1.  
All the above pharmacokinetic properties were described for pellitorine as well (Chapter VI). In a 
Caco-2 cell monolayer experiment, pellitorine penetrated the cells from the apical to basolateral 
direction (Papp between 0.6·10-5 and 4.8·10-5 cm/h) and from the basolateral to apical direction (Papp 
between 0.3·10-5 and 5.8·10-5 cm/h). Also in the in vivo oral gavage experiments with Wistar rats, 
pellitorine was rapidly absorbed from the intestinal lumen into the blood. Furthermore, once in the 
blood, pellitorine rapidly penetrated the blood-brain barrier in mice with a unidirectional influx rate 
K1 of 153 μl/(g·min). 97% of pellitorine was able to reach the brain parenchyma, while only 3% was 
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captured in the brain capillaries. Furthermore, efflux from the brain into the blood was also 
demonstrated (efflux transfer constant kout: 0.05 min-1).  
Lastly, in Chapter VII, the regulatory status of N-alkylamide containing health products was 
discussed. First, the traditional use of N-alkylamide containing plants was described, i.e. their use in 
food and their use to treat diseases in an ethnopharmacological context. Beneficial health effects 
were attributed to the NAA containing plants. Moreover, an overview of the different product classes 
of health products was presented mainly from an European viewpoint, followed by a selection of 
products containing N-alkylamides available on the market. From this information, the legal-
regulatory classification system of N-alkylamide containing products was discussed as currently, 
there is no unambiguous legal product classification for these products: their classification is 
dependent on the dose of the bioactive NAA compounds, their (claimed) use and their biological 
functionalities.  
To conclude, the relevance of this research was discussed and some hot topics for future 
investigations were suggested.  
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“La perfection est atteinte, non pas lorsqu'il n'y a plus rien à ajouter, mais lorsqu'il n'y a plus 
rien à retirer.”  
 
 
 Antoine de Saint Exupéry 
(°1900-†1944, French writer, poet) 
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SAMENVATTING & ALGEMENE CONCLUSIES 
Het doel van dit onderzoeksproject was om twee plantextracten analytisch te karakteriseren en om 
de farmacokinetische eigenschappen aan te tonen van twee N-alkylamides (NAA’s): spilanthol en 
pellitorine. In Hoofdstuk I werden NAA’s beschreven als secondaire metabolieten die in meer dan 25 
plantfamilies voorkomen. Van hun structurele diversiteit getuigt de online database Alkamid®, die 
regelmatig geüpdatet wordt en informatie bevat over NAA’s en hun structuur, botanische en 
fysicochemische eigenschappen en de bijhorende functionaliteiten. Planten die NAA’s bevatten 
worden al decennia lang ethnofarmacologisch gebruikt voor hun geneeskundige eigenschappen en 
komen vaak voor in voeding. In deze scriptie werd gefocust op twee bioactieve NAA’s, namelijk de 
‘triene’ NAA spilanthol (deca-2E,6Z,8E-trienoic acid isobutylamide) en de ‘diene’ NAA pellitorine 
(deca-2E,4E-dienoic acid isobutylamide). Die NAA’s zijn de meest voorkomende NAA’s in 
respectievelijk de planten Spilanthes acmella en Anacyclus pyrethrum, die beide behoren tot de 
Asteracea plantfamilie.   
In Hoofdstuk II werden twee andere planten van de Asteracea familie analytisch gekarakteriseerd, 
namelijk Achillea ptarmica en Achillea millefolium. NAA’s werden gerapporteerd in ethanolische 
extracten van deze planten (wortels, bladeren, stengels, bloemen) met twee verschillende 
analytische methodes: HPLC-ESI-MS en GC-EI-MS. Door gebruik te maken van beide technieken 
werden 14 NAA’s structureel toegewezen in Achillea ptarmica: 6 NAA’s met een isobutylamide 
functie, 3 NAA’s met een piperide functie, 1 NAA die een piperideide functie bezit, 2 NAA’s met een 
N-methyl isobutylamide functie, 1 NAA met een fenylethylamide functie en 1 NAA met een N-methyl 
isobutylamide functie. In het Achillea millefolium extract daarentegen, werden 15 NAA’s 
gerapporteerd: 6 NAA’s met een isobutylamide functie, 1 NAA met een tyramide functie, 1 NAA die 
een 2-methylbutylamide functie bezit, 2 NAA’s met een piperidide functie, 4 NAA’s die een 
piperideide functie bezitten en 1 NAA met een 4-methoxy fenylethylamide functie. In beide 
plantextracten werden nieuwe NAA’s gerapporteerd: deca-2E,6Z,8E-trienoic acid 2-
methylbutylamide (homospilanthol) of een isomeer hiervan werd voor de eerste keer gerapporteerd 
in beide extracten, terwijl er nog een nieuw NAA werd gevonden in Achillea ptarmica: deca-2E,4E-
dienoic acid N-methyl isobutylamide. In beide extracten werd het hoogste aantal NAA’s aangetroffen 
in de wortels.  
In Hoofdstuk III werden voor het eerst de transdermale eigenschappen van pellitorine onderzocht. Er 
werd aangetoond dat pellitorine in staat is om de humane huid te penetreren in een Franz diffusiecel 
experiment. De permeabiliteitskinetieken werden onderzocht van (1) zuiver pellitorine (geïsoleerd 
uit Anacyclus pyrethrum) en van (2) pellitorine aanwezig in het Anacyclus pyrethrum extract. Stalen 
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werden geanalyseerd met (U)HPLC-UV. De permeabiliteitscoëfficiënt (Kp) van zuiver pellitorine was 
lager (Kp = 1.1·10-4 cm/h) vergeleken met de Kp van pellitorine in het extract (Kp = 2.3·10-4 cm/h), wat 
verklaard kan worden door het feit dat andere NAA’s aanwezig in het extract de 
permeabiliteitseigenschappen van pellitorine kunnen verhogen. Pellitorine werd aangetroffen in de 
epidermis, dermis en de receptor vloeistof, wat aangeeft dat pellitorine in staat is om de 
bloedcirculatie te bereiken. Daardoor zijn lokale en/of systemische effecten mogelijk na topicaal 
toedienen van pellitorine. Aangezien het moeilijk is om componenten accuraat te kwantificeren die 
niet basislijn gescheiden zijn van elkaar met UV, werd de transdermale kinetiek van NAA’s in 
complexe plantextracten opnieuw onderzocht met een ander type detector, namelijk UHPLC 
gekoppeld aan een enkelvoudige quadrupool massaspectrometrische detector. De toepasbaarheid 
van het beschreven nieuwe type enkelvoudige quadrupool massaspectrometrische detector in 
transdermaal onderzoek werd beschreven in Hoofdstuk IV. De detector bleek verschillende 
voordelen te hebben ten opzichte van een UV-detector, zoals een winst aan selectiviteit en een 
lagere detectielimiet. Het bleek bovendien mogelijk om de twee N-alkylamides pellitorine en 
anacycline, aanwezig in het Anacyclus pyrethrum extract, in transdermale stalen te kwantificeren 
zonder dat die NAA’s basislijn gescheiden waren. De lokale huid farmacokinetische eigenschappen 
van spilanthol, aanwezig in Spilanthes acmella, werden ook onderzocht en transdermale stalen 
werden gekwantificeerd met een UHPLC-enkelvoudige quadrupole MS. Een voordeel van dit type 
detector is dat de lag time van componenten meer accuraat en precies bepaald kan worden in 
transdermaal onderzoek. Samenvattend, kunnen we stellen dat een ‘enkelvoudige quadrupole MS’ 
detector kan gebruikt worden voor biomedische-farmaceutische toepassingen in transdermaal 
onderzoek en ontwikkeling.   
In hoofdstuk V werden de permeabiliteitseigenschappen van spilanthol doorheen de darmbarrière 
en de bloed-hersenbarrière (BBB) onderzocht. Om de biologische stalen te analyseren met een bio-
analytische UHPLC-MS² methode, werd een staalvoorbereidingsmethode ontwikkeld, gebruik 
makend van vaste fase-extractie. In een in vitro Caco-2 cel monolaag experiment, werd aangetoond 
dat spilanthol in staat is om de Caco-2 cel monolaag te penetreren in de apicale tot basolaterale 
richting (absorberende richting) en in de basolaterale tot apicale richting. 
Permeabiliteitscoëfficiënten (Papp) tussen 5.2·10-5 en 10.2·10-5 cm/h werden verkregen. Die resultaten 
werden in vivo bevestigd in Wistar ratten. In een orale gavage experiment werden spilanthol 
concentraties gedetecteerd en gekwantificeerd in het bloed. Bovendien werden voor het eerst de 
BBB-karakteristieken van spilanthol bestudeerd in een gouden standaard in vivo muismodel. 
Spilanthol penetreerde snel de BBB na intraveneuze injectie met een hoge unidirectionele influx 
snelheidsconstante K1 van 796 μl/(g·min). In een verdere studie van die resultaten werd 98% van 
spilanthol teruggevonden in het hersenparenchym en slechts 2% in de hersencapillairen. Daarnaast 
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werd ook de efflux van spilanthol uit de hersenen naar het bloed geobserveerd met een efflux 
transfer constante kout van 0.11 min-1.  
De beschreven farmacokinetische eigenschappen werden ook onderzocht voor pellitorine 
(Hoofdstuk VI). In een Caco-2 cel monolaag experiment werd aangetoond dat pellitorine die cellen 
penetreerde van de apicale tot basolaterale richting (Papp tussen 0.6·10-5 en 4.8·10-5 cm/h) en van de 
basolaterale tot apicale richting (Papp tussen 0.3·10-5 en 5.8·10-5 cm/h). Ook in het in vivo orale 
gavage experiment met Wistar ratten, werd pellitorine vlug geabsorbeerd in het bloed vanuit het 
darmlumen. Bovendien werd aangetoond dat pellitorine, eens aanwezig in het bloed, de 
bloedhersen-barrière van muizen snel penetreerde met een unidirectionele influx 
snelheidsconstante K1 van 153 μl/(g·min). 97% pellitorine was in staat om het hersenparenchym te 
bereiken en slechts 3% werd vastgehouden in de hersencapillairen. Daarnaast werd ook de efflux 
aangetoond van pellitorine van de hersenen naar het bloed (transfer constante kout: 0.05 min-1).  
Tot slot werd in Hoofdstuk VII het wetgevend kader van gezondheidsproducten met N-alkylamides 
bediscussieerd. Eerst werd het traditionele gebruik van planten met N-alkylamides beschreven, met 
onder andere toepassingen in de voedingsindustrie en de ethnofarmacologische ziektebehandeling. 
Gunstige gezondheidseffecten worden immers toegeschreven aan planten die NAA’s bevatten. 
Daarnaast werd ook vanuit een hoofdzakelijk Europees standpunt een overzicht geschetst van 
verschillende productklassen van gezondheidsproducten, gevolgd door een selectie van NAA-
producten die aanwezig zijn op de markt. Op basis van die informatie werd het wettelijk-
regelgevende classificatiesysteem van NAA-producten besproken. Daaruit bleek dat er momenteel 
geen eenduidige wettelijke productclassificatie voor die producten wordt toegepast. Hun classificatie 
is afhankelijk van de dosis van de bioactieve NAA’s, hun (voorgesteld) gebruik en hun biologische 
functionaliteiten.      
Op het einde van deze scriptie werd de relevantie van het onderzoek besproken en sommige 
interessante studies werden voorgesteld voor verder onderzoek.  
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 “Each problem that I solved became a rule which served afterwards to solve other problems.”  
 
 
 Rene Descartes  
(°1596-†1650, a French philosopher, mathematician, and scientist) 
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